VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 14 (11-21 junio / 2026)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Noticias en la Web

Reino Unido vacunará a miles de jóvenes para reducir los brotes por meningococo B en el país

12 jun. Los datos de la Agencia de Seguridad Sanitaria del Reino Unido (UKHSA, por sus siglas en inglés) muestran que hubo 313 casos confirmados de meningococo del grupo B (MenB) en Inglaterra durante 2024/2025. A principios de 2026, se produjo el mayor brote de meningitis B tanto en crecimiento como en magnitud jamás registrado en Reino Unido. Ante esta situación, el gobierno ha anunciado que miles de jóvenes de todo el país recibirán protección contra la enfermedad a través de un programa de vacunación único que se pondrá en marcha antes del año académico 2026.

"El Servicio Nacional de Salud espera que las vacunas estén disponibles a finales de julio para comenzar su inyección antes del nuevo curso académico."

La enfermedad meningocócica es potencialmente mortal y puede provocar discapacidades permanentes como amputaciones, pérdida de audición y daño cerebral, mientras que la mortalidad se produce en aproximadamente el 10% de los casos. Los virus y bacterias que causan la meningitis se transmiten por contacto cercano con una persona infectada. Esto puede ocurrir al besar, compartir bebidas o cigarrillos electrónicos, o por contacto prolongado con la persona, como vivir en el mismo hogar.

La vacuna del meningococo B reduce alrededor del 75% en la incidencia de la enfermedad.

Este programa de vacunación contra el meningococo B estará a disposición de las personas que completen el último año de estudios en el verano de 2026, nacidas entre el 1 de septiembre de 2007 y el 31 de agosto de 2008, así como de las personas menores de 25 años que comiencen la universidad o se trasladen por primera vez a algún centro de educación superior residencial en otoño de 2026. Los estudiantes que cumplan los requisitos podrán recibir una vacuna de dos dosis antes de comenzar el nuevo año académico.

En palabras del Dr. Thomas Waite, subdirector médico de Reino Unido, "para una protección máxima se necesitan dos dosis de la vacuna contra el meningococo B, con un intervalo de al menos cuatro semanas, y animo a todos los que vayan a asistir a la universidad o a un centro de estudios superiores por primera vez este otoño a que acudan a recibir su primera dosis lo antes posible".

La vacuna contra el meningococo B tiene un historial de seguridad comprobado y ya se ofrece de forma rutinaria a los lactantes a través del programa de vacunación infantil del Servicio Nacional de Salud (NHS) del Reino Unido. La evidencia del programa de vacunación infantil del Reino Unido muestra que la vacunación ha logrado una reducción de alrededor del 75 % en la incidencia de la enfermedad por meningococo B entre los grupos vacunados que cumplen los requisitos.

Kent fue una de las ciudades que sufrió uno de los mayores brotes de meningococo B jamás registrados en Inglaterra.

La UKHSA estima que el riesgo relativo de enfermedad meningocócica invasiva B en estudiantes universitarios de primer año es considerablemente mayor que en sus compañeros. Se sabe que los casos de enfermedad meningocócica invasiva suelen alcanzar su punto máximo entre octubre y noviembre de cada año. El programa de vacunación ayudará a proteger a quienes corren mayor riesgo inmediato de padecer una enfermedad grave al mudarse a residencias compartidas.

Este programa de vacunación único ayudará a proteger a las personas con mayor riesgo inmediato mientras el gobierno supervisa y evalúa las nuevas pruebas para determinar si ha habido un cambio en la forma en que la meningitis B afecta a las personas y si se requiere alguna respuesta adicional de vacunación. Las sospechas de una posible mutación están basadas por el brote en Kent y los recientes casos que indican un posible cambio en la forma en que la meningitis B afecta a las personas.

El NHS ha comenzado la planificación de la implementación operativa, y se espera que las vacunas estén disponibles en Inglaterra a partir de finales de julio de 2026, antes del inicio del nuevo año académico. Paralelamente a la puesta en marcha del programa, el DHSC, el NHS England y la UKHSA llevarán a cabo una campaña de información pública para fomentar la participación entre los grupos que cumplan los requisitos.

Fuente: ISANIDAD. Disponible en https://n9.cl/ht2nz

Enfermedad X: la amenaza desconocida que mantiene a la OMS en alerta permanente



12 jun. La Organización Mundial de la Salud (OMS) lleva varios años preparándose para una amenaza que todavía no tiene nombre ni rostro. Se trata de la denominada Enfermedad X, un concepto incorporado por la organización en 2018 para representar la posibilidad de que una futura pandemia sea provocada por un agente infeccioso desconocido para la ciencia.

A diferencia de otras enfermedades incluidas en la lista de vigilancia de la OMS, la Enfermedad X no corresponde a un virus, bacteria o patógeno específico. Más bien, reconoce una realidad cada vez más evidente: las mayores amenazas para la salud pública podrían surgir de microorganismos que aún no han sido detectados o de virus conocidos que evolucionen y se vuelvan más transmisibles o peligrosos.

La experiencia de la COVID-19 reforzó la preocupación

Para muchos expertos, el SARS-CoV-2, causante de la pandemia de COVID-19, se convirtió en el primer ejemplo real de lo que representa la Enfermedad X. El virus apareció de manera inesperada, se propagó rápidamente por todo el mundo y generó una emergencia sanitaria global antes de que existieran vacunas o tratamientos específicos.

Esta experiencia impulsó a la OMS y a la comunidad científica internacional a fortalecer la preparación frente a amenazas emergentes, promoviendo el desarrollo de plataformas de vacunas adaptables, sistemas de diagnóstico rápidos y redes de vigilancia epidemiológica capaces de identificar brotes inusuales de manera temprana.

La Enfermedad X forma parte del Plan Director de Investigación y Desarrollo para Prevenir Epidemias, una iniciativa creada por la OMS en 2015 para acelerar la disponibilidad de diagnósticos, tratamientos y vacunas frente a enfermedades emergentes.

Para elaborar su lista de prioridades, la organización reúne expertos en microbiología, epidemiología, salud pública, veterinaria, antropología y seguridad. Estos especialistas analizan factores como la capacidad de transmisión entre personas, la gravedad de la enfermedad, el potencial de expansión internacional, el impacto social y económico y la posibilidad de que el patógeno evolucione con el tiempo.

Las enfermedades que actualmente preocupan a la OMS

Además de la Enfermedad X, la OMS mantiene bajo vigilancia varios patógenos considerados de alto riesgo, entre ellos:

⇒ Virus del Ébola, virus de Marburg, fiebre de Lassa, virus Nipah, MERS, SARS, virus Zika, fiebre hemorrágica de Crimea-Congo y fiebre del Valle del Rift.

Estas enfermedades han sido identificadas como amenazas que requieren investigación acelerada debido a su potencial de provocar brotes graves y por la limitada disponibilidad de herramientas para su control.

Aunque la influenza no figura en la lista de prioridades del Plan Director, porque ya cuenta con vacunas y sistemas de vigilancia establecidos, una encuesta realizada entre especialistas de 57 países encontró que los virus de la gripe siguen siendo considerados la principal amenaza pandémica actual. La Enfermedad X ocupó el segundo lugar entre las preocupaciones de los expertos.

Esta aparente contradicción refleja uno de los mayores desafíos de la salud pública moderna: prepararse tanto para amenazas conocidas como para aquellas que todavía no han sido descubiertas.

Más que intentar predecir cuál será la próxima pandemia, la estrategia de la OMS busca garantizar que el mundo esté listo para responder rápidamente cuando surja una nueva amenaza. La Enfermedad X simboliza precisamente ese reto: desarrollar herramientas, sistemas de vigilancia y capacidades de respuesta que permitan actuar con rapidez frente a lo desconocido. «La Enfermedad X representa la posibilidad de que un patógeno actualmente desconocido para la medicina pueda surgir y propagarse a escala mundial».

Fuente: PHL PUBLIC HEALTH LATAM. Disponible en https://n9.cl/4t6jj

Brazil Suspends New Dengue Vaccine After Two Fatalities

Jun 12. The Brazilian Ministry of Health has announced a temporary suspension of its mass immunization campaign using the domestically produced Butantan-DV vaccine, pending an investigation into the deaths of two vaccine recipients.

Brazilian health authorities have ordered a precautionary halt to the rollout of Butantan-DV, a newly developed single-dose dengue vaccine produced by the country's renowned Instituto Butantan in

partnership with WuXi Vaccines. The decision follows reports of two suspected fatalities, a 58-year-old man and a 48-year-old woman, as well as a third recipient who required emergency admission to an intensive care unit. These severe adverse events occurred among approximately 500,000 individuals who have received the vaccine since its recent introduction.

Approved Dengue Vaccines

⇒ Qdenga (Takeda): A live-attenuated vaccine designed to provide protection against all four dengue virus serotypes. Qdenga is administered as a two-dose regimen, with doses given three months apart.

⇒ Dengvaxia (Sanofi Pasteur): The first dengue vaccine to receive regulatory approval. However, its use is now highly restricted. It is indicated exclusively for individuals aged 9 to 45 years with laboratory-confirmed evidence of a previous dengue infection.

The current concern in Brazil inevitably recalls one of the most controversial public health crises of the 21st century. In 2015, the French pharmaceutical company Sanofi Pasteur launched Dengvaxia to widespread acclaim. In collaboration with the Philippine government, the company initiated a large-scale school-based immunization program that ultimately vaccinated more than 800,000 children.

However, in 2017, the manufacturer disclosed a critical scientific finding: while the vaccine provided substantial protection to individuals who had previously experienced a natural dengue infection, it posed a significant risk to dengue-naïve (seronegative) individuals who had never been infected with the virus. In these children, the vaccine effectively simulated a primary infection. When they were subsequently exposed to wild-type dengue virus, their immune systems could respond through a phenomenon known as Antibody-Dependent Enhancement (ADE), increasing the risk of severe and potentially life-threatening disease.

The resulting fallout in the Philippines triggered unprecedented political, legal, and criminal investigations involving public health officials, led to the revocation of the vaccine's local registration, and contributed to a profound and long-lasting decline in public confidence in vaccination programs throughout the region.

Fuente: POULTRY MED. Disponible en https://n9.cl/qs5iqw

How New Technologies Are Impacting the Vaccine Market

Jun 13. In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for use in vaccine development. Pfizer reportedly paid an upfront total of $30 million, with an additional $500 million agreed upon based on development and commercial milestones.

At the 2026 JP Morgan Healthcare conference, Novavax CEO John Jacobs said, ““This company is no longer about one product or one season. It’s about building a sustainable engine for value creation built on technology, discipline, and long-term partnerships.”

This news came during a period of regulatory uncertainty surrounding vaccines. Due to abrupt leadership changes at HHS, ACIP was forced to cancel its February meeting this year. In 2025, incoming HHS Secretary Kennedy fired the previous council and replaced the members with his own picks.

However, this hasn't stopped vaccines from being developed and approved. In May of this year, FDA's advisory panel voted to update COVID-19 vaccine shots to target the XFG variant. This update includes the vaccine developed in partnership with Novavax and Sanofi.

Silvia Taylor spoke with Pharmaceutical Executivex about the current vaccine landscape and how new technologies are allowing more players to enter the space and develop new therapies. She also discussed the regulatory landscape and how vaccine developers are working around any potential issues.

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Silvia Taylor: Vaccine technologies are really having a major impact on the vaccine environment right now. Since the onset of COVID, people are disproportionately attuned to what different technology platforms are in vaccines.

Novavax is twofold: one, we have a protein-based nanoparticle technology platform that enables us to develop vaccines for a wide range of diseases, such as COVID. We also have our adjuvant matrix, which is an important part of our technology platform.

Basically, an adjuvant is an ingredient that's added to a vaccine to stimulate a potentially broader, more durable, and more potent response. It can be added to vaccines to potentially lower the cost of goods, side effect profile, and the amount of antigen a vaccine needs.

That's an incredibly important component in vaccine development, and we're finding that our adjuvant, called Matrix M, has broad applicability in a variety of disease areas. We've already proven it in COVID 19. We have an approved vaccine that's on the market, and we also proved it in malaria.

There's a malaria vaccine that utilizes matrix M, and right now we're generating data and working with partners to understand how our matrix potentially improve the immune response of existing vaccines in their portfolios, or the creation of entirely new vaccines altogether.

Fuente: PharmExec.com. Disponible en https://n9.cl/7w955

Intravacc And SynphaBase Announce Strategic Partnership To Advance Conjugate Vaccine Development

Jun 15. The companies will combine their complementary expertise in synthetic oligosaccharides, conjugation process development and GMP vaccine manufacturing to support partners developing next-generation conjugate vaccines

- SynphaBase brings deep expertise in glycochemistry and the application, production, supply and regulatory support of synthetic oligosaccharides for conjugate vaccine development
- Intravacc contributes proven capabilities in conjugation process development, scale-up and GMP production of conjugate vaccines
- The partnership will offer vaccine developers a streamlined route from synthetic oligosaccharide supply to conjugation development and clinical manufacturing

Intravacc, a leading global contract development and manufacturing organization specializing in vaccine and biologics development and manufacturing, and SynphaBase AG, a Swiss contract

research and development organization rooted in glycochemistry and complex molecule synthesis, today announced a strategic partnership to support the development and supply of conjugate vaccines.

Under the partnership, the companies will jointly offer their complementary capabilities to third parties developing conjugate vaccines, as well as to selected Intravacc internal vaccine programs at Intravacc's discretion. The collaboration is designed to provide clients with access to SynphaBase's synthetic oligosaccharide expertise and Intravacc's conjugation development, scale-up and GMP manufacturing capabilities.

Ivo Lemmens, Managing Director of Intravacc, says:

"We are pleased to announce our strategic partnership with SynphaBase. By combining SynphaBase's expertise in synthetic oligosaccharides with Intravacc's capabilities in conjugation process development and GMP vaccine manufacturing, we aim to provide vaccine innovators with an integrated and efficient development pathway for conjugate vaccines."

Arthur Bodenmüller, CEO of SynphaBase, further comments:

"SynphaBase is excited to partner with Intravacc to bring together our complementary strengths in glycochemistry and vaccine development. Synthetic oligosaccharides are an important enabling technology for modern conjugate vaccines, and this collaboration will help developers access the expertise, materials and manufacturing support needed to advance promising vaccine candidates."

This partnership brings together the synergistic strengths of both companies. Intravacc contributes its technical expertise, facilities and capabilities in antigen conjugation process development, scale-up and GMP production and supply of conjugate vaccines. SynphaBase complements this with its expertise in the application, production, supply and regulatory support of synthetic oligosaccharides used in research, clinical development, production and supply of conjugate vaccines.

Through the partnership, SynphaBase may promote Intravacc as a preferred CDMO for conjugate vaccine services, while Intravacc may promote SynphaBase as a preferred supplier within relevant internal or client conjugate vaccine programs. The partnership is non-exclusive, and clients remain free to select the products and services that best meet their development needs.

The collaboration reflects a shared commitment to enabling faster, more efficient development of conjugate vaccines by connecting high-quality synthetic oligosaccharide supply with specialist conjugation and GMP manufacturing expertise.

About Intravacc

Intravacc is a leading global CDMO specializing in vaccine and biologics development and manufacturing for biotech and pharmaceutical partners. Leveraging its cell-culture, bacterial and conjugation platforms and extensive GMP capabilities, Intravacc supports the full development pathway from early-stage research to Phase I/II clinical production. With a strong track record in technology transfer and scalable vaccine solutions, Intravacc enables partners to accelerate timelines, reduce risk and efficiently bring innovative vaccines to the clinic. For more information, visit www.intravacc.nl.

About SynphaBase AG

SynphaBase AG is a Swiss contract research and development organization specializing in bioorganic chemistry, with deep expertise in glycochemistry and the custom synthesis of complex

molecules including glycans, peptides, RNA and conjugates. SynphaBase supports partners through route design, process development and material supply, applying its know-how to help advance complex chemistry programs for the pharmaceutical, biotechnology and life sciences sectors. For more information, visit www.synphabase.ch.

Fuente: OUTSOURCED PHARMA. Disponible en https://n9.cl/c9ha60

WHO and Brazil urge world leaders to finalise Pandemic Agreement to prevent future global health crises

Jun 15. Penned by Brazilian President Luiz Inácio Lula da Silva and WHO chief Tedros Adhanom Ghebreyesus, the message underscored a shared global responsibility to protect humanity from repeating such devastation seen during the COVID-19 pandemic, which claimed up to 20 million lives and wiped out $13 trillion in global economic output.

During the COVID-19 pandemic in 2020, hospitals were overwhelmed, families lost loved ones in isolation and frontline healthcare workers endured unprecedented strain. This collective trauma birthed a promise among nations: to never again face a pandemic unprepared, they wrote.

© WHO/Khaled Mostafa An elderly woman receives her third COVID-19 booster shot at a vaccination centre in Lisbon, Portugal, in 2024. (file)

'An act of hope' in a divided world

Over a year ago, countries made significant strides by adopting the WHO Pandemic Agreement, committing to cooperate more effectively in preventing, preparing for and responding to pandemics.

"In a divided world, that outcome was not to be taken for granted," the letter stated. "It was an act of hope and an act of faith in one another. We write to you now because that hope is not yet fulfilled and because it lies within your hands to help fulfil it."

Standing in the way is the pathogen access and benefit-sharing (PABS) annex, a vital element of the agreement, which remains incomplete, President Lula and Tedros wrote.

This framework is essential for enabling countries to quickly identify and share genetic information of dangerous pathogens so that scientists can develop lifesaving tests, treatments and vaccines.

Without the annex, the Pandemic Agreement cannot formally come into force, leaving the promise unfulfilled, the joint message stated.

Complex challenges remain

The challenges in finalising the PABS annex are complex, particularly around defining how the benefits of shared pathogens are equitably distributed and how governance ensures fairness.

These were the very questions left unresolved previously, contributing to gaps in protection during COVID-19.

Negotiators are scheduled to meet again from 6 to 17 July to close these gaps.

Three critical requests

The appeal highlights three critical requests for global leaders:

Political will at the highest level: Leaders must prioritise finalising the annex and empower negotiators to seek bold consensus. The agreement does not compromise national sovereignty nor does it grant WHO authority to impose measures like lockdowns or vaccination mandates. Those decisions remain firmly with individual nations.

Spirit of equity: The PABS system is built on fairness. Those who share pathogens swiftly must trust that resulting vaccines and treatments will also reach their populations, an approach acknowledging that pandemic prevention is not charity but sound strategy, reducing costs and lives lost by containing outbreaks early. Equitable access must be guaranteed, ensuring clear, stable rules to replace the current case-by-case, crisis-driven process.

A sense of urgency: Scientists estimate a nearly 25 per cent chance of another pandemic within the next decade. Shifting environmental and social factors are creating new hotspots for disease emergence worldwide while biotechnology advances raise risks of accidental or intentional releases. The letter calls for 17 July to be treated as a firm deadline for agreement, signaling global commitment and avoiding dangerous delays.

The next crucial chapter

Current outbreaks, such as Ebola in multiple countries with no approved vaccine, highlight the ongoing risks, they warned.

Reminding readers of the staggering human and economic toll of COVID-19, the letter stated that, by comparison, investing in early outbreak detection and response systems like the PABS framework is modest and essential.

Historically, the world has united to save countless lives by defeating smallpox, pushing polio to near eradication and combating HIV, tuberculosis and malaria.

“Finishing this agreement is not a departure from that legacy,” the letter stated. “It is its natural next chapter, and it is within reach.”

Fuente: UNITED NATIONS NEWS. Disponible en https://n9.cl/5pfd6u

Maternal RSV vaccine shows 68% protection against infant RSV hospitalization

Jun 16. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections and hospitalization in young infants. Maternal vaccination with the RSV prefusion F vaccine was associated with a substantially lower risk of RSV-related hospitalization for respiratory disease in infants, according to a recent study published in JAMA Network Open.

“A real-world US study finds maternal RSVpreF vaccination may help shield newborns from severe RSV illness during their most vulnerable first months of life.”

RSV remains the leading cause of lower respiratory tract disease (LRTD) among infants globally and is responsible for 33 million cases and 3.6 million hospitalizations each year, with 100,000 deaths among under-fives. Approximately half of RSV-linked hospitalizations are in infants below six months, corresponding to a US rate of 24 /1,000 infants below three months with RSV-associated hospitalization.

In 2023, the bivalent RSV prefusion F vaccine was approved for use in pregnant individuals in the United States. It protects against RSV-A and RSV-B. It is intended to reduce the risk of RSV-associated LRTD and severe LRTD in newborns via maternal antibodies. The vaccine is recommended between 32 and 36 weeks and 6 days of gestation.

Study: Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants. Image Credit: Perfect Angle Images / Shutterstock.

The current study aimed to assess the vaccine's real-world effectiveness in this situation. This ongoing study is designed to cover four years of maternal vaccination and RSV-associated ARI and LRTD outcomes in infants.

A retrospective case-control study using a test-negative design was conducted during two RSV seasons from 2023 to 2025. The current cohort included 274 hospitalized infants with ARI, 90 days or younger. All were tested for RSV.

Maternal vaccination rates were compared between babies with RSV (cases) and those without (controls). Vaccine effectiveness against RSV-associated hospitalization of infants with acute respiratory illness (ARI) and LRTD was estimated from birth through 90 days of life.

Cohort Characteristics

The mean age of the 274 infants in the study was 30 days, with 48% being female. Over 60% were White and 14% Black. On average, they were born at 38 weeks. About 16% were born preterm between 34 weeks 0 days and 36 weeks 6 days of gestation. Most were born healthy.

Maternal Vaccination Linked to Reduced Severe RSV Disease in Infants

Of the 274 infants, 83 tested positive for RSV. These babies were more likely to have been born between October and December, at about 74%. They were also more likely to have been born preterm, male, Black, and to have siblings. They were also more likely to live in neighborhoods with higher levels of deprivation.

About 87% of cases had LRTD, compared with 45% in controls. While 34% of cases required intensive care unit (ICU) admission, this was true of only 17% of the controls. Similarly, about 21% of controls required oxygen or respiratory support compared to 68% of cases.

The investigators found that about 30% of the infants were born to prefusion F-vaccine recipients. This proportion was skewed towards the controls, with 37% of controls being born to vaccinated mothers versus 13% of cases.

Maternal Prefusion F Vaccination Associated with Infant Protection

This suggests that maternal vaccination was associated with lower odds of RSV-associated hospitalization among infants with ARI in the test-negative analysis. The estimated effectiveness of the vaccine when administered in pregnancy within the recommended gestational window and at least 14 days before delivery against this outcome was 68% in infants up to 90 days, with a 95% confidence interval of 33% to 85%.

For the same period, the estimated effectiveness against RSV-linked LRTD was 69% with a 95% confidence interval of 26% to 88%.

In the first month of life, the estimated vaccine effectiveness against RSV-linked ARI hospitalization was 74% (95% confidence interval: 25% to 93%).

The results are comparable to those from the key clinical trial that led to approval, and to broader surveillance studies. They are among the earliest real-world evidence that maternal RSV prefusion F vaccination may provide protection against the risk of severe RSV illness requiring hospitalization in the first three months of life. The point estimate was highest during the first month of life, although confidence intervals were wide, and this is also the period of greatest vulnerability.

Strengths and Limitations

The study used a real-world cohort to examine how maternal vaccination reduced infant hospitalizations for RSV-associated ARI. The cohort included preterm or sick infants and those born from multiple pregnancies, indicating the potentially broad utility of protection. The vaccination window was also much narrower than that used in the clinical trial, but yielded a similar magnitude of protection.

Moreover, the investigators used hospitalization data over two RSV seasons following vaccine introduction within a single health system in western Pennsylvania.

However, it has some limitations. It involved a single healthcare system with a small sample. Its observational design precludes causal inference; residual confounding may influence outcomes, though the study was designed to minimize bias from health-seeking behavior and misclassification. The relatively small sample resulted in wide confidence intervals for estimated effectiveness, particularly in subgroup analyses, which were not adequately powered.

Additional studies from other regions are needed to confirm effectiveness estimates and assess the duration of protection. The outcomes of earlier vaccination (allowing more time for antibody development and transplacental transfer) should be determined in larger samples to increase confidence in the findings.

Pfizer supported the study through a collaboration with the University of Pittsburgh, and several authors reported Pfizer employment, stock holdings, or grant support. The paper states that Pfizer reviewed and approved the manuscript but had no role in data collection, management, analysis, or the decision to submit it for publication.

Conclusion

Maternal RSV prefusion F vaccination during late pregnancy was associated with evidence of protection against RSV-related hospitalization in infants 90 days or younger. The findings suggest that this may be an effective strategy for preventing severe RSV disease during early infancy, and thus support current recommendations for maternal RSV immunization.

Fuente: NEWS MEDICAL LIFE SCIENCES. Disponible en https://n9.cl/ucu6t

Could a hantavirus vaccine be on the horizon?

Jun 17. When a rare, lethal virus broke out aboard a cruise ship this May and then scattered across two dozen countries with its passengers, it exposed an uncomfortable gap in the world's defences: there is no licensed vaccine or treatment for Andes hantavirus.

"A single shot of an experimental mRNA vaccine completely protected animals against the deadly Andes hantavirus, even at a fraction of the usual dose."

Now scientists at the University of Texas Medical Branch (UTMB) report that a single dose of an mRNA vaccine gave animals complete protection against the virus.

The finding, published in The Lancet, could offer protection against one of the few hantaviruses able to spread between people.

"Every vaccinated animal remained completely healthy and showed no symptoms or weight loss," said lead author Dr Michelle Meyer.

"When we looked at the tissues from the vaccinated animals a month after infection, the virus was entirely gone."

Why the Andes virus worries scientists

Most hantaviruses spread to people through contact with the droppings, urine or saliva of infected rodents.

Andes virus is the exception as it is the only known member of the hantavirus family that can pass from one person to another through close contact with respiratory secretions, such as coughing.

That capacity for spread between people has driven alarming clusters before, explain the authors.

In the paper, they explain how during the 2018 and 2019 outbreak in Epuyén, Argentina, four successive waves of infection traced back to a single social gathering produced 34 confirmed cases and 11 deaths.

The May 2026 outbreak aboard the Dutch cruise ship MV Hondius, which had departed from Argentina, took that threat global. So far it has caused 13 reported cases and three deaths, but the wider worry is what came next.

Nearly 150 passengers dispersed across 23 countries under a patchwork of quarantine rules, all within a virus incubation window that can stretch to 42 days.

Because people can carry the virus without symptoms before they fall ill, tracing everyone who may have been exposed is a daunting task.

"When we looked at the tissues from the vaccinated animals a month after infection, the virus was entirely gone." - Dr Michelle Meyer, Senior Scientist at the University of Texas Medical Branch.



A transmission electron micrograph of Sin Nombre virus.
Credit: CDC/Cynthia Goldsmith

Inactivated vaccines against other hantaviruses have been used in China and South Korea for decades.

But none protects against Andes virus, and no hantavirus vaccine of any kind is approved in the Americas or Europe.

With nothing licensed by either the US Food and Drug Administration or the European Medicines Agency, an Andes outbreak is precisely the kind of scenario the UTMB team is racing to prepare for.

One dose, full protection

The researchers had already shown that two of their mRNA vaccine candidates could protect animals against Andes virus, but only after two doses given weeks apart.

An international outbreak that moves fast rarely allows that luxury, so the team set out to test whether a single shot would be enough.

The vaccine uses the same basic design that powered the COVID-19 mRNA shots: genetic instructions that teach the body's own cells to make harmless pieces of the virus, in this case two surface proteins that train the immune system to recognise and fight the real thing.

The team gave 30 hamsters a single injection of the vaccine, then exposed them to a lethal dose of Andes virus four weeks later.

This hamster model is the only animal model that closely mirrors the fatal lung disease the virus causes in humans, and infection is almost always deadly: in the unvaccinated control group, by day nine, four of five animals hadn't survived.

In the vaccinated animals, meanwhile, every animal was protected from disease, and when the study ended, no replicating virus could be found in their tissue. The shots triggered detectable antibodies within 14 days, fast by most vaccine standards.

Reassuringly, the vaccine worked even at fractional doses. The team tested three dose levels: 25, 5 and 1 μg. Protection held even at the lowest dose, which still generated antibodies in four of five animals.

The ability to protect with so little vaccine matters because in an outbreak, the number of doses that can be squeezed from a limited supply can decide how many people get protected.

Post-exposure protection

The speed of the immune response opens a second possibility: using the vaccine not just to prevent infection, but to stop it in people who have already been exposed.

Andes virus disease has a median incubation of around 18 days in humans. If a vaccine can stimulate the immune system within two weeks, there may be a window to intervene after exposure but before illness sets in.

"If given quickly to high-risk contacts during an outbreak, such as the Andes virus situation on the cruise ship, the vaccines could theoretically jump-start their immune systems fast enough to intercept the virus, stopping it from replicating and preventing them from getting sick or spreading it further," said Dr Alexander Bukreyev, who heads UTMB's Laboratory of Viral Pathogenesis and Vaccine Development.

Used this way, a quick shot could double as an emergency tool to box in an outbreak, though the researchers are clear that this remains a hypothesis to be tested, not an established use.

From hamsters to humans

These results, encouraging as they are, come with the caveats that accompany any preclinical study.

The work was done in animals, not people. The team measured the virus only in the liver, so they cannot rule out its presence elsewhere, such as the lungs, though in this model liver levels reliably track with those in the lungs.

The crucial next step is human clinical trials. With backing from the US National Institutes of Health, the UTMB team says it is working to speed the single-dose vaccines toward testing in people.

Fuente: GAVI. Disponible en https://n9.cl/vis0n

Sinergium Biotech consolidará a la Argentina como proveedor regional de vacunas de alta complejidad

18 jun. El titular de la cartera sanitaria recorrió la planta en la que se producen las vacunas antigripales y neumocócicas para el país y que se exportarán a toda la región.

El ministro de Salud de la Nación, Mario Lugones, visitó las instalaciones de Sinergium Biotech para conocer los avances de dos proyectos estratégicos para el desarrollo biotecnológico del país. Por un lado, la producción local de vacunas antigripales que consolidarán al país como proveedor regional de vacunas de alta complejidad. Por el otro, la construcción de una nueva planta para el desarrollo y escalado de vacunas y terapias basadas en ARN mensajero (mRNA).

Este año, Sinergium ya ha producido y exportado más de 18 millones de dosis de la vacuna antigripal con ingresos que superaron los 60 millones de dólares. Además, prevé alcanzar los 120 millones de dólares en lo que resta del 2026, gracias al acuerdo firmado en 2025 con Pfizer y OPS para producción y exportación de la vacuna antineumocócica a través de los Fondos Rotatorios Regionales (FRR), posicionándose como un proveedor estratégico desde la Argentina para la región.

A partir del acuerdo con CSL Seqirus y la Organización Panamericana de la Salud (OPS), Sinergium Biotech comenzará a producir vacunas antigripales para abastecer al país y a toda la Región de las Américas a través de los FRR de la OPS. El proyecto permitirá generar empleo altamente calificado, fortalecer la cadena de valor local y aumentar la capacidad exportadora nacional en 100 millones de dólares anuales.

Como parte de su visita, Lugones también recorrió las obras de la nueva planta de producción piloto de vacunas basadas en ARN mensajero, con una inversión de 20 millones de dólares en dos etapas. El proyecto se enfoca en la investigación, el desarrollo y escalada de vacunas y otras tecnologías sanitarias para la prevención de enfermedades respiratorias y patógenos emergentes y

reemergentes, incluyendo influenza, COVID-19, virus sincicial respiratorio y hantavirus en colaboración con ANLIS Malbrán, entre otras líneas de investigación.

Como parte de este proyecto, la ANLIS Malbrán actuará además como institución receptora de la transferencia tecnológica vinculada a la producción de lípidos estratégicos y nanopartículas lipídicas (LNP), insumos esenciales para la formulación de vacunas de mRNA. Su participación contempla también la incorporación de capacidades para la caracterización, evaluación y futura producción de estos componentes bajo estándares de Buenas Prácticas de Manufactura Internacional (GMP, por sus siglas en inglés), así como el fortalecimiento de recursos humanos, infraestructura y plataformas tecnológicas.

Cabe destacar que el desarrollo de una vacuna de ARN mensajero contra hantavirus constituye una de las iniciativas más innovadoras teniendo en cuenta que esta enfermedad no cuenta con vacunas aprobadas y registra tasas de letalidad superiores al 30% en América. El proyecto incluye el desarrollo de cuatro candidatos vacunales que serán evaluados en modelos experimentales.

En conjunto, el proyecto combina infraestructura, pipeline y alianzas internacionales para consolidar una plataforma sostenible, escalable y de alto valor estratégico para la región. La primera etapa, que se encuentra en desarrollo, contempla la construcción de una planta destinada a investigación, desarrollo y escalado piloto de vacunas y terapias basadas en mRNA y nanopartículas lipídicas (LNP). En una segunda etapa, se buscará desarrollar capacidades completas de producción bajo estándares GMP y permitir la fabricación de lotes clínicos y comerciales.

La visita del Ministro de Salud de la Nación permitió conocer de primera mano proyectos que fortalecen las capacidades científicas, tecnológicas e industriales del país y que consolidan la cooperación entre el sector público y privado. En el marco del proceso de estabilización económica, previsibilidad y apertura impulsado por el Gobierno nacional, ambas iniciativas contribuyen a posicionar a la Argentina como un actor relevante en el desarrollo y producción de tecnologías sanitarias estratégicas para la región, atraer inversiones y ampliar el acceso a innovaciones sanitarias.

Fuente: PMFARMA Disponible en https://n9.cl/f4gfm

Merck logra aval de la FDA para usar Capvaxive en niños y adolescentes con alto riesgo

18 jun. La FDA amplió la indicación de Capvaxive, la vacuna neumocócica de Merck, para aplicarla en una sola dosis a niños y adolescentes de 2 a 17 años con enfermedades crónicas —como cardiopatías, afecciones respiratorias, renales, hepáticas o diabetes— que ya completaron el esquema infantil estándar, pero siguen con mayor riesgo de infecciones graves por neumococo.

Capvaxive se abre paso más allá de los adultos

Capvaxive es una vacuna conjugada diseñada para proteger frente a múltiples serotipos de la bacteria *Streptococcus pneumoniae*, responsable de neumonía, meningitis e infecciones graves de la sangre.

Hasta ahora, el producto estaba aprobado en Estados Unidos solo para adultos, tras la autorización de la FDA en junio de 2024 para la prevención de enfermedad neumocócica invasiva y neumonía en mayores de 18 años.

La nueva luz verde del regulador se centra en un grupo particularmente vulnerable: "pacientes de 2 a 17 años que ya completaron el calendario de vacunación neumocócica infantil, pero presentan enfermedades crónicas como patologías cardíacas, pulmonares, renales, hepáticas o diabetes, que incrementan su riesgo de infecciones graves".

En estos casos, Capvaxive no reemplaza a las vacunas infantiles, sino que "se administra como dosis única" suplementaria, con la intención de complementar la protección obtenida con los esquemas previos.

Qué mostró el ensayo y cómo se compara con PPSV23

La decisión de la FDA se basó en un ensayo de fase avanzada con 874 participantes, en el que Capvaxive "igualó o superó" la respuesta inmunitaria de PPSV23, la vacuna neumocócica polisacárida más antigua utilizada como refuerzo en pacientes de riesgo.

Según Merck, en este estudio los efectos adversos "fueron en general de corta duración", alineados con lo esperado para este tipo de inmunizaciones, lo que respalda su perfil de seguridad en población pediátrica con comorbilidades.

PPSV23 ha sido durante años el estándar en refuerzos para adultos y ciertos niños con condiciones médicas de base, pero la nueva opción de 21 valencias introduce una cobertura más amplia frente a serotipos de neumococo que circulan hoy con mayor frecuencia.

En el contexto de niños y adolescentes ya vacunados en la infancia, la ampliación de Capvaxive aporta una herramienta adicional para cerrar brechas de protección en quienes, por enfermedades crónicas, tienen más probabilidades de desarrollar cuadros graves.

Niños crónicos en el centro de la estrategia preventiva

La enfermedad neumocócica se transmite por secreciones respiratorias —saliva y mucosidad— y puede derivar en neumonía, meningitis o infecciones sanguíneas potencialmente mortales.

Los niños pequeños menores de 5 años y los adultos de 50 años o más se consideran grupos de mayor riesgo, pero los chicos y adolescentes con patologías crónicas también cargan con una probabilidad incrementada de hospitalización y complicaciones.

Al focalizar esta expansión de indicación en pacientes de 2 a 17 años con enfermedades cardíacas, pulmonares, renales, hepáticas o diabetes, la FDA reconoce ese riesgo adicional y habilita un uso más dirigido de Capvaxive como complemento de los esquemas estándar.

Para sistemas de salud y pagadores, la posibilidad de agregar una dosis única de una vacuna de espectro amplio en un subgrupo bien definido abre la puerta a estrategias de inmunización más personalizadas, con potencial para reducir internaciones y costos asociados a neumonía y otras infecciones graves en población pediátrica de alto riesgo.

En un mercado global de vacunas neumocócicas donde la competencia entre formulaciones y valencias es intensa, la entrada de Capvaxive en el segmento de niños y adolescentes de riesgo consolida a Merck como un actor clave en la inmunización frente a *Streptococcus pneumoniae* y refuerza la tendencia a ampliar la protección más allá de la población adulta.

Fuente: CURE COMPASS. Disponible en https://n9.cl/w8v802

Ministerio de Salud no tiene vacunas contra la COVID-19, mientras repuntan casos en Guatemala

18 jun. En los dos hospitales de referencia del país, el Roosevelt y el General San Juan de Dios, los casos de COVID-19 han aumentado en las últimas semanas. El reporte se acerca al centenar de personas contagiadas entre pacientes y personal sanitario. Pero, fuera de lo que sucede en estos centros, no hay una actualización oficial de casos.

Desde mayo del 2023, la Organización Mundial de la Salud declaró a la COVID-19 como una enfermedad endémica, con lo que confirmó que el virus se volvía estacional. Guatemala se sumó a esa declaración en diciembre de ese año.

En las épocas frías, la enfermedad tiene mayor presencia en el país, y la recomendación de los médicos es la vacunación anual contra el virus. Sin embargo, actualmente la existencia del biológico en los servicios de salud pública es nula. Se consultó a varios y se indicó que no se cuenta con el biológico.

El Ministerio de Salud informó que la disponibilidad de la vacuna obedece a criterios técnicos, epidemiológicos y de abastecimiento nacional.

Agregó que, luego de la emergencia sanitaria, el monitoreo del covid-19 se mantiene en el país como parte de la vigilancia de enfermedades respiratorias.

Por ahora no hay vacunas, pero Salud señaló que se prevé el ingreso de dosis durante el tercer trimestre del año, con el fin de fortalecer la prevención en la población, conforme la planificación del Programa de Inmunizaciones de la cartera.

La primera dosis de la vacuna contra el covid-19 se aplicó el 25 de febrero del 2021, y las últimas dosis ingresaron al país en diciembre del 2023, con fecha de caducidad en mayo del 2024. Desde entonces, el sistema de salud pública no cuenta con el biológico.

El consolidado del Ministerio de Salud de dosis administradas contra el coronavirus en el país es de 20 millones 491 mil 871, cifra que incluye primeras y segundas dosis, refuerzos y vacunas adicionales.

Nancy Sandoval, jefa del Servicio del Departamento de Medicina Interna de la Unidad de Infectología del Hospital Roosevelt de Guatemala y vicepresidenta de la Asociación Panamericana de Infectología (API), indicó que el repunte de casos que se registra en el país ocurre por la disminución de la inmunidad contra la enfermedad entre la población, adquirida por infección natural o por vacunación; la circulación de nuevas variantes; la reducción de las medidas de vigilancia, y porque la población “subestima” la circulación comunitaria del virus.

Si bien las medidas básicas de prevención son importantes, como el lavado de manos, el uso de alcohol en gel, cubrirse al toser o estornudar, ventilar los espacios, usar mascarilla y aislarse voluntariamente ante síntomas de la enfermedad, la infectóloga indica que la vacunación es la acción “más eficaz” para evitar cuadros graves, hospitalización y muerte.

Por ello, recomienda mantener al día el esquema de vacunación contra el covid-19, principalmente en el personal de salud, las personas mayores de 50 años, quienes padecen enfermedades crónicas o inmunosupresión, las embarazadas y los niños con factores de riesgo.

Fuente: PRENSA LIBRE. Disponible en https://n9.cl/z9esf

República Democrática del Congo, entre la fiesta del fútbol y un brote de ébola que podría ser el peor de la historia

19 jun. Al mismo tiempo que miles de personas en la República Democrática del Congo se reunieron para el debut de su selección en el Mundial y celebraron en las calles el empate 1 a 1 contra Portugal, *Africa News* registró que se cumple un mes desde que la Organización Mundial de la Salud (OMS) declaró como emergencia de salud pública de importancia internacional el brote de ébola que afecta tres provincias del oeste del país. Funcionarios advierten que podría convertirse en la peor epidemia registrada de esa enfermedad, superando la que afectó a países de África Occidental entre 2014 y 2016 con más de 11.000 decesos.

Panorama: La diseminación de la rara variante Bundibugyo ya produjo más de 800 casos confirmados (con 181 decesos) y los trabajadores de la salud carecen de personal necesario para identificar los casos sospechosos, ambulancias para transportarlos e incluso materiales de construcción para edificar salas de aislamiento, reportó Reuters. Tampoco se conoce la verdadera magnitud del brote: "Solo estamos monitoreando a 12 % de nuestra población [que estuvo en contacto con los casos confirmados]. Esto es un indicador importante para nosotros", advirtió el Dr. Jean Kaseya, maestro en salud pública, director general de los Centros de Prevención y Control de Enfermedades (CDC) de África. También hay grave escasez de equipos de sepelio y de equipos de protección personal. "Si no detenemos el brote, muy pronto será peor que lo que tuvimos [antes]". Uganda también tiene alrededor de dos decenas de casos confirmados, cinco por transmisión local y el resto importados.

Vacuna: En tanto, vacunas desarrolladas por la Universidad de Oxford del Reino Unido, y Moderna contra la variante Bundibugyo del ébola, podrían entrar en la fase 1 de ensayos clínicos a partir de julio y quizá los ensayos de campo comenzarían en los próximos meses, declaró Richard Hatchett, director de la Coalición para las Innovaciones en la Preparación ante Epidemias (CEPI).

Fuente: MEDSCAPE. Disponible en https://n9.cl/15kte

FDA respalda primera vacuna antigripal que utiliza ARNm, tecnología que fue clave para poner fin a la pandemia de COVID-19

19 jun. Los estudios han mostrado que la vacuna de Moderna ha reducido los casos de gripe en un 27 % en un estudio de 40,000 participantes mayores de 50 años.

El comité asesor independiente de la Administración de Alimentos y Medicamentos (FDA) votó por unanimidad a favor de la vacuna mFlusiva de Moderna, afirmando que sus beneficios superan los riesgos para los grupos de edad de 50 a 64 años y 65 años o más, lo que marca un paso importante hacia la aprobación final que se espera en agosto.

Los estudios han mostrado que la vacuna de Moderna ha reducido los casos de gripe en un 27 %

en un estudio de 40,000 participantes mayores de 50 años, generando también una fuerte respuesta inmune en personas de 65 años o más, en comparación con las vacunas existentes.

La tecnología de ARNm permite una adaptación más rápida a las cepas mutadas del virus de la gripe, una tecnología que fue clave para poner fin a la pandemia de COVID-19. Esta posición del Comité Asesor de Vacunas y Productos Biológicos Relacionados (VRBPAC) está en abierta oposición a medidas de la administración Trump, que en agosto pasado canceló 500 millones de dólares de fondos que serían destinados a 22 proyectos de investigación para crear nuevas vacunas de ARNm contra enfermedades respiratorias que podrían desencadenar otra emergencia sanitaria.

Las vacunas con este tipo de tecnología tienen la ventaja de que se fabrican más rápidamente que otros tipos, algo que, según los expertos, podría ser útil si el virus de la gripe, con su capacidad de cambiar de forma, muta de tal manera que requiera la producción repentina de nuevas dosis.

“Disponer de esta tecnología nos coloca en una mejor posición para estar preparados ante la aparición de nuevas cepas en el futuro”, dijo la Dra. Flor Muñoz-Rivas, del Texas Children’s Hospital, una de las asesoras de la FDA.

“Creemos que el ARNm-1010 tiene el potencial de ofrecer una nueva e importante opción para la prevención de la gripe estacional y demostrar aún más la versatilidad de nuestra plataforma de ARNm”, declaró Stephane Bancel, MBA, MSc, director ejecutivo de Moderna, en un comunicado de prensa. “Esperamos seguir colaborando con la FDA mientras completa su revisión”, recalcó.

Preparación para la temporada de gripe

Se anticipa que, si es aprobada, la vacuna mFlusiva asegurará una mayor disponibilidad de dosis actualizadas en años donde las predicciones de cepas son inciertas.

Moderna planea un estudio de seguimiento que incluirá a 400,000 personas mayores de 65 años para continuar evaluando la seguridad y efectividad de la vacuna.

La solicitud de Moderna enfrentó desafíos regulatorios en el pasado, incluyendo críticas sobre sus métodos de comparación de vacunas. A pesar de esto, se espera que la FDA avance con una evaluación más positiva, considerando la importancia del desarrollo de esta vacuna en el contexto de la salud pública.

Comprendiendo la tecnología ARNm

La tecnología del ARN mensajero (ARNm) es una de las innovaciones biomédicas más importantes de las últimas décadas. Su principio básico es sencillo y elegante: en lugar de administrar directamente una proteína terapéutica o un virus atenuado para enseñar al sistema inmune, se entrega la instrucción genética necesaria para que las propias células del paciente construyan la proteína deseada.

El ARNm actúa como un manual de instrucciones transitorio que las células leen para sintetizar una proteína específica; esa proteína puede servir como vacuna, como terapia génica temporal o como herramienta para modular procesos biológicos.

Una de las ventajas clave del ARNm es su velocidad y flexibilidad. Las secuencias de ARNm se diseñan y sintetizan rápidamente en laboratorio, lo que permite respuestas ágiles frente a nuevos patógenos o para personalizar tratamientos.

En vacunas, por ejemplo, una secuencia de ARNm codifica una proteína del patógeno (como la proteína de superficie de un virus). Al administrarse, las células producen esa proteína, el sistema

inmune la reconoce como extraña y genera respuestas defensivas —anticuerpos y células T— que confieren inmunidad sin exponer al organismo al patógeno completo.

Para que el ARNm sea útil en el cuerpo, tiene que sortear varios desafíos: es una molécula inestable y fácilmente degradable por enzimas; además, debe entrar eficientemente en las células.

Más allá de las vacunas, las aplicaciones potenciales del ARNm son amplias. En terapia contra el cáncer, por ejemplo, se diseña ARNm que codifica antígenos tumorales específicos para estimular una respuesta inmune dirigida contra las células tumorales. En enfermedades genéticas, se puede usar ARNm para proporcionar una versión funcional temporal de una proteína faltante o defectuosa, evitando algunas complicaciones de las terapias génicas permanentes. También existen investigaciones que exploran el uso del ARNm para producir medicamentos directamente en el organismo, o para regeneración tisular mediante la expresión temporal de factores de crecimiento.

Fuente: LA OPINIÓN. Disponible en https://n9.cl/qzh62w

Brasil comienza vacunación infantil con nuevo inyectable neumocócico

20 jun. La incorporación del nuevo inyectable al Programa Nacional de Inmunizaciones representa un avance en la estrategia de prevención de infecciones respiratorias y otras afecciones potencialmente mortales que impactan principalmente a menores de edad, ancianos y personas con sistemas inmunológicos debilitados.

"El Ministerio de Salud de Brasil comenzó hoy la aplicación de la vacuna neumocócica conjugada 20-valente (Pneumo 20) en niños, con el objetivo de ampliar la protección contra enfermedades graves causadas por la bacteria *Streptococcus pneumoniae*."

Agencia Brasil agregó que Pneumo 20 sustituirá de manera progresiva a la versión neumocócica 10-valente utilizada hasta ahora en la red pública de salud.

Según el Ministerio del sector, el nuevo preparado ofrece cobertura contra 20 serotipos de la bacteria neumococo y amplía significativamente la protección frente a variantes responsables de enfermedades invasivas y complicaciones respiratorias.

Entre las patologías prevenibles mediante la inmunización figuran neumonías, meningitis, otitis, sinusitis y septicemias.

Autoridades sanitarias destacan que la ampliación de la cobertura vacunal permitirá reducir hospitalizaciones, secuelas y fallecimientos asociados a estas enfermedades.

La nueva vacuna será administrada de forma gratuita a través del Sistema Único de Salud (SUS) y estará destinada inicialmente a niños menores de un año, siguiendo el calendario nacional de vacunación.

El esquema prevé la aplicación de dosis durante los primeros meses de vida y una de refuerzo posteriormente, conforme a las orientaciones del programa de inmunización.

Tal decisión se basa en evidencias científicas y recomendaciones técnicas que demuestran una mayor capacidad de protección frente a los serotipos actualmente en circulación.

Asimismo, la actualización permitirá mantener la eficacia de las estrategias de prevención ante los cambios observados en el comportamiento epidemiológico de la bacteria.

Pneumo 20 forma parte de los esfuerzos gubernamentales para fortalecer las coberturas vacunales y ampliar el acceso a tecnologías más avanzadas en salud pública.

Brasil ha impulsado en los últimos tiempos diversas acciones para recuperar los índices de inmunización infantil, afectados por la disminución de la adhesión a las campañas de vacunación durante la pandemia de COVID-19.

Millones de niños, recalcó el Ministerio de Salud, podrán beneficiarse anualmente de la nueva vacuna, con lo cual disminuirá la circulación de cepas peligrosas del neumococo y se fortalecerá la capacidad del sistema sanitario para enfrentar enfermedades respiratorias.

Fuente: Prensa Latina. Disponible en https://n9.cl/vo9g5o

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2026/06/11"[Date - Publication] : "2026/06/21"[Date - Publication])) 460 records

COVID-19 Vaccines.

[No authors listed]2026 Jun 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–.PMID: 33355732

Progress toward an Epstein-Barr virus vaccine.

Laferriere C, Bland E, Channon W, Young L.Expert Rev Vaccines. 2026 Dec;25(1):2686294. doi: 10.1080/14760584.2026.2686294. Epub 2026 Jun 11.PMID: 42253055

Human vaccine responses regulated by parallel cytokine pathways.

Chen G, Guo J, Heath J, Prestwood TR, Kwon WJ, Smith AR, Nguyen TT, Kathuria KR, Sola E, Sangare A, Mallajosyula V, Furuichi Fong R, Mohsin A, Chen L, Siva O, Padilla C, Tan M, Dekker CL, Grant P, Lu Y, Greenberg HB, Robinson WH, Blish C, Shen-Orr SS, Salehi A, Maecker HT, Khatri P, Utz PJ, Chien YH, Davis MM.Nat Immunol. 2026 Jun 12. doi: 10.1038/s41590-026-02547-x. Online ahead of print.PMID: 42286357

Beyond Strain-Specific Immunity: Conserved Antigenic Targets, Emerging Platforms, and Translational Challenges in Universal Influenza and Pan-Coronavirus Vaccine Development.

Ikrar T, Muchsin W, Sophian A.J Virol Methods. 2026 Jun 21:115432. doi: 10.1016/j.jviromet.2026.115432. Online ahead of print.PMID: 42324038

Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.

Skelly AN, Gristick HB, Li H, Gavor E, Connell AJ, Kreider EF, Marchitto L, Hogarty MP, Newby ML, Allen JD, Liu W, West AP Jr, Ayyanathan K, Campion MS, Winters K, Gordon CG, Osbaldeston RA, Akeley MJ, Lewis E, Li Y, Singh A, Cruickshank K, Park Y, Zhao C, Li X, Amereh K, Van Itallie E, Carey JW, Albertus A, DeLaitsch AT, Keeffe JR, Lituchy MG, Walsh AA, Morris DJ, Habib R, Bibollet-Ruche F, Mishra N, Avillion G, Koranda NS, Plante SJ, Martella CL, Lora J, Wang EJD, Lewis MG, Martin MA, Nussenzweig MC, Seaman MS, Irvine DJ, Wiehe KJ, Haynes BF, Wagh K, Korber B, Andrabi R, Crispin M, Weissman D, Bjorkman PJ, Hahn BH, Shaw GM.Science. 2026 Jun 18;392(6804):eaec6396. doi: 10.1126/science.aec6396. Epub 2026 Jun 18.PMID: 42096521

Self-reported vaccine hesitancy and refusal among parents of children with autism spectrum disorder and other developmental delays: a cross-sectional study.

Kara-Aksay A, Özyurt G, Emir B, Özgül-Katırcıoğlu D, Erten-Almak T.Eur J Pediatr. 2026 Jun 19;185(7):508. doi: 10.1007/s00431-026-07179-9.PMID: 42319500

Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial.

Ostergaard L, Czajka H, Roque-Guerrero L, Maguire JD, Pregaldien JL, Zolotas L, Moughan B, Maansson R, O'Neil R, Balmer P, Jodar L, Gruber WC, Anderson AS, Scott DA, Beeslaar J.Lancet Child Adolesc Health. 2026 Jun 18:S2352-4642(26)00095-7. doi: 10.1016/S2352-4642(26)00095-7. Online ahead of print.PMID: 42314722

Emerging lipids-based adjuvant delivery technologies for vaccines.

Dhuri K, Ubhe A.Vaccine. 2026 Jun 20;84:128662. doi: 10.1016/j.vaccine.2026.128662. Epub 2026 May 6.PMID: 42097105

An HIV vaccine blueprint.

Binley J.Science. 2026 Jun 18;392(6804):1241-1242. doi: 10.1126/science.aei3106. Epub 2026 Jun 18.PMID: 42313978

An mRNA-LNP vaccine expressing TP0435 provides protective immunity in rabbits against Treponema pallidum challenge.

Lu Z, Lu Y, Liu D, Du F, Wu Q, Liao G, Wu Y, Zhang RL, Zhou J, Wang QQ.Emerg Microbes Infect. 2026 Dec;15(1):2685927. doi: 10.1080/22221751.2026.2685927. Epub 2026 Jun 21.PMID: 42324733

mRNA-based influenza vaccine expands the B cell response breadth in humans.

Matz HC, Yu TG, Dixit K, Kikawa C, Zhou JQ, Pena Alzua G, Peyton L, Madsen A, Han F, Farrell AG, Hoelzl R, Schmitz AJ, Horvath SC, Keplinger HK, Strnad BS, Hoegger MJ, Middleton WD, Klebert MK, Lin NH, Nachbagauer R, Krammer F, Paris R, Bloom JD, Turner JS, Presti RM, Lee J, Ellebedy AH.Nat Immunol. 2026 Jun 15. doi: 10.1038/s41590-026-02569-5. Online ahead of print.PMID: 42297975

Examining the whole-cell pertussis vaccine scare and its repercussions.

Elliman DA, Bedford HE, Ross EM.Arch Dis Child. 2026 Jun 18:archdischild-2026-330511. doi: 10.1136/archdischild-2026-330511. Online ahead of print.PMID: 42315294

Consultation report - gonococcal immunoassays and standards for vaccine development.

MacLennan CA, Davis P, Gottlieb SL, Seib KL, Harrison OB, Duncan JA, Gorringe A, Criss AK, Jerse A, Russell MW, Isbrucker R, Kaminski RW, Connolly K, Vipond C, Belcher T, Campbell H, Delany-Moretlwe S, Finco O, Wilson S, Vichos I, Rhyne P, Pizza M, Deal C, Bash MC, Stickings P.Vaccine. 2026 Jun 20;86:128694. doi: 10.1016/j.vaccine.2026.128694. Epub 2026 May 22.PMID: 42176439

Barriers to dengue vaccine uptake in international travelers: a mixed-methods study.

Charoenwisedsil R, Lawpoolsri S, Rattanaumpawan P, Ruenroengbun N, Flaherty GT, Parker DM, Ngamprasertchai T.Expert Rev Vaccines. 2026 Dec;25(1):2689612. doi: 10.1080/14760584.2026.2689612. Epub 2026 Jun 21.PMID: 42289086

Advances in the development of malaria vaccines.

Sorgho H, Rouamba T, Natama HM, Tinto H.BMJ. 2026 Jun 15;393:e084166. doi: 10.1136/bmj-2025-084166.PMID: 42297417

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

Agrawal N, Ates LS, Schille SA, Chaturvedi A, Vogt J, Vukovic N, Dulberger CL, Vogel AB, Diekmann J, Diken M, Şahin U.Nat Immunol. 2026 Jun 12. doi: 10.1038/s41590-026-02545-z. Online ahead of print.PMID: 42286358

Engagement Trends in Online Vaccine Content: Longitudinal YouTube Study.

Tizzani M, Mejova Y.J Med Internet Res. 2026 Jun 19;28:e88519. doi: 10.2196/88519.PMID: 42320022

Targeting Herpesvirus Recombination Proteins for Antiviral Therapy.

Wright DL, Weller SK.Annu Rev Virol. 2026 Jun 16. doi: 10.1146/annurev-virology-100424-125623. Online ahead of print.PMID: 42302262

Antifungal vaccine development: where we are, where we are headed.

Janeczko M, Kubiński K, Wawiórka L.Vaccine. 2026 Jun 20;86:128766. doi: 10.1016/j.vaccine.2026.128766. Epub 2026 May 27.PMID: 42202425

Long-term protection following a primary series of hepatitis B vaccine in Alaska Native children and adults.

Steinberg J, Blake I, Stevenson T, Wheelock H, Bruden D, Townshend-Bulson L, Klejka J, Peterson M, Cartwright EJ, Drobeniuc J, Scobie HM, Bruce MG, Fischer M, McMahon B.Hepatol Commun. 2026 Jun 19;10(7):e0978. doi: 10.1097/HC9.0000000000000978. eCollection 2026 Jul 1.PMID: 42319091

Bridging Science and Society: Public Engagement as a Catalyst for Infectious Disease Control and Prevention.

Eberl M, Pérez-Gracia MT.Immunol Cell Biol. 2026 Jun 11. doi: 10.1111/imcb.70139. Online ahead of print.PMID: 42276823

Accelerating *Shigella* vaccines: from decades of research to global access.

Tilahun ST, Kim SB, D'Cor NA, Cowden J, Saluja T.Expert Rev Vaccines. 2026 Dec;25(1):2686291. doi: 10.1080/14760584.2026.2686291. Epub 2026 Jun 11.PMID: 42249601

Corneal Lesions Associated With Feline Herpesvirus-1 Modified Live Vaccine Strain F2 in Two Cats.

Suga Y, Maehara S, Saito A, Kitamura Y, Kirisawa R.Case Rep Vet Med. 2026 Jun 17;2026:8387185. doi: 10.1155/crve/8387185. eCollection 2026.PMID: 42328412

Advancing protozoan vaccine research: A review of promising candidates and emerging technologies.

Subudhi M, Suresh A, Singh S, Ramesh S, Sharma P.Microb Pathog. 2026 Jun 11;218:108627. doi: 10.1016/j.micpath.2026.108627. Online ahead of print.PMID: 42276531

Human monoclonal antibodies from Donors Vaccinated with Recombinant Vaccinia Vaccine Targeting A35 and B6 Effectively Inhibit Orthopoxvirus Spread and Infection.

Zhang J, Hao Y, Li D, Shen X, Song H, Shi Y, Wang S, Wang S, Liu Y.Antiviral Res. 2026 Jun 21:106466. doi: 10.1016/j.antiviral.2026.106466. Online ahead of print.PMID: 42323973

Global determinants of dengue vaccine acceptance: An updated systematic review and meta-analysis.

Arriaga-Izabal D, Morales-Lazcano F, Angulo-Zamudio UA, Canizalez-Román A, León-Sicairos N.Public Health. 2026 Jun 11;257:106350. doi: 10.1016/j.puhe.2026.106350. Online ahead of print.PMID: 42275853

Beyond the Immunization Schedule: Unmasking Vaccine Failure in a Child With Down Syndrome.

Buchanan SB, Terry M.Case Rep Pediatr. 2026 Jun 19;2026:9928987. doi: 10.1155/crpe/9928987. eCollection 2026.PMID: 42328352

Combination adjuvants: clinical value and mechanisms of action.

Madelon N, Didierlaurent AM.Curr Opin Virol. 2026 Jun 19;76:101564. doi: 10.1016/j.coviro.2026.101564. Online ahead of print.PMID: 42320106

Vaccination strategies for responding to public health emergencies of infectious diseases.

Wang Y, Cui F, Lu QB.Vaccine. 2026 Jun 11;83:128642. doi: 10.1016/j.vaccine.2026.128642. Epub 2026 Apr 28.PMID: 42054722

Caregiver COVID-19 vaccine status and its influence on pediatric vaccination decisions in a US cohort.

Ricke IJ, Ward C, Spaulding AB, Sherwood NE, Nguyen RHN.Vaccine. 2026 Jun 17;88:128847. doi: 10.1016/j.vaccine.2026.128847. Online ahead of print.PMID: 42308977

Aptamer-based Salmonella enteritidis-inactivated vaccine injected intradermally elicits local leukocyte recruitment and mucosal immunity in broiler chickens.

Uribe-Diaz S, Omolewu AI, Santamaria JM, Beck CN, Stein A, Marcon R, Vuong CN, Erf GF, Hargis BM, Kwon YM.Poult Sci. 2026 Jun 17;105(10):107311. doi: 10.1016/j.psj.2026.107311. Online ahead of print.PMID: 42330764

Preparation and comparative evaluation of conjugate and whole-cell killed vaccine candidates against Salmonella enterica serovar Typhimurium.

Ahmad A, Yousaf Z, Naeem M, Yasin M, Saleemi MK, Tahir MW, Raza QS, Afzal F, Karamat RS, Ambreen M, Sarwar Y, Iqbal M, Ali A.Vaccine. 2026 Jun 11;83:128601. doi: 10.1016/j.vaccine.2026.128601. Epub 2026 May 5.PMID: 42090745

Development of canine parvovirus-2-based recombinant pseudoviruses expression system: a potential vaccine platform.

Miao B, Du Q, Yang L, Yan J, Tu F, Jiang Y, Xu N, Chen S, Huang Y, Tong D.Vet Res. 2026 Jun 18;57(1):110. doi: 10.1186/s13567-026-01789-9.PMID: 42316335

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Norman FF, McGuinness SL, Chen LH.Curr Opin Infect Dis. 2026 Jun 11. doi: 10.1097/QCO.0000000000001211. Online ahead of print.PMID: 42296464

Immunogenicity and safety of Sabin-strain inactivated poliovirus vaccine in infants: a systematic review and meta-analysis.

Hussain M, Hassan M, Athar M, Khan S, Azam MT, Rathi D, Nawaz J.Vaccine. 2026 Jun 11;83:128643. doi: 10.1016/j.vaccine.2026.128643. Epub 2026 Apr 29.PMID: 42060979

Not just another shot: Tailoring vaccination in the era of modern liver transplantation.

Papic N, Kosuta I, Ljubas D, Vrsaljko N, Sesa V, Domislovic V, Ahsan S, Mrzljak A.World J Transplant. 2026 Jun 18;16(2):118012. doi: 10.5500/wjt.v16.i2.118012.PMID: 42281865

Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.

Bouzidi HS, De Lamballerie X, Touret F.Emerg Microbes Infect. 2026 Dec;15(1):2686471. doi: 10.1080/22221751.2026.2686471. Epub 2026 Jun 21.PMID: 42253092

In-line Raman spectroscopy real-time glucose prediction method for commercial pneumococcal vaccine drug substance fermentation manufacturing process control.

Thomas GP, Marks BC, Alvarado-Hernandez BB, Woodling M, O'Connor J, Ortiz R, Higgins J, Shanter J.Biotechnol Prog. 2026 Jun 21:e88532. doi: 10.1002/btpr.88532. Online ahead of print.PMID: 42324489

Inside the Push for a Fentanyl Vaccine.

Schweitzer K.JAMA. 2026 Jun 12. doi: 10.1001/jama.2026.6392. Online ahead of print.PMID: 42284036

Is the impact of malaria infection on immune memory of a clinical concern?

Yui K, Macalinao ML, Hafalla J.Expert Rev Clin Immunol. 2026 Jun 14. doi: 10.1080/1744666X.2026.2688976. Online ahead of print.PMID: 42289357

Conjugate vaccine technology enhances responses to influenza virus.

Myburgh L, van Loon K, Koetsier J, Hansen Q, Huijbers EJM, van Beijnum JR, Griffioen AW.Vaccine. 2026 Jun 20;86:128728. doi: 10.1016/j.vaccine.2026.128728. Epub 2026 May 22.PMID: 42172691

Impact of standing orders on vaccine uptake: A systematic review.

Ellingson MK, Sudarsanam V, Goddard K, Tomar A, Nachman S, Brewer NT.Vaccine. 2026 Jun 20;84:128664. doi: 10.1016/j.vaccine.2026.128664. Epub 2026 May 8.PMID: 42105399

Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.

Soroush Fard A, Kalantar K, Teimoori A, Barati M, Arezumand R, Fani M.Hum Vaccin Immunother. 2026 Dec;22(1):2686506. doi: 10.1080/21645515.2026.2686506. Epub 2026 Jun 11.PMID: 42277989

Perspectives on chikungunya vaccinology: from traditional platforms to epitope-driven rational design.

Sagheer U, Deng L.Int J Pharm. 2026 Jun 17:127088. doi: 10.1016/j.ijpharm.2026.127088. Online ahead of print.PMID: 42309198

mRNA Vaccines for Influenza: Hope for a Universal Vaccine?

Omotara P, Zhu W, Wang BZ.BioDrugs. 2026 Jun 15. doi: 10.1007/s40259-026-00791-z. Online ahead of print.PMID: 42295617

2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans.

Cai M, Xie Y, Al-Aly Z.JAMA Intern Med. 2026 Jun 15:e261929. doi: 10.1001/jamainternmed.2026.1929. Online ahead of print.PMID: 42295793

Vaccine management systems with a focus on cold chain management and delivery of immunization services in low- and middle-income countries: A scoping review.

Qadeer AS, Ay N, Paulson W, Rachel J, Nanda L, Dutta A, Rout SK.PLoS One. 2026 Jun 16;21(6):e0350231. doi: 10.1371/journal.pone.0350231. eCollection 2026.PMID: 42302058

Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults.

Wilson A, Lerman B, Ramsamooj R, Mischka J, Ehrenhaus J, Aracena A, Figueroa Y, Farrugia K, Gonzalez-Reiche AS, Nardulli J, Khalil Z, Gleason C, Hermann E, Srivastava K, Sordillo EM, van Bakel H, Abbad A, Krammer F, Simon V.EBioMedicine. 2026 Jun 12;129:106321. doi: 10.1016/j.ebiom.2026.106321. Online ahead of print.PMID: 42284681

Recombinant AcHERV-baculovirus vaccine elicits robust immune responses against human norovirus.

Yoon D, Lee H, Lee Y, Chun J, Hong SY, Oh JW, Kim YB, Lee HJ.Vaccine. 2026 Jun 11;83:128641. doi: 10.1016/j.vaccine.2026.128641. Epub 2026 Apr 30.PMID: 42066579

Epidemic features and potential impact of vaccine campaigns on the 2025 chikungunya outbreak in southern China: a mathematical modelling study.

Zheng Q, Ding Y, Wang X, Yang Y, Meng Q, Al-Tawfiq JA, Zhong Z, Wang W, Pan Q.New Microbes New Infect. 2026 Jun 11;72:101791. doi: 10.1016/j.nmni.2026.101791. eCollection 2026 Aug.PMID: 42327491

Effectiveness of recombinant zoster vaccine against herpes zoster and postherpetic neuralgia: a systematic review and meta-analysis of post-licensure observational studies.

Mbinta JF, Awuni PMA, Muhammed Basheer ST, Generao HK, Su'a-Tavila A, Bowe S, Harrison A, Sporle A, French N, Simpson CR.Vaccine. 2026 Jun 17;88:128842. doi: 10.1016/j.vaccine.2026.128842. Online ahead of print.PMID: 42308980

Hepatitis B in pregnancy and breastfeeding: current approaches to prophylaxis and treatment.

Pan CQ, Pan BL, Li J, Wang FS.Expert Rev Anti Infect Ther. 2026 Jun 15. doi: 10.1080/14787210.2026.2690003. Online ahead of print.PMID: 42298392

Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America.

Gebremariam AG, Genie M, Le H, Regan A, Beard F, Macartney K, Paolucci F, Moore H, Attwell K, Blyth CC.Vaccine. 2026 Jun 12;88:128825. doi: 10.1016/j.vaccine.2026.128825. Online ahead of print.PMID: 42284807

Bacterial extracellular vesicles: emerging players in antimicrobial resistance and clinical translation.

Asgharzadeh S, Pourhajibagher M, Bahador A.Mol Biol Rep. 2026 Jun 18;53(1):953. doi: 10.1007/s11033-026-12143-9.PMID: 42313295

Effects of hydro-meteorological and geological disasters on vaccine-preventable disease outbreaks and routine immunisation amongst children: A scoping review.

Barnidge IT, Ferreira AJF, Kovats S, Velasco SRM, Leyland A, Galvao LA, Santos GF, Paixao ES, Barreto ML, Brickley EB, Pescarini JM; Global Health Research Unit on the Social and Environmental Determinants of Health Inequalities (SEDHI).PLOS Glob Public Health. 2026 Jun 12;6(6):e0005712. doi: 10.1371/journal.pgph.0005712. eCollection 2026.PMID: 42284248

cGAMP-Loaded M2e Nanovaccine Elicits Cross-Reactive Immunity and Mitigates H6N1 Avian Influenza Infection in Chickens.

Chen LY, Tsai HH, Peng L, Yao BY, Chiu J, Hu CJ, Chen HW.Int J Nanomedicine. 2026 Jun 15;21:607946. doi: 10.2147/IJN.S607946. eCollection 2026.PMID: 42325400

Correction to "Political Ideology and HPV Vaccine Awareness: Sex Differences and Nursing Implications Using the Health Information National Trends Survey (HINTS)".

[No authors listed]Nurs Res Pract. 2026 Jun 18;2026:9867503. doi: 10.1155/nrp/9867503. eCollection 2026.PMID: 42325599

Bivalent foot-and-mouth disease virus mRNA vaccine induces well-balanced humoral and cellular immune responses.

Wang L, Li Z, Zhu H, Jia X, Su Z, Zhang S.Vaccine. 2026 Jun 19;88:128840. doi: 10.1016/j.vaccine.2026.128840. Online ahead of print.PMID: 42320384

Acacetin-incorporated lipid nanoparticles for inhaled mRNA vaccines.

Huang X, Fan K, Zhang Y, Yang Y, Wang Y, Yang X, Meng Z, Guo Q, Li Y, Gong N, Wang S, Li J, Zhang Z.Nanoscale Horiz. 2026 Jun 16. doi: 10.1039/d5nh00794a. Online ahead of print.PMID: 42301134

From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus.

Vicente C, Froes F, Lopalco PL, Heffernan C, Nilforooshan R, Martin F, Leroux-Roels I, Nesher L, Déplanque T, Dani N, Coelho A, Pinto de Castro N, Tayarani-Binazir K.Expert Rev Vaccines. 2026 Dec;25(1):2684962. doi: 10.1080/14760584.2026.2684962. Epub 2026 Jun 17.PMID: 42257651

Multiscale modeling guided potency assessment of mRNA-lipid nanoparticles.

Yang Y, Qiu Y, Wang K, Liu Y, Sanyal G, Whitford PC, Rouhanifard SH, Xie W.Mol Ther Nucleic Acids. 2026 May 26;37(2):102965. doi: 10.1016/j.omtn.2026.102965. eCollection 2026 Jun 16.PMID: 42306083

Drivers of and implementation strategies for influenza vaccination for cardiovascular populations in China: a scoping review.

Liu R, Fan Y, Xiong S, Lin J, Patel A, Du X, Di Tanna GL, Liu H.Vaccine. 2026 Jun 20;86:128761. doi: 10.1016/j.vaccine.2026.128761. Epub 2026 May 27.PMID: 42202423

Characterization of RNA using mass photometry: Method and technical perspectives.

Barnes LF, Watt B, Jalal S, Karunanithy G, Ranaghan MJ, Rood J, Wang HL.Mol Ther Nucleic Acids. 2026 Mar 30;37(2):102919. doi: 10.1016/j.omtn.2026.102919. eCollection 2026 Jun 16.PMID: 42003882

Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults.

Wiegand RE, Payne AB, Mak J, Chickery S, Reese SE, Klein NP, Grannis SJ, Ong TC, Rowley EAK, DeSilva M, Dascomb K, Irving SA, Zerbo O, Hansen JR, Block L, Jacobson KB, Dixon BE, Rogerson CM, Duszynski TJ, Fadel WF, Barron MA, Mayer D, Chavez C, Yang DH, Ball SW, McEvoy CE, Akinsete OO, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Naleway AL, Natarajan K, Najdowski M, Ciesla AA, Kautz A, DeCuir J, Link-Gelles R.JAMA Intern Med. 2026 Jun 15:e261936. doi: 10.1001/jamainternmed.2026.1936. Online ahead of print.PMID: 42295789

Perceptions of acceptability and preferences surrounding a hypothetical syphilis vaccine in Lima, Peru.

Fulqui V, Hamasaki W, Perez J, Orta Portillo GA, Klausner JD, Konda KA.Int J STD AIDS. 2026 Jun 12:9564624261459952. doi: 10.1177/09564624261459952. Online ahead of print.PMID: 42284552

Comparative analysis of expression, immunogenicity, and safety profiles between linear and circular RNA vaccine platforms.

Lee SY, Lee J, Ahn JH, Lee SY, Choi EJ, Ha D, Oh A, Jo S, Yoon S, Lee S, Bae HJ, Lee NY, Youn H, Kang BC, Nam JH.Mol Ther Nucleic Acids. 2026 May 15;37(2):102954. doi: 10.1016/j.omtn.2026.102954. eCollection 2026 Jun 16.PMID: 42282251

Comparative evaluation of lateral flow immunoassay and real time PCR for detection of canine morbillivirus antigen in live attenuated vaccines.

Abousenna MS, Shafik NG, Shasha FA, Khafagy HA, Ahmed SES, Mohamed AAEM, Nassif SA.Vet Immunol Immunopathol. 2026 Jun 11;299:111155. doi: 10.1016/j.vetimm.2026.111155. Online ahead of print.PMID: 42330679

Isotype cross-reactivity of anti-porcine IgG and IgA reagents.

Erbs G, Jakobsen JT, Crossley S, Munir D, Hammond JA, Jungersen G.J Immunol Methods. 2026 Jun 11;549:114078. doi: 10.1016/j.jim.2026.114078. Online ahead of print.PMID: 42276452

Vaccination coverage and timeliness among children in Ethiopia.

Pons-Duran C, Hunegnaw BM, Bekele C, Alemu K, Mohammed Y, Kurowski KM, Tadesse F, Ayalew M, Alebie A, Taddesse L, Bekele D, Chan GJ.BMJ Glob Health. 2026 Jun 19;11(6):e021447. doi: 10.1136/bmjgh-2025-021447.PMID: 42320939

Language and racial disparities in COVID-19 vaccination during pregnancy and lactation.

Ukah UV, Haapala JL, Benitez GV, DeSilva MB, Vesco KK, Daida YG, Sidebottom A, Kharbanda EO, Ehresmann K, Seburg EM, Chumba L, Banigo DR, Cullens CJ, Palmsten K.Vaccine. 2026 Jun 11;83:128638. doi: 10.1016/j.vaccine.2026.128638. Epub 2026 May 1.PMID: 42068907

Cost-effectiveness of human papillomavirus vaccination in Jordan: A modelling study.

Mousa AAB, Thneibat FM, Al-Hamdan Z, Al-Hawarat MN, Maswadi N, Pecenka CJ, Al-Shboul RA, Bdour I.Vaccine. 2026 Jun 11;83:128640. doi: 10.1016/j.vaccine.2026.128640. Epub 2026 May 2.PMID: 42070373

Global cessation of bivalent oral polio vaccine (bOPV): A comprehensive review of modeling studies from 2000 to 2025.

Sun Y, Keskinocak P, Peak CM, Steimle LN.Vaccine. 2026 Jun 20;86:128707. doi: 10.1016/j.vaccine.2026.128707. Epub 2026 May 29.PMID: 42208276

Comparison of Tdap vaccine immunogenicity between pregnant and non-pregnant active duty service members.

Khodr ZG, Hall C, Bukowinski AT, Gumbs GR, Lee RU, Mimica Porras FJ, Pineda G, Conlin AMS.Vaccine. 2026 Jun 11;83:128627. doi: 10.1016/j.vaccine.2026.128627. Epub 2026 Apr 30.PMID: 42066578

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

Kushner BH, Modak S, White C, Basu EM, Roberts SS, Mauguen A, Cheung NV.Int J Cancer. 2026 Jun 15;158(12):3232-3240. doi: 10.1002/ijc.70374. Epub 2026 Feb 11.PMID: 41670398

Neoantigen-based multi-epitope vaccine designing against glioblastoma using reverse vaccinology and immunoinformatic approaches.

Din MU, Ahmad S, Liu X, Jiang H, Wang X.Int Immunopharmacol. 2026 Jun 12;185:117015. doi: 10.1016/j.intimp.2026.117015. Online ahead of print.PMID: 42284765

Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.

Harvey R, Welsh C, Byrne AM, Greenwood D, Stevenson-Leggett P, Galiano M, Bailey D, Chan YW, Boateng J, Wolmuth-Gordon H, Whitaker H, Brown KE, Jeffery-Smith A, Allen A, Amirthanlingam G, Fossum E, Vikse EL, Rohringer A, Hungnes O, Bragstad K, Swanton C, Williams B, Gandhi S, Gamblin S, Carr EJ, Lewis NS, Wall EC, Wu MY; Crick Serology Pipeline; Legacy Investigators.EBioMedicine. 2026 Jun 11;129:106332. doi: 10.1016/j.ebiom.2026.106332. Online ahead of print.PMID: 42276011

Immunopharmacological and structural design of a polyprotein based multi epitope vaccine against Powassan virus.

Kalsoom A, Abidi SH, Marwat SA, Shabbir G, Naveed M, Mughal AMA, Majeed MN, Korany SM, Korany BM, Alzhrani K, Aziz T.Naunyn Schmiedebergs Arch Pharmacol. 2026 Jun 13. doi: 10.1007/s00210-026-05519-y. Online ahead of print.PMID: 42287315

Maternal and infant immunizations for respiratory diseases, United States, may 2025.

Razzaghi H, Garacci E, Kahn KE, Meghani M, Kriss JL, Lindley MC, Jones JM, Ellington S, Hughes M, Black CL.Vaccine. 2026 Jun 12;88:128823. doi: 10.1016/j.vaccine.2026.128823. Online ahead of print.PMID: 42284808

Evaluation of EcoCRM, virus-like particles, and mRNA as vaccine platforms against Borrelia burgdorferi.

Rocuskie-Marker CM, Huckaby AB, Conaway OM, Pyles GM, Dublin SR, Witt WT, Blackwood CB, de la Paz Gutierrez M, Hall JM, Ulicny SR, Padden E, Shephard S, Chapman J, Zapotocky T, Cannon-Blachere J, Peasak K, Rader NA, Miller M, Hankinson BR, Wong I, Long DA, Nunley M, Willis D, Lee KS, Cunningham C, Weaver KL, Damron FH, Barbier M.Vaccine. 2026 Jun 20;86:128696. doi: 10.1016/j.vaccine.2026.128696. Epub 2026 May 23.PMID: 42176436

Reverse genetics strategies for coronaviruses: platform construction and applications in vaccine development.

Jia Y, Han X, Ma Y, Wang X, Yang Y, Zhang A, Ding K, Chen S.Virus Genes. 2026 Jun 12. doi: 10.1007/s11262-026-02249-4. Online ahead of print.PMID: 42286395

Broad-Spectrum Vaccines: Challenges and Opportunities (A Systematic Review).

Pandey SK, Singh S.Curr Mol Med. 2026 Jun 11. doi: 10.2174/0115665240442393260519141157. Online ahead of print.PMID: 42304743

A nationwide survey on knowledge, attitude, and practice regarding human papillomavirus (HPV), HPV-related disease, and HPV vaccine among adolescents and their parents in China.

Wang H, Hu S, Yuan M, Zhao X, Yan Y, Zhang X, Bian R, Jia L, Zhao F.Hum Vaccin Immunother. 2026 Dec;22(1):2681256. doi: 10.1080/21645515.2026.2681256. Epub 2026 Jun 15.PMID: 42295870

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.

Zhang H, Liang H, Dai T, Shen N, Liu C, Zhou Y, Wei Z, Wu Z, Yu P, Zhang Q, Zhang X, Yu J, Ji X, Yang A, An C, Han Y, Jiao X, Qian L, Lu Z.NPJ Vaccines. 2026 Jun 19. doi: 10.1038/s41541-026-01503-y. Online ahead of print.PMID: 42315874

Bacterialized tumor cells as vaccine.

Huang FY, Lin YY, Tan GH.EMBO Mol Med. 2026 Jun 19. doi: 10.1038/s44321-026-00465-x. Online ahead of print.PMID: 42321431

Behavioural and social drivers of HPV vaccine uptake in Tonga: a mixed-methods study using the WHO BeSD framework and Talanoa in a Pacific Island setting.

Alamgir M, Randimbivololona J, Patelisio PN, Tukia O, Fifita ST, Kafoa ST, Manoncourt E.Vaccine. 2026 Jun 16;88:128843. doi: 10.1016/j.vaccine.2026.128843. Online ahead of print.PMID: 42308978

Prevalence and correlates of COVID-19 vaccine uptake among sexual and gender minority adolescents in the southern United States.

Lambert D, Luisi N.Vaccine. 2026 Jun 20;84:128661. doi: 10.1016/j.vaccine.2026.128661. Epub 2026 May 8.PMID: 42105394

Designing a multi-epitope vaccine against yellow fever virus using immunoinformatics approaches.

Naveed M, Asim M, Aziz T, Toheed M, Athar A, Majeed MN, Khan AA, Alharbi M, Shami A, Alwethaynani MS, Almsaud MM, Al-Joufi FA.Open Med (Wars). 2026 Jun 18;21(1):20261453. doi: 10.1515/med-2026-1453. eCollection 2026 Jan.PMID: 42317441

HPV vaccine: Influencing peer recommendations through information provision at no-cost vaccine clinics.

Ky SL, Coblentz EG, Swanson E, Shah R, Fritsch A, Rudd TM, Malcolm SD, Kasting ML.Vaccine. 2026 Jun 12;88:128807. doi: 10.1016/j.vaccine.2026.128807. Online ahead of print.PMID: 42284811

TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.

Jufuku R, Shinchi H, Murata K, Chan M, Hayashi T, Cottam HB, Carson DA, Suda Y, Wakao M.Vaccine. 2026 Jun 20;86:128762. doi: 10.1016/j.vaccine.2026.128762. Epub 2026 May 27.PMID: 42202427

Evaluation of Knowledge About Human Papillomavirus and Vaccination Among Women Screened for Cervical Cancer.

Kucukceran H, Demirbas N, Karaoglu N, Cihan FG, Hamzaoglu FK, Demir ET.Int J Health Plann Manage. 2026 Jun 11. doi: 10.1002/hpm.70094. Online ahead of print.PMID: 42272316

Exploring offspring behaviour after prenatal COVID-19 vaccination in mice.

Otrokocsi L, Maácz F, Tod P, Gölöncsér F, Sperlágh B.Transl Psychiatry. 2026 Jun 15. doi: 10.1038/s41398-026-04147-7. Online ahead of print.PMID: 42297775

HPV vaccine and age of sexual debut of adolescents: A nationwide cross-sectional study.

Theotonio Dos Santos LF, Gomes AM, Oliveira DA, Mattos AJC, Ribeiro GA, Cruz SS, Sant'Anna VAR, Rizzo LV, Fonseca HAR.Vaccine. 2026 Jun 20;84:128677. doi: 10.1016/j.vaccine.2026.128677. Epub 2026 May 8.PMID: 42105393

Preformulated, Shelf-Stable, Dendritic Cell-Targeting Nanogel mRNA Vaccine Delivery Platform.

Laturski AE, Durán V, Schaar BT, Dulay MT, Einav S, DeSimone JM.Bioconjug Chem. 2026 Jun 17;37(6):1172-1184. doi: 10.1021/acs.bioconjchem.6c00069. Epub 2026 Jun 1.PMID: 42225260

Human papillomavirus vaccination: knowledge, acceptance, and barriers among medical students. An Egyptian multicenter cross sectional study.

Omar DI, Althobaiti S, Nabil N, Mohammed SG, Hani BM.Sci Rep. 2026 Jun 15;16(1):18528. doi: 10.1038/s41598-026-51547-2.PMID: 42297846

Role of quaternary epitopes in eliciting broad neutralization response against multiple flaviviruses.

Chatterjee A, Mangala Prasad V.J Virol. 2026 Jun 15:e0177725. doi: 10.1128/jvi.01777-25. Online ahead of print.PMID: 42294909

A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin and matrix protein 2 induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse model.

Ao Z, Vendramelli R, Buyu M, Truong T, Liu D, Gao N, Ma H, Amos S, Lawrynuik P, Nyamekye M, Fowke KR, Pelka P, Shmulevitz M, Kung SKP, Kobasa D, Yao X.J Virol. 2026 Jun 16:e0009726. doi: 10.1128/jvi.00097-26. Online ahead of print.PMID: 42300735

Non-Clinical Toxicology of Therapeutic Vaccines: Regulatory Considerations and Species Selection: A comprehensive review.

Gould S, Londono-Hayes P.Regul Toxicol Pharmacol. 2026 Jun 13:106133. doi: 10.1016/j.yrtph.2026.106133. Online ahead of print.PMID: 42288182

In silico design of a citrullinated protein-based multi-epitope vaccine for rheumatoid arthritis using immunoinformatics.

Brindhaa R, Pathak N, Kohila V.Int Immunopharmacol. 2026 Jun 15;179:116615. doi: 10.1016/j.intimp.2026.116615. Epub 2026 Apr 9.PMID: 41962465

New determinant of influenza hemagglutinin cleavability identified through random mutagenesis for acid-stabilizing mutations.

Rimaux S, Oliva MF, Mestdagh C, Van Berwaer R, Chen J, Schurmans L, Schoofs G, Vanmechelen B, Stroobants J, Jacquemyn M, Laporte M, Maes P, Vermeire K, Das K, Stevaert A, Naesens L.Microbiol Spectr. 2026 Jun 15:e0412325. doi: 10.1128/spectrum.04123-25. Online ahead of print.PMID: 42294944

Self-reported vaccine uptake across six infectious diseases among gay, bisexual, transgender, and non-binary individuals in Australia: findings from a 2024 national survey.

Wang C, Kong FYS, Aung ET, Maddaford K, Martin SJ, Khaw C, Varma R, Thng C, Gunathilake M, Cornelisse VJ, Fairley CK, Heath-Paynter D, McCabe F, Ooi C, Ludwick T, Cardwell ET, Traeger MW, Bradshaw CS, Latt PM, Chow EPF.Sex Health. 2026 Jun 15;23(3):SH25250. doi: 10.1071/SH25250.PMID: 42219251

RIG-I-dependent sensing of PEDV shapes epithelial antiviral immunity in the intestinal mucosa.

Zeng H, Shi Y, Zhong Q, Tang R, Cao Y, Wang W, Miao X, Zhang X, Qin T, Li Y, Yang Q.J Virol. 2026 Jun 16:e0048326. doi: 10.1128/jvi.00483-26. Online ahead of print.PMID: 42300736

Multi-antigen transmission-blocking malaria vaccine elicits Th1-biased antibody responses and SMFA-confirmed oocyst reduction in Anopheles stephensi.

Pourhashem Z, Siasi S, Nourani L, Yousefi H, Sani JJ, Vand-Rajabpour H, Raz A, Pirahmadi S, Zargar M, Djadid ND, Zakeri S, Mehrizi AA.Vaccine. 2026 Jun 20;84:128683. doi: 10.1016/j.vaccine.2026.128683. Epub 2026 May 9.PMID: 42107903

A narrative review of COVID-19 epidemiology and mRNA vaccine impact in children <12 years during the omicron era (November 2021 - December 2025).

Zheng Z, Yousefi M, Marks M, Dixit A, Wahid R, Viscidi E, Anderson EJ.Expert Rev Vaccines. 2026 Dec;25(1):2684961. doi: 10.1080/14760584.2026.2684961. Epub 2026 Jun 14.PMID: 42246405

Psychological Harms of HIV Vaccine Trial Participation in Tanzania: Could Post-Trial Participants Engagement Help?

Shayo J, Anaeli A, Urassa D, Addissie A, Lyamuya E, Ulrich CM.AJOB Empir Bioeth. 2026 Jun 11:1-14. doi: 10.1080/23294515.2026.2675971. Online ahead of print.PMID: 42274386

Economic implications of switching to the hexavalent infant vaccine in an immunization program in India.

Kumar P, Singh K, Ray A, Kumari A, Chatterjee S, Hernandez H, Deb Roy A.Hum Vaccin Immunother. 2026 Dec;22(1):2676400. doi: 10.1080/21645515.2026.2676400. Epub 2026 Jun 15.PMID: 42295252

Live viral measles-mumps-rubella revaccination and varicella vaccination in children and adolescents with juvenile idiopathic arthritis: a systematic review.

Dipasquale RF, Sinopoli P, Mendicino A, Gallizzi R.Eur J Pediatr. 2026 Jun 16;185(7):505. doi: 10.1007/s00431-026-07160-6.PMID: 42297949

Adverse events following immunization with human papillomavirus vaccine: post-marketing surveillance in China, 2021-2024.

Zhang L, Li K, Li Y, Fan C, Li Y, Ren M, Cao L, Yu W, Yin Z.Vaccine. 2026 Jun 15;88:128826. doi: 10.1016/j.vaccine.2026.128826. Online ahead of print.PMID: 42296833

Prevalence of antibiotic resistance in invasive non-typhoidal Salmonella across 19 developing countries, 2000-2026: A systematic review and meta-analysis.

Zhan Z, Xie Z, Lin H, Guo J, Cai M, Wu Y, Liang S.J Glob Antimicrob Resist. 2026 Jun 20:S2213-7165(26)00090-1. doi: 10.1016/j.jgar.2026.06.011. Online ahead of print.PMID: 42323080

How PLGA Microspheres are Emerging as a Key Drug Delivery System.

Qian S, Ma L, Liu C, Lin Y, Wu J, Wang X.Int J Nanomedicine. 2026 Jun 15;21:600160. doi: 10.2147/IJN.S600160. eCollection 2026.PMID: 42325401

Infectious disease hospitalization rates before and after introduction of vaccine against human papillomavirus in Denmark, Norway, and Sweden: controlled interrupted time series analyses.

Laake I, Feiring B, Sørup S, Englund H, Nieminen H, Cardél LG, Benn CS, Trogstad L.Vaccine. 2026 Jun 17;88:128851. doi: 10.1016/j.vaccine.2026.128851. Online ahead of print.PMID: 42308975

Immunopharmacological design of a multi-epitope vaccine targeting sarbecovirus Spike glycoprotein.

Aziz T, Alshehri MA, Aljumaa MA, Alzhrani K, Tombozara N.Naunyn Schmiedebergs Arch Pharmacol. 2026 Jun 11. doi: 10.1007/s00210-026-05534-z. Online ahead of print.PMID: 42274768

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Ranque B, Galtier F, Nunes H, Le Jeunne C, Roguet G, Sève P, Israël-Biet D, Charbit B, Pacheco Y, Crestani B, Deplanque D, Detoc M, Dualé C, Meritet JF, Abdoul H, Brauner M, Valeyre D, Launay O, Guilpain

P.Vaccine. 2026 Jun 20;86:128732. doi: 10.1016/j.vaccine.2026.128732. Epub 2026 May 22.PMID: 42167137

Mechanistic insights into Bluetongue virus immunodynamics: a Bayesian within-host modelling approach.

Majumder A, Westrich JA, McNulty E, Sherman T, Carpenter M, Mayo C, Mathiason C, Perkins A.J R Soc Interface. 2026 Jun 17;23(239):20251309. doi: 10.1098/rsif.2025.1309.PMID: 42303268

Recombinant production of human papillomavirus type 16 E6 and E7 vaccine antigens in Chlamydomonas reinhardtii.

Dubey SK, Upadhyay M, Singh V, Tripathi BN.J Biotechnol. 2026 Jun 18;417:265-273. doi: 10.1016/j.jbiotec.2026.06.013. Online ahead of print.PMID: 42314773

Building a Healthier Workforce: The Value of Employer-Sponsored Vaccinations and Vaccination Programs in the Workplace.

Cook JM, Alexander M, Lo J, Chen B, Dabrowski D, Baker B, Montoya IS, Ording J.J Occup Environ Med. 2026 Jun 16. doi: 10.1097/JOM.0000000000003793. Online ahead of print.PMID: 42302233

Parental hesitancy and refusal toward routine childhood vaccination after the COVID-19 vaccination period: a cross-sectional study.

Eliaçık OE, Çöme O, Günvar T.BMC Prim Care. 2026 Jun 12. doi: 10.1186/s12875-026-03418-y. Online ahead of print.PMID: 42286487

Determination of antigen components in inactivated SARS-CoV-2 vaccine using ultra-high-performance liquid chromatography tandem mass spectrometry.

Shi J, Deng F, Li Y, Li J, Peng R, Yuan J, Tan L.J Pharm Biomed Anal. 2026 Jun 15;273:117388. doi: 10.1016/j.jpba.2026.117388. Epub 2026 Feb 2.PMID: 41643282

Parental awareness, knowledge, and hesitancy toward HPV vaccination for adolescents: A cross-sectional study.

Güven D, Köle MT, Örün E, Çaylan N, Küçük E, Kandemir I, Öztürk S, Kondolot M.Arch Argent Pediatr. 2026 Jun 18:e202611021. doi: 10.5546/aap.2026-11021.eng. Online ahead of print.PMID: 42301822

SEROLOGIC RESPONSES IN PATIENTS WITH INVASIVE GROUP A STREPTOCOCCAL DISEASE.

Kailankangas V, Gröndahl-Yli-Hannuksela K, Vilhonen J, Rantakokko-Jalava K, Seiskari T, Lönnqvist E, Oksi J, Syrjänen J, Vuopio J.Int J Infect Dis. 2026 Jun 17:108891. doi: 10.1016/j.ijid.2026.108891. Online ahead of print.PMID: 42309481

Design, synthesis and immunological evaluation of novel monosaccharide TLR4 agonists.

Zhang ZM, Wen Y, Luo MQ, Sun HL, Ding D, Liao CM, Guo J.Bioorg Chem. 2026 Jun 15;174:109717. doi: 10.1016/j.bioorg.2026.109717. Epub 2026 Mar 3.PMID: 41795437

Post-pandemic impact on the epidemiology of invasive pneumococcal disease: consensus statement from the Latin American Society of Pediatric Infectious Diseases (SLIPE).

Debbag R, Avila-Agüero ML, Gentile A, Torres J, Torres C, Vazquez L, Beltran C, Brea-Del Castillo J, Dagan R.Expert Rev Vaccines. 2026 Dec;25(1):2689604. doi: 10.1080/14760584.2026.2689604. Epub 2026 Jun 19.PMID: 42300867

What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.

Teixeira AR, Caskey M.J Infect Dis. 2026 Jun 16;233(6):e1313-e1319. doi: 10.1093/infdis/jiag135.PMID: 41774769

Neoantigen-based T cell vaccines design strategies, therapeutic barriers, and clinical advances.

Shi J, Wang J, Luo H, Zhao Q, Yao Z, Wu G, Li Z, Wang H, Chen G, Wu D.Vaccine. 2026 Jun 11;83:128659. doi: 10.1016/j.vaccine.2026.128659. Epub 2026 May 1.PMID: 42068906

Serotypes associated with invasive pneumococcal disease high-risk groups: a systematic review.

Arhin RE, Dayie NTKD, Donkor ES.Int Health. 2026 Jun 16:ihag058. doi: 10.1093/inthealth/ihag058. Online ahead of print.PMID: 42299676

Silica-coated papillomavirus-based nanoparticles: a shielded scaffold for HIV-1 vaccines.

Wang Y, Kostka-Wirtz K, Bartelsen N, Loza K, Weingärtner C, Arnold P, Damm D, Überla K, Epple M, Temchura V.Biomater Sci. 2026 Jun 16;14(12):3281-3294. doi: 10.1039/d5bm01792k.PMID: 42093535

Safety of supervised hospital vaccination in children at risk of hypersensitivity: A 9-year study.

Donesana M, Marseglia A, Laterza L, Caimmi SME, Odone A, Muzzi A, Marseglia GL, Licari A.Vaccine. 2026 Jun 20;84:128663. doi: 10.1016/j.vaccine.2026.128663. Epub 2026 May 8.PMID: 42105395

Development and immunoprotective evaluation of a thermostable mRNA vaccine targeting Vibrio harveyi flagellin in the large yellow croaker (Larimichthys crocea).

Zhang Y, Zhang X, Chen H, Mai W.Fish Shellfish Immunol. 2026 Jun 13;176:111510. doi: 10.1016/j.fsi.2026.111510. Online ahead of print.PMID: 42288299

Using non-primary care clinical settings to increase HPV vaccination uptake: a scoping review.

Surapaneni S, Baxter Z, Abdurrob A, Leonard K, Bernacchi V, Chang S, Yaremchuk K, Tam S, Adjei Boakye E.Vaccine. 2026 Jun 20;86:128759. doi: 10.1016/j.vaccine.2026.128759. Epub 2026 May 27.PMID: 42202426

Proteomics- and immunoinformatics-based design of a multi-epitope vaccine ZZ1 against Glaesserella parasuis.

Wang Z, Wei W, Feng S, Jia C, Fu J, Wang Y, Jin Y, Liu H, Chen H, Wang X.BMC Vet Res. 2026 Jun 12. doi: 10.1186/s12917-026-05621-6. Online ahead of print.PMID: 42286569

Willingness to receive Ebola vaccines among pregnant and lactating women in Kampala, Uganda: insights from a post-outbreak cross-sectional study.

Katana EB, Kiiza D, Odongpiny EAL, Simbwa BN, Nsubuga EJ, Namayanja J, Muhindo R, Castelnuovo B, Ario AR, Waitt C.Vaccine. 2026 Jun 20;86:128737. doi: 10.1016/j.vaccine.2026.128737. Epub 2026 May 22.PMID: 42172692

Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis.

Chen WH, Beckett CG, Al-Ibrahim M, Datar R, Sikorski MJ, Liang Y, Pasetti MF, Sztein MB, Wahid R, Tennant SM, Simon R, Baliban SM, Galen JE, Lees A, Ella R, Mohan K, Naidu MG, Rao DY, Ella KM, Levine MM.J Infect Dis. 2026 Jun 16;233(6):1081-1090. doi: 10.1093/infdis/jiag156.PMID: 41885624

Global misinformation, local consequences: conspiracy theory endorsement and a graded association with COVID-19 vaccine refusal across Nigeria.

Asaga PM, Kroeger A, Yako A, Makpo J.Vaccine. 2026 Jun 16;88:128827. doi: 10.1016/j.vaccine.2026.128827. Online ahead of print.PMID: 42308979

mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network.

Muller MP, Soe P, Shulha HP, Isenor JE, Valiquette L, Sadarangani M, Vanderkooi OG, Kellner JD, Top KA, De Serres G, McGeer A, Kiely M, Marty K, Irvine M, Bettinger JA; Canadian Immunization Research Network.Vaccine. 2026 Jun 20;84:128630. doi: 10.1016/j.vaccine.2026.128630. Epub 2026 May 5.PMID: 42092317

Report from the BV-BRC, CDC, NCBI, and NIAID Viral Sub-Species Classification Workshop.

Lefkowitz EJ, Rutvisuttinunt W, Brister JR, Capria A, Click ES, Caravas J, Hatcher E, MacCannell D, Rota P, Singh I, Stewart L, St John A, Zmasek C, Brown LL.J Virol. 2026 Jun 12:e0021026. doi: 10.1128/jvi.00210-26. Online ahead of print.PMID: 42283465

Emergenet: A Digital Twin of Influenza A Evolution for Vaccine Strain Forecasting and Emergence Risk Assessment.

Wu K, Li F, Chattopadhyay I.Mil Med. 2026 Jun 12:usag255. doi: 10.1093/milmed/usag255. Online ahead of print.PMID: 42287696

Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?

Jamwal S, Omene B, Giri A, Rojas K, Mohanty S, Calhoun C, Krishnamurti L, Montgomery RR, Shaw AC, Andemariam B, Yildirim I.Vaccine. 2026 Jun 20;88:128866. doi: 10.1016/j.vaccine.2026.128866. Online ahead of print.PMID: 42322679

GMMA as delivery system for Klebsiella pneumoniae O-antigens and K-antigens.

Raso MM, Nappini R, Gnoni G, Aruta MG, Molfetta M, Arato V, Durante S, Cescutti P, Carducci M, Alfini R, Giannelli C, Rossi O, Pizza M, Micoli F, Gasperini G.Sci Rep. 2026 Jun 11. doi: 10.1038/s41598-026-57020-4. Online ahead of print.PMID: 42270892

Evaluation of immunogenicity and efficacy of a Plasmodium vivax nanoparticle vaccine in mice.

Ntumngia FB, Kolli SK, Howard GP, Subramani PA, Barnes SJ, Ogbondah MM, Mahdavi P, Lu J, Nicholas J, De SL, Barnes BB, Dinglasan RR, Janse CJ, Mao HQ, Adams JH.Vaccine. 2026 Jun 20;88:128857. doi: 10.1016/j.vaccine.2026.128857. Online ahead of print.PMID: 42322682

Stability of the two enveloped viruses NDV LaSota and YF-ZIKprM/E to support process development.

Göbel S, Jacobtorweihe L, Rössig ML, Braatz F, Perugi F, Genzel Y, Reichl U.PLoS One. 2026 Jun 15;21(6):e0351417. doi: 10.1371/journal.pone.0351417. eCollection 2026.PMID: 42296128

A reverse genetics-based NS1-truncated live attenuated vaccine confers broad heterologous protection against swine influenza viruses.

Xiang F, Xu Y, Liu C, Li X, Wang R, Zhang H, Dong S, Huang J, Luo T, Qin Y, Ouyang K, Yin Y, Wei Z, Huang W, Chen Y.Microb Pathog. 2026 Jun 16;218:108638. doi: 10.1016/j.micpath.2026.108638. Online ahead of print.PMID: 42303005

Comparative immunogenic and structural analysis of virus-like particle and inactivated whole-virion vaccines against enterovirus D68.

Senpuku K, Kunishima Y, Hirose M, Karaki T, Taniguchi K, Kataoka-Nakamura C, Hirai T, Yasuda K, Kuroda E, Kato T, Ito T, Yoshioka Y.Mol Ther Nucleic Acids. 2026 May 20;37(2):102957. doi: 10.1016/j.omtn.2026.102957. eCollection 2026 Jun 16.PMID: 42293247

Prokaryotically Expressed IBDV VP2 Virus-Like Particles: Stability and Protective Efficacy.

Zhang J, Zhang X, Li L, Jia Y, Ai Y, Du Y, Qu G.Microb Pathog. 2026 Jun 18:108617. doi: 10.1016/j.micpath.2026.108617. Online ahead of print.PMID: 42315049

Community perspectives on mass malaria vaccine and drug administration in the Chittagong Hill Tracts, Bangladesh: a qualitative study.

Rabby MF, Tripura R, Khalil I, Ahmed DI, Peto TJ, Cheah PY, Hossain MA, Rahman AKMF, Samad R, Rashid R, Sayeed AA, White NJ, Day NPJ, Dondorp AM, von Seidlein LP, Adhikari B, Faiz MA.Malar J. 2026 Jun 16. doi: 10.1186/s12936-026-05999-6. Online ahead of print.PMID: 42304478

The association between populist-aligned views and engagement with public health interventions: a systematic review of longitudinal studies.

Conway-Moore K, Birch JM, McKinlay AR, Graham F, Oliver EJ, Bambra C, Kelly MP, Bonell C.BMC Public Health. 2026 Jun 16. doi: 10.1186/s12889-026-28020-w. Online ahead of print.PMID: 42304269

Deep learning analysis of trajectories and spatial variations in HPV vaccine discussions on Chinese Weibo.

Wang Y, Yang H, Ding Z, Zhou X, Zhou Y, Ma L, Lin L, Hou Z.Commun Med (Lond). 2026 Jun 13. doi: 10.1038/s43856-026-01720-5. Online ahead of print.PMID: 42288636

Better Health for All in a Changing World: Sparks From the 14th ECTMIH.

Albonico M, Awa N, Eggers Y, Köhler C, May J, Rabl D, Schneitler S, Jara-Reznakova B, Rausche P.Trop Med Int Health. 2026 Jun 15. doi: 10.1111/tmi.70172. Online ahead of print.PMID: 42294563

CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses.

Li Y, Nakkala JR, Akter L, Kang X, Song Y, VanLuinen E, Chen X.Mol Ther Oncol. 2026 May 9;34(2):201230. doi: 10.1016/j.omton.2026.201230. eCollection 2026 Jun 18.PMID: 42256206

Engineered Probiotics Protect against *Pseudomonas aeruginosa* Post Antibiotic Exposure.

Wang S, Zhang B, Zhang S, Zhang J, Yang Y.ACS Synth Biol. 2026 Jun 19;15(6):2403-2415. doi: 10.1021/acssynbio.6c00063. Epub 2026 Jun 10.PMID: 42267686

A self-amplifying RNA vector based on rubella virus for mRNA therapeutics and vaccine applications.

Jing M, Law MCY, Phung CD, He Y, Tan YB, Le MTN, Luo D.Mol Ther Nucleic Acids. 2026 May 25;37(2):102967. doi: 10.1016/j.omtn.2026.102967. eCollection 2026 Jun 16.PMID: 42293248

From COVAX deliveries to vaccination uptake in LMICs: a monthly panel analysis.

Qi X, Smolders C.Vaccine. 2026 Jun 20;86:128763. doi: 10.1016/j.vaccine.2026.128763. Epub 2026 May 29.PMID: 42214872

Autologous tumor-based vaccines in canine oncology: a systematic review of safety, immunogenicity, and therapeutic potential.

Leitão JR, Tuani BRV, Vicente IST, Matera JM, de Oliveira Massoco C, Fonseca-Alves CE.Vaccine. 2026 Jun 12;88:128836. doi: 10.1016/j.vaccine.2026.128836. Online ahead of print.PMID: 42284812

Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins.

Halfmann PJ, Duffy A, Wee A, Anderson N, Terrell J, Kawaoka Y, Kane RS.Biotechnol Prog. 2026 Jun 15:e88530. doi: 10.1002/btpr.88530. Online ahead of print.PMID: 42290307

The World Expected More of Canada: Canada and the Pandemic Agreement.

Lexchin J.Int J Soc Determinants Health Health Serv. 2026 Jun 18:27551938261458695. doi: 10.1177/27551938261458695. Online ahead of print.PMID: 42312458

A protocol for computational design of mRNA vaccines with high functionality and specificity.

Ramadan MA, ElGohary HM, Faraag AH, Mysara M.Biol Direct. 2026 Jun 13;21(1):103. doi: 10.1186/s13062-026-00846-9.PMID: 42288920

Cost-effectiveness of ongoing COVID-19 vaccination in the context of high population immunity: A structured review of international economic evidence.

Tuite AR, Forbes N, Salvadori MI, Tunis M.Vaccine. 2026 Jun 11;83:128660. doi: 10.1016/j.vaccine.2026.128660. Epub 2026 May 6.PMID: 42085748

Computational identification of antigens and development of a multi-epitope vaccine for bacterial vaginosis caused by Gardnerella vaginalis.

Niknezhad MA, Doosti A, Shakhsi-Niaei M.Amino Acids. 2026 Jun 14. doi: 10.1007/s00726-026-03537-x. Online ahead of print.PMID: 42289006

Conserved genetic and antigenic profiles of Pf12 and Pf41 in asymptomatic Plasmodium falciparum carriers in Tanzania.

Fitriana F, Lee WJ, Sim HY, Jun H, Syahada JH, Muh F, Lee SJ, Na S, Lee KJ, Nam JW, Han ET, Todd J, Manjurano A, Kidima W, Mazigo E, Han JH.Sci Rep. 2026 Jun 12. doi: 10.1038/s41598-026-55360-9. Online ahead of print.PMID: 42286103

Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial.

Espersen C, Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Janstrup KH, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Köse G, Fussing FH, Pareek M, Køber L, Solomon SD, Jensen JUS, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Zhang P, Begier E, Biering-Sørensen T.Eur J Prev Cardiol. 2026 Jun 18:zwag327. doi: 10.1093/eurjpc/zwag327. Online ahead of print.PMID: 42312606

Genomic Evolution of Influenza A Virus During the 2024-2025 Season, the Johns Hopkins Health System: Antigenic Drift Reduces Serum Neutralization.

Villafuerte D, Fall A, Akin E, Werner AP, Pinsley M, Vue Y, Abdullah O, Zhuang TX, Norton JM, Rothman RE, Fenstermacher KZJ, Morris CP, Klein E, Pekosz A, Mostafa HH.J Infect Dis. 2026 Jun 16;233(6):e1386-e1395. doi: 10.1093/infdis/jiag069.PMID: 41639986

Vaccination coverage and inequalities in childhood immunisation in Ethiopia: a secondary analysis of the PMA national longitudinal survey.

Hagos A, Tariku MK, Mekuriya GE, Abuhay HW, Demoze L, Masresha GA, Aweke MN, Getahun HA, Chanie ST, Yitageasu G, Alemu GG.BMJ Open. 2026 Jun 18;16(6):e109481. doi: 10.1136/bmjopen-2025-109481.PMID: 42315276

Preferences for rapid implementation science: a real-time discrete choice experiment.

Geng EH, Ramaswamy R, Ramsey AT, Kanyike AM, Eboreime E, Sturke R, Vorkoper S, Le Tourneau N.Implement Sci Commun. 2026 Jun 19. doi: 10.1186/s43058-026-00986-z. Online ahead of print.PMID: 42321928

Real-World Effectiveness of Sequential Pneumococcal Vaccination in Older Adults: A Cohort Study.

Tan YY, Ho RWL, Lim JT, Chiew CJ, Lim SK, Lye DCB, Tan KB, Wee LE.J Infect Dis. 2026 Jun 16;233(6):1069-1080. doi: 10.1093/infdis/jiag147.PMID: 41790729

Respiratory syncytial virus (RSV) vaccination program for older Australians reduces health inequalities: a distributional cost-effectiveness analysis.

Paul KK, Torres M, Shih STF, Gray RT, Wood JG, Nazareno AL, Jan S, Newall AT.Vaccine. 2026 Jun 11;83:128644. doi: 10.1016/j.vaccine.2026.128644. Epub 2026 May 2.PMID: 42070372

Perceptions of HPV vaccination among children aged 9-13 and parents: A qualitative study from Ankara, Türkiye.

Ozeller E, Sarıca Çevik H, Peremans L.Public Health. 2026 Jun 15;257:106378. doi: 10.1016/j.puhe.2026.106378. Online ahead of print.PMID: 42296926

Tailoring the Australian vaccine barriers assessment tool (VBAT) for Aotearoa New Zealand: Using a local equity approach.

Turner N, Castelino L, Paynter J, Willing E, Henseler J, Best E, Kaufman J, Danchin M.Vaccine. 2026 Jun 11;83:128636. doi: 10.1016/j.vaccine.2026.128636. Epub 2026 Apr 30.PMID: 42066580

Prophylactic Active Immunization Protects against Xylazine-Induced Pharmacological Effects in Rats.

Kim CM, Seaman RW Jr, Marecki C, Jahan R, Hannon B, Kang J, Luengas D, Runyon SP, Pravetoni M.J Med Chem. 2026 Jun 11;69(11):12898-12909. doi: 10.1021/acs.jmedchem.5c02529. Epub 2026 May 29.PMID: 42212607

mRNA vaccine design targeting Merkel cell polyomavirus for immunotherapy of Merkel cell carcinoma.

Zubair A, Ahmad F, Shahani MY, Afghan N.Sci Rep. 2026 Jun 20. doi: 10.1038/s41598-026-59194-3. Online ahead of print.PMID: 42323496

Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.

Hastie A, Gupta V, Lese P, Moya J, Schoonbroodt S, Beudjekian S, Struyf F.Hum Vaccin Immunother. 2026 Dec;22(1):2649314. doi: 10.1080/21645515.2026.2649314. Epub 2026 Jun 11.PMID: 42274331

Vaccine-preventable disease outbreaks in schools, part 2: pertussis, meningococcal disease, diphtheria, poliomyelitis, hepatitis A, and rotavirus infection.

Cassimos DC, Effraimidou E, Irakleidou I, Medic S, Maltezou HC.Vaccine. 2026 Jun 20;86:128750. doi: 10.1016/j.vaccine.2026.128750. Epub 2026 May 28.PMID: 42208275

Distinct Innate Immune Responses Following Inoculation With a Replicon mRNA COVID-19 Vaccine.

Nakayama T, Ito T, Katayama K.Microbiol Immunol. 2026 Jun 15. doi: 10.1111/1348-0421.70068. Online ahead of print.PMID: 42290597

Enhancing detection efficiency of RD-proteins in Mycobacterium tuberculosis culture filtrate by biomimetic affinity chromatography coupled with LC-MS/MS.

Han Y, Ma S, Ma R, Li J, Qiu L, Ma JW, Ma Y, Tang M, Cao Z, Li Z, Zhang S, Ma G.J Chromatogr B Analyt Technol Biomed Life Sci. 2026 Jun 15;1278:125081. doi: 10.1016/j.jchromb.2026.125081. Epub 2026 Apr 19.PMID: 42048679

Immunogenicity, Safety, and Determinants of Recombinant Zoster Vaccine Response in Idiopathic Inflammatory Myopathies: A Phase 4 Randomized Trial.

Pasoto SG, Gorayeb THB, Luppino-Assad AP, Aikawa NE, Medeiros-Ribeiro AC, Kupa LVK, Borges BS, Shinjo SK, de Souza FHC, Miossi R, Bonfa E, Silva CA.Arthritis Care Res (Hoboken). 2026 Jun 15. doi: 10.1002/acr.80103. Online ahead of print.PMID: 42294825

Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guerin vaccine in high-risk bladder cancer.

Brown RJ, Khan MT, Houston AJ, Niu H, Podojil JR, Choy B, Cui W, Meeks JJ.J Clin Invest. 2026 Apr 21;136(12):e200442. doi: 10.1172/JCI200442. eCollection 2026 Jun 15.PMID: 42081487

Designing of a conserved subunit multiepitope vaccine candidate against Francisella tularensis Schu S4 using immunoinformatics.

Ahmed SS, Rahman MO, Banu M, Begum M, Ahmed MZ, Ali MA, Lee J, Hamid K, Alqahtani AS.Sci Rep. 2026 Jun 20. doi: 10.1038/s41598-026-58834-y. Online ahead of print.PMID: 42323435

Antibody reactivity to the VAR2CSA DBL5 domain among pregnant women in Northern Ghana.

Adda RB, Dassah SD, Mohammed AR, Kulariba J, Anabire NG, Abugri J.BMC Infect Dis. 2026 Jun 12. doi: 10.1186/s12879-026-13785-7. Online ahead of print.PMID: 42286496

Programming regulated cell death to engineer whole-tumor-cell vaccines for cancer immunotherapy.

Guan Y, Bai D, Bu N, Hao W, Maimaitiyiming Y.Biochim Biophys Acta Rev Cancer. 2026 Jun 19;1881(4):189640. doi: 10.1016/j.bbcan.2026.189640. Online ahead of print.PMID: 42320845

Human Metapneumovirus: An Underestimated Cause of Severe Respiratory Infection.

Cilloniz C, Ho A, Rhee C.Ann Am Thorac Soc. 2026 Jun 20:aaoag172. doi: 10.1093/annalsats/aaoag172. Online ahead of print.PMID: 42323864

Targeted delivery of the BCG vaccine to dendritic cells improves protective efficacy against Mycobacterium tuberculosis.

Counoupas C, Nisa A, Baker L, Pinto R, Bhattacharyya N, Demangel C, Britton WJ, Triccas JA.Vaccine. 2026 Jun 20;86:128753. doi: 10.1016/j.vaccine.2026.128753. Epub 2026 May 22.PMID: 42172693

Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System.

Zhang S, Li Y, Liu M, Yang J, Wang X, Wang M.PLoS One. 2026 Jun 17;21(6):e0351652. doi: 10.1371/journal.pone.0351652. eCollection 2026.PMID: 42308205

Adulthood diagnosis of Nijmegen breakage syndrome in twins with antibody deficiency clinical presentation.

González MAM, Rodríguez-Sainz C, Cardenas PP, Recio MJ, Gil-Herrera J.Clin Immunol. 2026 Jun 15;286:110732. doi: 10.1016/j.clim.2026.110732. Online ahead of print.PMID: 42297123

Medical Therapy for NF2-related Schwannomatosis: A Systematic Review of Current Evidence.

Zalaquett NG, Khandalavala KR, Marinelli JP, Lohse CM, Chelf CJ, Carlson ML.Otol Neurotol. 2026 Jun 11. doi: 10.1097/MAO.0000000000004968. Online ahead of print.PMID: 42276040

Protein-dependent CD4+ T cell specialization and CD8+ T cell-driven IL-2 production in HIV.

Pušnik J, Heinemann FM, Heinold A, Richter E, Esser S, Streeck H.iScience. 2026 Apr 27;29(6):115895. doi: 10.1016/j.isci.2026.115895. eCollection 2026 Jun 19.PMID: 42181234

Maternal antibody-mediated protection against chicken astrovirus: efficacy of novel inactivated vaccine.

Yahia N, Mahmoud SH, Abdelhalim A, Rhazi H, Salman AB, Atmah RB, Kamar S, Hussien HA, Eid S, Khalil AA.Vet Res Commun. 2026 Jun 16;50(5):396. doi: 10.1007/s11259-026-11346-6.PMID: 42301581

Modeling optimal deployment strategies for Nipah vaccines and monoclonal antibodies.

Cortes-Azuero O, Vegvari C, Sutcliffe E, Roney E, Scarponi D, Mukandavire C, Cauchemez S, Gurley E, Salje H.Vaccine. 2026 Jun 20;84:128688. doi: 10.1016/j.vaccine.2026.128688. Epub 2026 May 12.PMID: 42119335

Factors associated with severe health outcomes among community-dwelling older adults hospitalized with respiratory syncytial virus.

Atukorale VN, Kwong JC, Hernandez A, Moineddin R, Lee N, Kopp A, Andrew MK, Bronskill SE, Brown KA, Daneman N, Deeks SL, Johnstone J, McGeer AJ, McNally JD, Mubareka S, Murti M, Smieja M, Wilson SE, Zahariadis G, Bolotin S, Buchan SA.J Infect. 2026 Jun 16;93(2):106797. doi: 10.1016/j.jinf.2026.106797. Online ahead of print.PMID: 42302913

Global whole-genome, phylodynamic, and machine-learning analysis of *Glaesserella parasuis* serovars 2, 5, and 12.

Xu Z, Peng J, Wu Y, Du H, Chen J, Hong Q, Wu P, Xu C, Peng Z, Zhang J.Appl Environ Microbiol. 2026 Jun 17;92(6):e0252525. doi: 10.1128/aem.02525-25. Epub 2026 May 18.PMID: 42149609

Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms.

Weber LG, Wolff MW.Expert Rev Vaccines. 2026 Dec;25(1):2689611. doi: 10.1080/14760584.2026.2689611. Epub 2026 Jun 18.PMID: 42287073

Distinct Humoral Response Development to Measles Virus across Vaccine Platforms.

Chan AKP, Brockhurst JK, Liu L, Ghimire S, Baumgarth N, Griffin DE.J Infect Dis. 2026 Jun 17:jiag309. doi: 10.1093/infdis/jiag309. Online ahead of print.PMID: 42308538

Association Between COVID-19 Vaccination During Pregnancy and Safety Among Infants.

Quincer EM, Vazquez-Benitez G, Weintraub ES, Walton K, Wang L, Vesco KK, Henninger ML, Daley MF, Hambidge SJ, Williams JTB, Donahue JG, Zerbo O, Getahun D, Jackson LA, Fuller CC, Lipkind HS, Naleway AL, McNeil MM, Kharbanda EO.J Pediatric Infect Dis Soc. 2026 Jun 12;15(6):piag036. doi: 10.1093/jpids/piag036.PMID: 42231558

Integrated evaluation of antibody responses to mosquitoes and mosquito-borne pathogens using highly multiplexed serology.

Anahtar M, Striplet D, Philbin E, Lacsina JR, Valenzuela JG, Johansson MA, Oliveira F, Willen L, Kamhawi S, Cote-L'Heureux A, Crompton PD, Tran TM, Fortune SM, Neafsey DE.Sci Adv. 2026 Jun 12;12(24):eaeb7044. doi: 10.1126/sciadv.aeb7044. Epub 2026 Jun 12.PMID: 42284414

Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023.

Bush C, Desai S, Wang H, Hsu WC, Newbern EC, Toyip A, Grace S, Mues KE, Arakaki B, Khamamkar V, Esposito DB, Zhou CK.Vaccine. 2026 Jun 15;88:128821. doi: 10.1016/j.vaccine.2026.128821. Online ahead of print.PMID: 42296834

Multi-Modal Characterization of the Interactions between a Recombinant Protein Antigen and a Liposomal Adjuvant.

Qu F, Wagner AA, Payne EM, Pabit S, Foley DA, Bajoria S, Dick JE, Thompson DH, Kinsey C.Mol Pharm. 2026 Jun 14. doi: 10.1021/acs.molpharmaceut.5c01863. Online ahead of print.PMID: 42289982

MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.

Gay CL, Xu Y, Weideman AMK, Shaw FR, Kuruc JD, Conrad SZ, Mariano SA, Samir S, Kallon S, Sponaugle AT, Warren JA, Clutton GT, Abad-Fernandez M, Kapper C, Bradley AB, Baker CE, Pedersen SM, Moeser MJ, Burke L, Wee EG, Crook A, Laird GM, Cyktor JC, Mellors JW, Zhou S, Fox L, Eron JJ, Margolis DM, Hudgens MG, Hanke T, Goonetilleke N.J Clin Invest. 2026 May 5;136(12):e193547. doi: 10.1172/JCI193547. eCollection 2026 Jun 15.PMID: 42084923

Cross-sectional analysis of chikungunya vaccine acceptability among residents of Ponce, Puerto Rico, 2024-2025.

Guagliardo SAJ, Major CG, Rodriguez DM, Rivera-Amill V, Staples JE, Adams LE, Hills SL.Vaccine. 2026 Jun 19;88:128845. doi: 10.1016/j.vaccine.2026.128845. Online ahead of print.PMID: 42320381

Design and synthesis of RNA vaccines encoding SAG1 antigen of toxoplasma gondii and evaluation of immunogenicity and its protective efficacy against acute toxoplasmosis in BALB/c mice.

Zaki L, Ghaffarifar F, Sharifi Z, Horton J.Vaccine. 2026 Jun 11;88:128785. doi: 10.1016/j.vaccine.2026.128785. Online ahead of print.PMID: 42275801

Mapping Mpox vaccine hesitancy using an integrated machine learning and structural equation modeling approach.

Sultana N, Haque MA.Sci Rep. 2026 Jun 15. doi: 10.1038/s41598-026-58198-3. Online ahead of print.PMID: 42297967

The role of vaccinating pharmacists in public health advancement in Nigeria.

McKeirnan K, Alhayek J, Truter I, Fogarty TL, Akunne O.Curr Pharm Teach Learn. 2026 Jun 20;18(10):102725. doi: 10.1016/j.cptl.2026.102725. Online ahead of print.PMID: 42322768

A novel cystic fibrosis-mimetic Pseudomonas auxotrophic vaccine is protective in vivo and is associated with Th17 and IgA mucosal immunity.

Sereme Y, Villeret B, Caboche S, Ikeh S, Leroy H, Beury D, Maurier F, Desterke C, Born-Bony M, Xing Z, Voulhoux R, Sallenave JM.Mol Ther. 2026 Jun 17:S1525-0016(26)00506-X. doi: 10.1016/j.ymthe.2026.06.029. Online ahead of print.PMID: 42310961

Endocytosis-dependent and spleen-selective mRNA expression enabled by ionizable lipidoid linkers enhances therapeutic mRNA vaccination.

Shi L, You F, Sun Z, Hu Z, Zhang Y, Zhang Q, Chen J, Wang H, Ye Y, Chen J, Sun Y, Deng W, Sun C, Deng G.Acta Biomater. 2026 Jun 16:S1742-7061(26)00391-0. doi: 10.1016/j.actbio.2026.06.031. Online ahead of print.PMID: 42303148

Synthesis and Assessment of Imidazo-Fused β-Carbolines as Antileishmanial Agents.

Ghosh A, Hansda R, Bisht S, Acharjee P, Mishra G, Verma S, Bhatta RS, Purkait B, Batra S.ACS Infect Dis. 2026 Jun 12;12(6):2124-2135. doi: 10.1021/acsinfecdis.6c00223. Epub 2026 May 27.PMID: 42200351

A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.

Xu S, Zhang Q, Xie X, Zhou M, Chen Y, Liu Y, Luo C, Zhang Q, Zheng H, Feng S, Liao M.J Virol. 2026 Jun 11:e0056326. doi: 10.1128/jvi.00563-26. Online ahead of print.PMID: 42274212

Multiomics prediction and immunogenic validation of personalized neoantigens in cholangiocarcinoma patients.

Zhang B, Jin B, Wan X, Liu X, Wu X, Xing J, Wang Y, Xu H, Xu Y, Guan M, Mao Y, Bai Y, Zhu J, Chen Q, Du S.J Transl Med. 2026 Jun 17. doi: 10.1186/s12967-026-08471-w. Online ahead of print.PMID: 42310758

Innovative multi-epitope vaccine engineering for dual protection against Salmonella and Shigella leveraging FliC flagellin protein adjuvant properties: an immunoinformatics-based approach.

Afshari E, Soleimani N.J Transl Med. 2026 Jun 16. doi: 10.1186/s12967-026-08386-6. Online ahead of print.PMID: 42304404

Lipid nanoparticle formulations including stereochemically defined glycomacromolecules for delivery of saRNA.

Becker J, Dias-Barbieri B, Shattock RJ, Becer CR.Chem Sci. 2026 Jun 15. doi: 10.1039/d6sc03833f. Online ahead of print.PMID: 42306542

Comment on "Distinct differences between COVID-19 vaccine refusers and vaccine hesitant in the United States: Results from a population-based survey and latent class analysis".

Sati DM, Shinde VD, Agarwal C.Ann Epidemiol. 2026 Jun 16;121:110141. doi: 10.1016/j.annepidem.2026.110141. Online ahead of print.PMID: 42302953

Production of a Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases for Public Transportation Drivers: Protocol for a Scoping Review, a Delphi Study, and a Randomized Controlled Trial.

Salam M, El Dhaybe S, Ghannam L, Serhan M, Hassan M.JMIR Res Protoc. 2026 Jun 19;15:e89474. doi: 10.2196/89474.PMID: 42324927

Propagation and immunological characterization of three enterovirus D68 strains using serum-free HEK293A suspension cell culture.

Shen YS, Fang CY, Chan TT, Wu SR, Horng JT, Chow YH, Liao CL, Liu CC.Vaccine. 2026 Jun 20;84:128665. doi: 10.1016/j.vaccine.2026.128665. Epub 2026 May 5.PMID: 42086005

[Price effects of global vaccine pooled procurement].

Huang Y, Yu X, Xu M.Beijing Da Xue Xue Bao Yi Xue Ban. 2026 Jun 18;58(3):437-445. doi: 10.19723/j.issn.1671-167X.2026.03.001.PMID: 42287036

A bivalent mRNA-LNP vaccine confers broad-spectrum protection against both homologous and heterologous H5/H7 highly pathogenic avian influenza viruses in SPF chickens.

Wei D, Pan Y, Zhang X, Quan Y, Feng S, Huang M, Sun L, Yang Y, Zhou J, Han X, Niu B, Zhang Q, Jia W.Vet Res. 2026 Jun 18;57(1):111. doi: 10.1186/s13567-026-01790-2.PMID: 42316313

The Malaria Vaccine Implementation Programme reduced clinical malaria in Kenya, 2020 to 2022 : Impact evaluation with predictive time-series models of routine surveillance data.

Painter JA, Wallender E, Hill AN, Hamel M, Okine R, Furrer E, Jalang'o R, Keitany KK, Kariuki S, Nyang'au I, Seda B, Samuels AM, Westercamp N.Malar J. 2026 Jun 15. doi: 10.1186/s12936-026-05973-2. Online ahead of print.PMID: 42298619

Behavioural and social drivers of childhood immunisation uptake in sub-Saharan Africa: A rapid qualitative review.

Christian E, Tinessia A, Zhu J, Chutiyami M, Mahimbo A, King C, Abdi I.Vaccine. 2026 Jun 16;88:128844. doi: 10.1016/j.vaccine.2026.128844. Online ahead of print.PMID: 42302354

Regulation of antiviral immunity by PD-1 during respiratory syncitial virus infection and upon vaccination.

Rodríguez-Guilarte L, Méndez C, Rojas MF, Pereira-Sánchez P, Ríos M, Muñoz JT, Farías MA, Bueno SM, Kalergis AM.iScience. 2026 Jun 4;29(6):116157. doi: 10.1016/j.isci.2026.116157. eCollection 2026 Jun 19.PMID: 42305605

Recombinant subunit vaccine against Mycoplasma gallisepticum disease confers cross-protection against multiple pathogenic strains.

Miller JM, Ozyck RG, Mara AB, Hernandez EF, Malek JB, Tulman ER, Szczepanek SM, Geary SJ.Infect Immun. 2026 Jun 12:e0002526. doi: 10.1128/iai.00025-26. Online ahead of print.PMID: 42283569

Adherence to recommended immunization schedule during adolescence: findings of a cross-sectional study in the Southern part of Italy.

Licata F, Scicchitano CA, Ficara F, Di Gennaro G, Bianco A.BMC Public Health. 2026 Jun 18. doi: 10.1186/s12889-026-27991-0. Online ahead of print.PMID: 42316089

Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.

Ninmer EK, Zhu H, Sarkar A, Chianese-Bullock KA, Ross MI, Haas NB, von Mehren M, Boisvert ME, Kirkwood JM, Slingluff CL Jr.Clin Cancer Res. 2026 Jun 15;32(12):2381-2390. doi: 10.1158/1078-0432.CCR-25-4606.PMID: 41849224

Broadly cross-reactive mRNA COVID-19 vaccine encoding trimeric RBDs and NSP12 mitigates immune imprinting.

De Chiara A, Giachino C, Pirillo MF, Campanile A, Pellino E, Gallinaro A, Froechlich G, Falce C, Scognamiglio A, Totaro S, Liguori MV, Peltrini R, De Simone A, Capone S, Pietro Z, Negri D, Cara A, Nicosia A, Sasso E.Mol Ther Nucleic Acids. 2026 Mar 25;37(2):102918. doi: 10.1016/j.omtn.2026.102918. eCollection 2026 Jun 16.PMID: 42023032

The impact of unspecific viral adsorption on pharmaceutical container surfaces in vaccine process development.

Kress M, Heindl-Wruss J, Schlegl R, Jungbauer A.Vaccine. 2026 Jun 20;84:128635. doi: 10.1016/j.vaccine.2026.128635. Epub 2026 May 5.PMID: 42092316

Increasing prebunking effectiveness to aid disinformation-susceptible publics in overcoming vaccine-related disinformation.

Chou S, Boman CD.Vaccine. 2026 Jun 20;86:128749. doi: 10.1016/j.vaccine.2026.128749. Epub 2026 May 28.PMID: 42202424

Can a DNA vaccine protect against Chagas disease? A systematic review of preclinical studies.

Khan IA, Dos Santos EC, Novaes RD, Carvalho RPR, de Oliveira LL.Vaccine. 2026 Jun 11;83:128654. doi: 10.1016/j.vaccine.2026.128654. Epub 2026 May 4.PMID: 42085749

Comprehensive mapping of human CD4⁺ T cell epitopes for Nipah and measles as prototype Paramyxoviruses.

Tarke A, Macias M, Morales CF, Michaelis T, Siddiqui L, Yu ED, Trevizani R, Zuniga A, Zmasek C, Phillips E, Mallal S, Lin B, Estevez JO, Erlich JR, Johnson NV, McLellan JS, Frazier A, da Silva Antunes R, Tan GS, Grifoni A, Sette A.Cell Rep Med. 2026 Jun 16;7(6):102838. doi: 10.1016/j.xcrm.2026.102838. Epub 2026 Jun 2.PMID: 42229425

Timor-Leste's immunization journey: progress, challenges, and the road to IA2030 a viewpoint on leaving no child behind.

da Silva Marques M, de Neri Machado F, Soares NG, Dos Santos NB, de Oliveira JB, Sarmento N, da Costa Amaral BV, Babo LNMG, Amaral AXB, Mali MA.Vaccine. 2026 Jun 20;86:128746. doi: 10.1016/j.vaccine.2026.128746. Epub 2026 May 27.PMID: 42202422

Parental and Patients' Awareness, Knowledge, and Willingness for Human Papillomavirus Vaccination Among Survivors of Childhood Hematologic Malignancies.

Seyhanlı D, Karadag-Oncel E, Cakıl-Guzın A, Ozdem-Alatas Ş, Kasıkcı-Mermer E, İnce OT, Yılmaz Ş, Tufekcı-Gurocak Ö, Oren H, Belet N.Pediatr Hematol Oncol. 2026 Jun 20:1-14. doi: 10.1080/08880018.2026.2685015. Online ahead of print.PMID: 42322623

Structural basis and immunogenic efficacy of porcine circovirus type 3 virus-like particle.

Su J, Tong X, Jiang Y, Li Y, Yan H, Liu Y, Wang Y, Su X, Sun Z, Wang M, Xia N, Bostina M, Li S, Pang W, Zheng Q, Tian K.Nat Commun. 2026 Jun 16. doi: 10.1038/s41467-026-74388-z. Online ahead of print.PMID: 42303972

Dissecting serum polyclonal antibody escape to SARS-CoV-2 variants by deep mutational learning.

Shlesinger D, Sadilek V, Minot M, Stamkopoulos E, Bikias T, Kuhn R, Agrafiotis A, Taft JM, Yermanos A, Reddy ST.Cell Rep Methods. 2026 Jun 15;6(6):101417. doi: 10.1016/j.crmeth.2026.101417. Epub 2026 Apr 23.PMID: 42030951

Rational design and sequence optimization of an mRNA-LNP vaccine elicits protective immunity against infectious bronchitis virus in chickens.

Li R, Liukang C, Yang H, Zhang X, Liang R, Zhao J, Zhang G, Zhao Y.Vaccine. 2026 Jun 20;84:128685. doi: 10.1016/j.vaccine.2026.128685. Epub 2026 May 11.PMID: 42114415

Risk factors for community-acquired pneumonia in older adults in Japan after the introduction of the childhood PCV13.

Inoshima N, Nakashima K, Suzuki K, Nagasaka H, Niwa T, Nakahama C, Miyashita N, Iwamoto S, Kan S, Kondo K, Ohfuji S, Fukushima W.BMC Infect Dis. 2026 Jun 16. doi: 10.1186/s12879-026-13820-7. Online ahead of print.PMID: 42304222

HPV vaccination in people living with HIV: A network meta-analysis highlighting safety, immunogenicity, and evidence gaps.

Neto AAS, Souza ATB, Sarmento ACA, Gonçalves AK, Adedipe T, de Medeiros KS, Crispim JCO.Int J Gynaecol Obstet. 2026 Jun 20. doi: 10.1002/ijgo.71153. Online ahead of print.PMID: 42322124

Beyond Conventional Messaging: Critical Communication Strategies to Boost Vaccine Intentions.

Zhou M, Ramírez AS, Thompson H, Schillinger D.J Health Commun. 2026 Jun 15:1-12. doi: 10.1080/10810730.2026.2689094. Online ahead of print.PMID: 42294687

Highlights of 2025: Advances in the T-Cell Regulation of Germinal Center Response.

Zhou X, Chen Z.Immunol Cell Biol. 2026 Jun 16. doi: 10.1111/imcb.70141. Online ahead of print.PMID: 42304679

PREGNANT WOMEN COVID-19 IMMUNISATION IN 2026: EVIDENCE, UNCERTAINTY AND PRIORITIES.

Launay O, Ansellem O, Dashraath P, Loubet P, Baud D.Int J Infect Dis. 2026 Jun 13:108886. doi: 10.1016/j.ijid.2026.108886. Online ahead of print.PMID: 42288242

Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa: policy, evidence, and system readiness insights from a national workshop.

Ndjeka N, Subrayen P, Hanekom WA, Jassat W, Luabeya AKK, Mkhondo N, Muloiwa R, Tisile P, Ntshiqa T, Boffa J, Giersing B.Vaccine. 2026 Jun 20;86:128755. doi: 10.1016/j.vaccine.2026.128755. Epub 2026 May 26.PMID: 42190622

Immunological effects of β-glucan as a trained immunity-based adjuvant in vaccinated goats against anthrax.

Angulo M, Angulo C.Vet J. 2026 Jun 18;318:106748. doi: 10.1016/j.tvjl.2026.106748. Online ahead of print.PMID: 42309310

Optimization of chicory root polysaccharide liposomes and their adjuvant efficacy in Newcastle disease vaccination.

Tang Q, Li J, Hou C, Qiu Z, Huang L, Li Z, Chen K, Fei C, Liu Y, Wang M.Vaccine. 2026 Jun 20;86:128734. doi: 10.1016/j.vaccine.2026.128734. Epub 2026 May 22.PMID: 42167135

Prediction of pre- and postfusion conformations of class I fusion proteins with AlphaFold2.

Gülesen S, Most V, Schoeder CT, Meiler J.PLoS One. 2026 Jun 16;21(6):e0351662. doi: 10.1371/journal.pone.0351662. eCollection 2026.PMID: 42302011

Gaps and barriers preventing sustained delivery of HPV vaccination in Kano, Kaduna, and Lagos states: An exploratory qualitative study.

Ezechukwu C, Ayandipo EO, Osoteku D, Ibrahim R, Raheem O, Boldosser-Boesch A, Birse S, Weinstein E, Nonvignon J, Hadley G, Aigbogun E, Igbokwe U.PLoS One. 2026 Jun 18;21(6):e0350510. doi: 10.1371/journal.pone.0350510. eCollection 2026.PMID: 42313828

Booster vaccine reduces BCG-primed mice's protection against primary Mycobacterium tuberculosis infection by raising IL-10 levels.

Lei Q, Lin X, Yao Z, Fu H, Wang Y, Yuan Y, Ouyang Q, Xu X, Cao J, Gan M, Fan X.Vaccine. 2026 Jun 16;88:128841. doi: 10.1016/j.vaccine.2026.128841. Online ahead of print.PMID: 42308982

Streptococcus Pyogenes and Acute Rheumatic Fever: How Strong are the Links in the Chain?

Wirth SH, Beaton AZ, Steer A.Glob Heart. 2026 Jun 19;21(1):48. doi: 10.5334/gh.1564. eCollection 2026.PMID: 42327996

Engineered HSP90-MP65 Bivalent Fusion Antigen: A Novel Vaccine Candidate Against Invasive Candidiasis.

Wawiórka L.Proteins. 2026 Jun 18. doi: 10.1002/prot.70152. Online ahead of print.PMID: 42316901

Vaccination with live-attenuated Toxoplasma gondii mutants RHΔtkl1 and PruΔpp2a-c induces protective immunity in sheep.

Wu ZX, Kang Y, Hao WB, Wang YX, Zheng Z, Huang SB, Zheng XN, Zhu XQ.Parasit Vectors. 2026 Jun 16. doi: 10.1186/s13071-026-07516-9. Online ahead of print.PMID: 42304443

Single-Cell Sequencing Reveals Varying Cell-Mediated Immunity Profiles in Individuals With Distinct Antibody Responses Following Ad5-nCoV Booster.

Liao C, Long Y, Zha R, Cai L, Guan X, Bai J, Ye Y, Li X, Mao W, Wu J, Lu J, Ke Z, Guo C.J Infect Dis. 2026 Jun 16;233(6):1046-1057. doi: 10.1093/infdis/jiag078.PMID: 41640352

Pan- India molecular surveillance of dengue serotypes, 2023-2025.

Deshpande GRN, Tadkalkar N, Narayan J, Shinde P, Chalwad P, Gunjikar R, Salunke A, Srivastava R, Khutwad K, Vidhate S, Gupta N, Sapkal GN; VRDL network.Int J Infect Dis. 2026 Jun 20:108897. doi: 10.1016/j.ijid.2026.108897. Online ahead of print.PMID: 42323159

Correction to: Visual policy narrative messaging improves COVID-19 vaccine uptake.

[No authors listed]PNAS Nexus. 2026 Jun 19;5(6):pgag199. doi: 10.1093/pnasnexus/pgag199. eCollection 2026 Jun.PMID: 42327641

Recombinant subunit vaccines against invasive fungal infections: mechanisms, development progress, and therapeutic potential.

Xu X, Jiang B, Xiong J, Jiang Y, Lu H.Vaccine. 2026 Jun 18;88:128864. doi: 10.1016/j.vaccine.2026.128864. Online ahead of print.PMID: 42314309

Oral immunization with attenuated Salmonella enterica serovar Enteritidis expressing dual-toxin antigen induces protective immunity against avian necrotic enteritis.

Li W, Li YA, Liu X, Xie H, Zhao J, Feng Y, Shi H.Vaccine. 2026 Jun 20;84:128684. doi: 10.1016/j.vaccine.2026.128684. Epub 2026 May 8.PMID: 42105397

"I'll Never Get that Time Back": Public Health's Impact on Prolonged Incarceration in Los Angeles County.

Buchbinder L, Nguyen K, Samra S, Shoptaw S.J Correct Health Care. 2026 Jun 12:10783458261455723. doi: 10.1177/10783458261455723. Online ahead of print.PMID: 42283393

Comparative immunogenicity of monomeric and tetrameric Nipah virus G glycoprotein-based vaccine candidates demonstrate robust antibody responses in both forms.

Mishra S, Kumar V, Kaur G, Baby BA, Das A, Chatterjee A, Vishwakarma P, Sinha SK, Kumar A, Prasad VM, Dubey VD, Ahmed S, Samal S.Vaccine. 2026 Jun 20;84:128682. doi: 10.1016/j.vaccine.2026.128682. Epub 2026 May 9.PMID: 42107904

Effectiveness of seasonal mRNA COVID-19 vaccination against post COVID-19 condition between July 2023 and September 2024 among adults aged ≥ 60 years in Germany: a population-based cohort study.

Perumal N, Peine C, Steffen A, Wichmann O, Harder T.BMC Infect Dis. 2026 Jun 13;26(1):1140. doi: 10.1186/s12879-026-13803-8.PMID: 42288736

SKYVaricella (a live attenuated varicella vaccine) safety issues revisited.

Lee J.Ewha Med J. 2026 Jun 15. doi: 10.12771/emj.2026.01263. Online ahead of print.PMID: 42290266

Nanofiber Length Shapes Vaccine Immunity: Mechanistic Insights from M13 Bacteriophage.

Huang S, Madow A, Peng H, Qi J, Kumar A, Belcher AM.Nano Lett. 2026 Jun 17. doi: 10.1021/acs.nanolett.6c01556. Online ahead of print.PMID: 42308544

The 3'Untranslated region is a critical determinant of Getah virus replication, pathogenesis, and vector competence.

Ren T, Li P, Liu M, Zhang L, Zhong Z, Wang G, Wang X, Zhou L, Qin Y, Ouyang K, Yin Y, Chen Y, Huang W, Wei Z.Virulence. 2026 Dec;17(1):2687251. doi: 10.1080/21505594.2026.2687251. Epub 2026 Jun 18.PMID: 42262762

Influenza B mosaic HA mRNA-LNP vaccines are cross-reactive and protective in mice.

González-Domínguez I, Boza M, Abdeljawad A, Shea W, Puente-Massaguer E, Mishra M, Lemus N, Lai TY, Muramatsu H, Lam K, Heyes J, Martínez-Guevara JL, Krammer F, Palese P, Pardi N, Sun W.Mol Ther Nucleic Acids. 2026 Mar 30;37(2):102921. doi: 10.1016/j.omtn.2026.102921. eCollection 2026 Jun 16.PMID: 42028573

A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1).

Bettina H, Anna SJ, Reinhard K.Vaccine. 2026 Jun 20;86:128729. doi: 10.1016/j.vaccine.2026.128729. Epub 2026 May 18.PMID: 42155243

A dual-antigen mRNA-lipid polyplex vaccine elicits durable multistage immunity and sterile protection against malaria in mice.

Wang X, Wang A, Huang W, Tian P, Cao L, Xiao B, Han J, Huang Z, Jiang L.Acta Pharmacol Sin. 2026 Jun 16. doi: 10.1038/s41401-026-01850-5. Online ahead of print.PMID: 42304102

Uncovering COVID-19 vaccine acceptance and intent in 15 developing countries: a multi-level, clustered analysis of six months of repeated, cross-sectional data.

Smith CA, Handysides D, Cupino A, Nelson A, Beeson WL.BMC Infect Dis. 2026 Jun 19. doi: 10.1186/s12879-026-13739-z. Online ahead of print.PMID: 42321649

Decoding the human CD4(+) T cell epitope repertoire for Lassa fever virus reveals T cell-based pan-mammarenavirus vaccine candidates.

Lee Y, Siddiqui L, Tarke A, Kim M, Michaelis T, Macias M, Phillips E, Mallal S, Trevizani R, Frazier A, Scheuermann RH, Zuniga A, Zmasek C, Spurgers K, Akintunde G, Stonier SW, Gagliardi TB, Warfield K, Li H, Hastie KM, Saphire EO, Tan GS, Grifoni A, Sette A.Cell Rep Med. 2026 Jun 16;7(6):102824. doi: 10.1016/j.xcrm.2026.102824. Epub 2026 May 19.PMID: 42161271

Lessons from the 2024 avian influenza vaccination campaign in Finland: a qualitative inquiry.

Härmä V, Palsola M, Kuusipalo A, Lindh E, Melin M, Nohynek H.Vaccine. 2026 Jun 20;86:128736. doi: 10.1016/j.vaccine.2026.128736. Epub 2026 May 25.PMID: 42167136

From community mobilisation to school vaccination: experiences from Cameroon's first Expanded Programme on Immunisation-led school-based HPV campaign.

Haddison E, Nebongo D, Amponsah-Dacosta E.Vaccine. 2026 Jun 17;88:128848. doi: 10.1016/j.vaccine.2026.128848. Online ahead of print.PMID: 42308976

EpiMII: Structure-Aware Graph Neural Networks for MHC-II Epitope Generation.

Yuan J, Xu X, Sun ZY, Zhu S, Wei C, Liang T, Ge J, Xie XQ, Chen Y, Feng Z, Hou T, Xue Y.Research (Wash D C). 2026 Jun 15;9:1311. doi: 10.34133/research.1311. eCollection 2026.PMID: 42306778

Encapsulin-Protected Immunotherapeutic Complexes: Bacteria-Derived Nanoparticles for mRNA Delivery to Eukaryotic Cells.

Coffeen CF, Cayetano-Cruz M, Ilhuicatzi-Alvarado D, Méndez C, Moreno-Fierros L, Bustos-Jaimes I.ChemMedChem. 2026 Jun 15;21(11):e202501050. doi: 10.1002/cmdc.202501050.PMID: 42297566

Comparative risk of Guillain-Barré syndrome recombinant and live zoster vaccines: a pharmacovigilance study using VAERS and EudraVigilance database.

Xu Y, Li F, Huang L, Mei D, Du P.Immunol Med. 2026 Jun 11:1-13. doi: 10.1080/25785826.2026.2681258. Online ahead of print.PMID: 42275198

[Evaluation of bilateral vaccine cooperation priority countries on Chinese human papillomavirus vaccine using hierarchical K-means hybrid clustering].

Wu Y, Huang Y.Beijing Da Xue Xue Bao Yi Xue Ban. 2026 Jun 18;58(3):446-454. doi: 10.19723/j.issn.1671-167X.2026.03.002.PMID: 42287037

Representations of mpox in UK news media during the 2022 outbreak: a qualitative analysis.

Le Prevost M, Nicholls EJ, Bilardi D, David A, Kandasamy S, Stizioli M, Denford S, May T, Tan E, Tariq S.BMC Public Health. 2026 Jun 19. doi: 10.1186/s12889-026-28060-2. Online ahead of print.PMID: 42321700

Extracellular Vesicles of *Giardia duodenalis*: Unravelling Their Virulence Factors and Potential to Induce Protection Against Experimental Giardiasis.

Gerardo CR, Raúl AG, Dalia OL, Lizbeth SV, Onam PE, Martha EC, Daniel HC, Angélica SD, Abigail B, Guadalupe OM.J Extracell Biol. 2026 Jun 11;5(6):e70155. doi: 10.1002/jex2.70155. eCollection 2026 Jun.PMID: 42290664

Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study.

Malhotra G, Bilguche A, Eades O, Loftus MJ, Kennedy D, Giles ML, McGuinness SL.Vaccine. 2026 Jun 20;86:128735. doi: 10.1016/j.vaccine.2026.128735. Epub 2026 May 19.PMID: 42155244

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.

Zhang H, Liang H, Dai T, Shen N, Liu C, Zhou Y, Wei Z, Wu Z, Yu P, Zhang Q, Zhang X, Yu J, Ji X, Yang A, An C, Han Y, Jiao X, Qian L, Lu Z.NPJ Vaccines. 2026 Jun 19. doi: 10.1038/s41541-026-01503-y. Online ahead of print.PMID: 42315874

Measles epidemiology in Australia: 2014 to 2024. Erratum to 10.33321/cdi.2026.50.016.

Gorrell L, Polkinghorne B, Durrheim D.Commun Dis Intell (2018). 2026 Jun 16;50. doi: 10.33321/cdi.2026.50.048.PMID: 42296957

Second regulatory workshop on utilising in silico models to expedite vaccine development, testing, and lifecycle management - an expert meeting report.

Meln I, Van Molle W, Vélez MP, Baay M, Bracewell DG, Brusselmans K, Cardillo AG, Clénet D, Forestieri C, Girardon L, Gudjonsson A, Guzzi A, Hesselink R, Jørgensen JB, Lanzrath H, Lebrun P, Li X, von Lieres E, Mansois N, Natalis L, Pollinger JC, García LR, Şenel S, Spruth M, Welin M, Olesen OF, Calvosa E.Vaccine. 2026 Jun 20;86:128733. doi: 10.1016/j.vaccine.2026.128733. Epub 2026 May 24.PMID: 42177843

Systematic literature review on pneumococcal vaccination recommendations in national immunization programs for the pediatric population in select areas in the Asia Pacific region.

Zaidi O, Choi EH, Ip M, Yamada E, Du F, Bernauer M, Kim JO, Sukarom I.Hum Vaccin Immunother. 2026 Dec;22(1):2661118. doi: 10.1080/21645515.2026.2661118. Epub 2026 Jun 17.PMID: 42307717

Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.

Bhagchandani SH, Ehrenzeller S, Pires IS, Chaudhary N, Booth CJ, Kwon DI, Koutsioumpa C, Baker CA, Laxton C, Santos Guedes de Sá K, Matthews C, Gill P, Li S, Olszowka A, Hudak A, Fischer S, Bayarri-Olmos R, Hooper WB, Iwasaki A.Sci Immunol. 2026 Jun 19;11(120):eaea6419. doi: 10.1126/sciimmunol.aea6419. Epub 2026 Jun 19.PMID: 42319912

Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study.

Morio R, Takazono T, Morimoto S, Ashizawa N, Hirayama T, Yoshida M, Takeda K, Hirano K, Ide S, Iwanaga N, Hosogaya N, Funakoshi S, Yanagihara K, Mukae H.Vaccine. 2026 Jun 20;88:128861. doi: 10.1016/j.vaccine.2026.128861. Online ahead of print.PMID: 42322683

Multi-pathogen serosurveillance in Tonga examining demographic correlates and geographic clustering of 17 pathogens.

Lawford HLS, Tukia O, Takai J, Sheridan S, Ward S, Jian H, Martin BM, 'Ofanoa R, Vaccher S, Angrisano F, Robinson LJ, Lau CL.Sci Rep. 2026 Jun 18. doi: 10.1038/s41598-026-55309-y. Online ahead of print.PMID: 42315594

A ubiquitinated E2-based mRNA vaccine confers complete protection against lethal challenge with classical swine fever virus.

Zhai H, Gao Y, Wan N, Qu Y, Li S, Li L-F, Zhao T, Hou Q, Sun Y, Wu H, Li Y, Qiu H-J.J Virol. 2026 Jun 12:e0026926. doi: 10.1128/jvi.00269-26. Online ahead of print.PMID: 42283466

mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac).

Nakashima I, Saito S, Zhao J, Tanaka M, Akahoshi E, Hasegawa A, Sugano-Ishihara M, Yagyu S, Nakazawa Y.Mol Ther Oncol. 2026 May 14;34(2):201234. doi: 10.1016/j.omton.2026.201234. eCollection 2026 Jun 18.PMID: 42256207

Association of Respiratory Syncytial Virus Vaccination During Pregnancy With Adverse Obstetric and Neonatal Outcomes.

DeSilva M, Haapala J, Kharbanda EO, Vesco KK, Daley MF, Getahun D, Raisler K, Naleway AL, Jackson LA, Williams JTB, Klein NP, Jacobson KB, Jorgensen S, Dixon BE, Fuller CC, Weintraub ES, Quincer EM, Lipkind HS, Vazquez-Benitez G.Obstet Gynecol. 2026 Jun 18. doi: 10.1097/AOG.0000000000006354. Online ahead of print.PMID: 42314184

Nonclinical safety evaluation strategies for mRNA/LNPs platform agents: Evidence from comprehensive animal toxicity studies.

Ahn JH, Lee NY, Bae HJ, Kim J, Kwak J, Kwon E, Roh G, Bae SH, Lee SY, Hwang IK, Lee J, Park HJ, Kwon SP, Bang EK, Kim JE, Keum G, Nam JH, Kang BC.Toxicol Lett. 2026 Jun 14;422:111941. doi: 10.1016/j.toxlet.2026.111941. Online ahead of print.PMID: 42289207

Integration of modules on evidence-based vaccine communication strategies in disciplinary microbiology courses: two case studies.

Kelp NC, Worthington D, Ledbetter E, Mixter P.J Microbiol Biol Educ. 2026 Jun 16:e0011826. doi: 10.1128/jmbe.00118-26. Online ahead of print.PMID: 42300759

Immunogenicity and protective efficacy of an inactivated cluster 2.1 duck Tembusu virus vaccine in ducks: Evidence of cross-genotype immune responses.

Rungprasert K, Areeraksakul P, Tunterak W, Prakairungnamthip D, Wannaratana S, Yurayart N, Charoenvisal N, Limpavithayakul K, Jansen CA, Nedumpun T, Banlunara W, Thontiravong A.Vaccine. 2026 Jun 19;88:128867. doi: 10.1016/j.vaccine.2026.128867. Online ahead of print.PMID: 42320385

Evaluating the immunogenicity of clade 2 and clade 3 sarbecovirus spike protein nanoparticle vaccines in Syrian hamsters.

Halfmann PJ, Duffy A, Wang T, Kawaoka Y, Kane RS.Vaccine. 2026 Jun 20;84:128653. doi: 10.1016/j.vaccine.2026.128653. Epub 2026 May 11.PMID: 42114416

Early rheumatic heart disease is a recognized intermediate on the pathway to advanced rheumatic heart disease.

Marangou J, Wirth SH, Zühlke L, Rwebembera J, Mwita JC, Kim J, Kraus AA, Karron R, Carapetis J, Steer A, Beaton A.Int J Cardiol. 2026 Jun 15;453:134432. doi: 10.1016/j.ijcard.2026.134432. Epub 2026 Mar 14.PMID: 41833866

Health system stakeholders' perceptions of religious and socio-cultural influences on measles vaccine hesitancy in Madagascar: a qualitative study.

Alain F, Raharinivo M, Razafimahatratra MJJ, Randrianasolo FH, Ramananjanahary H, Andriambelo MM, Andrianirinarison JC, Tsivahiny P, Sahondranirina HP, Yasmine LL, Ratsiambakaina D.BMC Public Health. 2026 Jun 15. doi: 10.1186/s12889-026-28130-5. Online ahead of print.PMID: 42298532

Broadly reactive human monoclonal antibodies targeting influenza a nucleoprotein lack protective activity in vivo.

Harrington WN, Brice DC, Schmitz AJ, Turner JS, Brent R, Mudd PA, Ellebedy AH, Webby RJ.Sci Rep. 2026 Jun 16. doi: 10.1038/s41598-026-58084-y. Online ahead of print.PMID: 42304032

Validating sociodemographic disparities in HPV vaccine uptake in a universal, publicly funded, low barrier, school-based immunisation program in the Vancouver Coastal Health region of British Columbia, Canada: A cross-sectional study.

Lawal S, Bakos B, St Jean M, Symonds L, Rivers K, Demlow E, Dawar M.Can J Public Health. 2026 Jun 16. doi: 10.17269/s41997-026-01211-z. Online ahead of print.PMID: 42303949

Novel capsular diversity and antimicrobial resistance determinants of Staphylococcus aureus associated with bovine and bubaline mastitis.

Ghafoor M, Saqib M, Ashfaq K, Rehman SU.Pol J Vet Sci. 2026 Jun 15;29(2):313-326. doi: 10.24425/pjvs.2026.1277.PMID: 42299085

Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.

McCafferty K, Barratt J, Suzuki Y, Liew A, Rizk DV, Chacko B, Kooienga L, Lafayette R, Wong MG, Pasetti MF, Shriver MC, Follman K, Moc Willeford C, Sahay M, Honig G, Andrews L, Olinski LE, Mathur M, Oldach D.Clin J Am Soc Nephrol. 2026 Jun 11. doi: 10.2215/CJN.0000001089. Online ahead of print.PMID: 42275148

Engineering a dual-antigen mRNA vaccine to restore immune control in chronic hepatitis B.

Zhang B, Wang Y, Chen D, Li M, Zhang J, Wu Y, Xia J, Meng X, Wang Y, Li M.Nat Commun. 2026 Jun 18. doi: 10.1038/s41467-026-74006-y. Online ahead of print.PMID: 42315521

Understanding factors influencing HPV vaccine uptake among caregivers in Kwara State, Nigeria: A qualitative study.

Muhammad-Olodo AO, Asher L.PLoS One. 2026 Jun 16;21(6):e0351659. doi: 10.1371/journal.pone.0351659. eCollection 2026.PMID: 42302043

Mortality and Morbidity Benefit After Influenza Vaccination in High Cardiovascular Risk Population: A Systematic Review and Meta-analysis.

Hosseini K, Dastjerdi P, Sahzabi RY, Alipoor A, Masanabadi M, Rezvanian P, Daryabari Y, Mehdizadeh M, Soleimani S, Modin D, Skaarup KG, Biering-Sørensen T.Am J Cardiol. 2026 Jun 15;269:147-155. doi: 10.1016/j.amjcard.2026.03.040. Epub 2026 Apr 6.PMID: 41951138

Beyond the vaccine baseline: Optimizing mRNA stability and translation via regulatory element engineering.

Cagnin S.Mol Ther Nucleic Acids. 2026 Mar 15;37(2):102879. doi: 10.1016/j.omtn.2026.102879. eCollection 2026 Jun 16.PMID: 41883583

Association of COVID-19 vaccination before 12 weeks of gestation with ultrasound-detected congenital anomalies compared with later or no vaccination: A registry-based cohort study.

Taghavi SA, Bazarganipour F, Moradi-Joo M, Seyedi Z, Dabiri F, Bozorgian L, Manzori L.SAGE Open Med. 2026 Jun 15;14:20503121261460259. doi: 10.1177/20503121261460259. eCollection 2026.PMID: 42312222

Cascade active-targeting nanoplatform via multi-ligand regulation for spleen-selective mRNA delivery.

He X, Jiao X, Zheng Q, Li G, Shi H, He Z, Guo J, Song X.J Control Release. 2026 Jun 15;396:115087. doi: 10.1016/j.jconrel.2026.115087. Online ahead of print.PMID: 42297113

5'-End Translationalization: Iterative Assembly of Leaderless Polycistronic Amplifiers for Context-Independent Expression in the Food-Grade Bacterium *Corynebacterium glutamicum*.

Sun M, Ye B, Zhao Y, Ledesma-Amaro R, Eshboev F, Gao AX, Wang P.J Agric Food Chem. 2026 Jun 17. doi: 10.1021/acs.jafc.6c05362. Online ahead of print.PMID: 42308144

Oral immunization of Nile tilapia with Chlorella-bioencapsulated multi-epitope fusion antigen effectively protects against Streptococcus agalactiae infection.

Deng X, Xiao Z, Mu D, Xu D, Li J, Yang Y, Gu H, Hu Y, Fei X.Fish Shellfish Immunol. 2026 Jun 11;176:111504. doi: 10.1016/j.fsi.2026.111504. Online ahead of print.PMID: 42269990

Water, Hygiene and Inequality: Keys to Understanding and Combating the Current Cholera Epidemic in the Democratic Republic of Congo-A Narrative Review.

Yokolo H, Tayebelasma A, Lohano G, Khan BK, Junaid A.Health Sci Rep. 2026 Jun 11;9(6):e72658. doi: 10.1002/hsr2.72658. eCollection 2026 Jun.PMID: 42291719

Impact of confidence in scientific community, manufacturers, and regulatory authorities on acceptance of locally manufactured mRNA vaccines.

Wong LP, Alias H, Lee HY.Vaccine. 2026 Jun 12;88:128792. doi: 10.1016/j.vaccine.2026.128792. Online ahead of print.PMID: 42284810

Multiple broadly neutralizing antibody lineages can co-exist and mature in the same germinal centers.

Garg AK, Binder SC, Meyer-Hermann M.Cell Rep. 2026 Jun 12;45(6):117543. doi: 10.1016/j.celrep.2026.117543. Online ahead of print.PMID: 42287633

HERPUD1 suppresses porcine epidemic diarrhea virus replication by recruiting HRD1 to degrade viral ORF3 protein.

Xu Y, Mou C, Xiang Y, Liu H, Bao W, Chen Z.J Virol. 2026 Jun 17:e0062626. doi: 10.1128/jvi.00626-26. Online ahead of print.PMID: 42307246

A novel cross-species vaccine design and nasal immunization strategy based on recombinant Lactiplantibacillus plantarum expressing PEDV tS1.

Hao J, Zhou X, Zhang G, Deng L, Li L, Wang M.Appl Environ Microbiol. 2026 Jun 17;92(6):e0038626. doi: 10.1128/aem.00386-26. Epub 2026 May 11.PMID: 42112891

Factors contributing to incomplete vaccination among children aged 12 to 59 months in Mbale city, Eastern Uganda: a caregivers and health workers' perspective.

Bwade MA, Olowo S, Nakawuki A, Namubiru E, Mbwali I, Adongo PR, Nabirye RC, Oboth P, Nekaka R, Stanley IJ, Ssenyonga LV.BMC Pediatr. 2026 Jun 16. doi: 10.1186/s12887-026-07132-7. Online ahead of print.PMID: 42298493

Lipid nanoparticle composition directs systemic trafficking and tissue-specific T cell immunity after intramuscular injection.

Wei C, Zhu Y, Lu X, Goodier KD, Yu D, Liu X, Choy J, Téllez Calderón A, Su Y, Ma J, Lin J, Li S, Schneck JP, Murphy SC, Mao HQ.Nat Biomed Eng. 2026 Jun 12. doi: 10.1038/s41551-026-01706-7. Online ahead of print.PMID: 42286249

Dengue: Brazil suspends rollout of new vaccine after two deaths.

Taylor L.BMJ. 2026 Jun 15;393:e205610. doi: 10.1136/bmj-2026-205610.PMID: 42297416

Routine immunization uptake and timeliness in young children exposed to multidrug-resistant tuberculosis: A secondary analysis of the Tuberculosis Child Multidrug-Resistant Preventive Therapy multi-site randomised controlled trial.

Patel F, Purchase S, Dhar M, Horne E, Grab J, Soma-Kasiram H, Sabet N, Martinson N, Staples S, Brigden J, Wilkinson T, Schaaf HS, Seddon J, Fairlie L, Hesseling A, Duong T.BMC Glob Public Health. 2026 Jun 16;4(1):59. doi: 10.1186/s44263-026-00290-x.PMID: 42304464

Safety of diphtheria-tetanus-acellular pertussis (DTaP) vaccination during pregnancy in mothers and infants: The Shizuoka Study.

Ohfuji S, Kasamatsu A, Tanaka T, Mochizuki C, Takeuchi T, Sugawara Y, Fukuma H, Okada K, Fukushima W.Int J Infect Dis. 2026 Jun 17:108887. doi: 10.1016/j.ijid.2026.108887. Online ahead of print.PMID: 42309477

Influenza Vaccination Among Individuals With Type 1 Diabetes in Denmark: Coverage, Persistence, and Determinants, 2015-2022.

Karunakaran V, Pedersen IB, Hjelholt A, Kjølby M, Vestergaard ET, Frøbert O, Isaksen AA, Kristensen K.Diabetes Obes Metab. 2026 Jun 14. doi: 10.1111/dom.70965. Online ahead of print.PMID: 42289795

Beyond the clinic gate: barriers to childhood immunization access and strategies for improvement at a rural Zimbabwean clinic.

Shava E, Chiwungwe F, Chitura M.BMC Public Health. 2026 Jun 20. doi: 10.1186/s12889-026-28189-0. Online ahead of print.PMID: 42321741

Corrigendum to "Heterologous DNA prime-crude tachyzoite lysate antigen boost targeting MIC8 confers protection against acute and chronic Toxoplasma gondii infection in mice" [Vaccine 80 (2026) 128554].

Peter AM, Ambu SP, Davamani FA, Somanath SD, Chakravarthi S.Vaccine. 2026 Jun 11;83:128637. doi: 10.1016/j.vaccine.2026.128637. Epub 2026 May 2.PMID: 42070374

Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial.

Pley C, Jeffries DJ, Kanteh E, Strandmark J, Baldeh AK, Leigh MN, Ndow P, Clarke E, Kampmann B.Lancet Infect Dis. 2026 Jun 11:S1473-3099(26)00193-3. doi: 10.1016/S1473-3099(26)00193-3. Online ahead of print.PMID: 42276083

Occupational PFAS burden in German firefighters: Associations with aqueous film-forming foam contact frequency.

Rengelshausen J, Sauer D, Esser A, Fraune E, Safavi M, Kraus T, Schettgen T, Ziegler P.Int J Hyg Environ Health. 2026 Jun 11;276:114848. doi: 10.1016/j.ijheh.2026.114848. Online ahead of print.PMID: 42275870

Breakthrough varicella infection: a retrospective cohort study based on large-scale real-world data in Guangxi, China, 2014-2025.

Wang J, Li S, Zhou W, Huang J, Huang Y, He W, Nong X, Ning C, Lan G, Zeng X.Vaccine. 2026 Jun 17;88:128838. doi: 10.1016/j.vaccine.2026.128838. Online ahead of print.PMID: 42308974

SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.

Abdullahi A, Morse RB, Kin Cheng MT, Ige F, Onyemata J, Edun M, Kramna A, Sievers B, Turner S, Wisso H, Jonathan E, Balogun O, Salako A, Abdulazeez-Oha H, James A, Musa A, Oluwaseun O, Iwalokun B, Ezechi O, Anzaku A, Okpokoro E, Osawe S, Nwikue G, Kida IM, Musa BM, Murtala HA, Meng B, Rosenzweig L, Aliyu SH, Smith D, MacAry P, Doffinger R, Więcek W, Salako B, Tan CW, Abimiku A, Gupta RK.iScience. 2026 Apr 28;29(6):115910. doi: 10.1016/j.isci.2026.115910. eCollection 2026 Jun 19.PMID: 42221816

Influenza Vaccination Effectiveness Against Influenza-Associated Hospitalization in Children and the Effects of Repeated Vaccination.

Yu X, Lee SL, Kwan MYW, Zhong S, Murphy C, Chan ELY, Wong JSC, Sullivan SG, Peiris M, Cowling BJ.J Infect Dis. 2026 Jun 16;233(6):e1355-e1363. doi: 10.1093/infdis/jiag047.PMID: 41589063

A CXCL20a point mutant enhances the immune protection induced by an inactivated GCRV vaccine in grass carp.

Lu Y, Wang S, Chen G, Xu Y, Su J, Yang C.Fish Shellfish Immunol. 2026 Jun 18:111527. doi: 10.1016/j.fsi.2026.111527. Online ahead of print.PMID: 42315065

Biodistribution of mRNA vaccines in rats: Enrichment in injection site and lymph tissues and rapid clearance without tissue persistence.

Goody SMG, Rowbottom C, Liu Y, Chen N.Mol Ther Nucleic Acids. 2026 May 6;37(2):102948. doi: 10.1016/j.omtn.2026.102948. eCollection 2026 Jun 16.PMID: 42233109

Repeat Influenza Vaccination Effects in 2021/22 and 2022/23 in a Community-Based Cohort in Hong Kong.

Zhong JC, Zhong S, Touyon L, Ho F, Au NYM, Cheng SMS, Ip DKM, Peiris M, Martin ET, Cobey S, Wong SS, Leung NHL, Cowling BJ.J Infect Dis. 2026 Jun 16;233(6):e1364-e1373. doi: 10.1093/infdis/jiag051.PMID: 41601201

A novel subunit vaccine based on glycoprotein H and glycoprotein L fusion against pseudorabies virus infection.

Yu X, Xie S, Luo Y, Zheng J, Feng Z, Yang L, Qing R, Yu X.Vaccine. 2026 Jun 20;84:128681. doi: 10.1016/j.vaccine.2026.128681. Epub 2026 May 8.PMID: 42105396

A novel ferritin-based nanoparticle vaccine targeting IgE confers protection against chronic allergic asthma in a murine model.

Li W, Liu S, Cui W, Tang S, Huang Y, Li Y, Jin X, Ding Z, Tan W, Wei Z.Vaccine. 2026 Jun 20;86:128754. doi: 10.1016/j.vaccine.2026.128754. Epub 2026 May 27.PMID: 42202421

Molecular characterization of thioredoxin peroxidases 1 from Trichinella spiralis and its potential in generating protective immunity.

Tong M, Guo Z, Wang M, Yang Y, Fu M, Gao Y, Ren J, Wang Z, Yu P, Zhou X, Liu H, Wang H, Wang H.Parasit Vectors. 2026 Jun 20. doi: 10.1186/s13071-026-07517-8. Online ahead of print.PMID: 42323668

Bioinformatics, expression, and immunogenicity analysis of MPXV A7 protein.

Wang C, Xiong J, Zhou H, Zhu H, Li Z, Li J, Li M, Peng Q, Wang T, Kong L.Protein Expr Purif. 2026 Jun 20:106963. doi: 10.1016/j.pep.2026.106963. Online ahead of print.PMID: 42323035

Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies.

Singh B, Singh D, Sah A, Kumari P, Kumar D, Sharma D.Int Immunopharmacol. 2026 Jun 19;185:117042. doi: 10.1016/j.intimp.2026.117042. Online ahead of print.PMID: 42322854

The Plasmodium vivax high molecular weight (HMW) rhoptry 3 protein (RhopH3) is involved in human red blood cell binding.

Gutiérrez-Ortegón D, Barreto-Santamaría A, Arévalo-Pinzón G, Patarroyo MA.Acta Trop. 2026 Jun 18:108192. doi: 10.1016/j.actatropica.2026.108192. Online ahead of print.PMID: 42314857

Clinical and genomic characterization of Influenza A co-infection with SARS-CoV-2 and Influenza B: a respiratory surveillance study in Assam, India.

Sarmah N, Siddique AI, Dutta M, Jakharia A, Bali N, Vijay N, Gupta N, Kanungo S, Borkakoty B.Sci Rep. 2026 Jun 12. doi: 10.1038/s41598-026-55080-0. Online ahead of print.PMID: 42286013

A novel oral vaccine strategy utilizing a plasmid with CAG promoter-driven alphavirus RdRp for Co-expression of NA epitope and adjuvant in attenuated Salmonella boosts immune responses against H9N2 in mice.

Wang M, Gao Y, Zhang Y, Zhang G, Xu Y, Wang T, Yang T, Zhang Y, Sun Y, Guo Q, Wang Z, Wang C, Jiang Y.Microb Pathog. 2026 Jun 15;218:108640. doi: 10.1016/j.micpath.2026.108640. Online ahead of print.PMID: 42297223

Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.

Di Cecca M, V B, M G, F F, V T, G B, C L, A R, B R, S R, F P, L P, L F, M T T, B A, L C, E S, F F, T CDT, A M Q, S P, M L, A T, A P, M T P, L R, O A.Adv Hematol. 2026 Jun 15;2026:5597825. doi: 10.1155/ah/5597825. eCollection 2026.PMID: 42311698

Association between deployment and Gulf War Illness and adverse COVID outcomes in a nationwide cohort of 1990-1991 Gulf Era war veterans in the VA's Million Veteran Program.

White DL, NonoDjotsa ABS, Ahmed ST, Boyle SH, Gaziano JM, Thompson AD, Johnson MG, Gifford EJ, Polimanti R, Aslan M, Hauser ER, Helmer DA; Million Veterans Program (MVP).PLoS One. 2026 Jun 15;21(6):e0348594. doi: 10.1371/journal.pone.0348594. eCollection 2026.PMID: 42296096

A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines.

Seo HY, Jung H, Lee SY, Jung HG, Cho H, Son YM, Bak Y, Hwang SY, Kim JH, Park IH, Shin JS, Oh JW.Mol Ther Nucleic Acids. 2026 Mar 5;37(2):102886. doi: 10.1016/j.omtn.2026.102886. eCollection 2026 Jun 16.PMID: 41883582

Nonclinical Safety Profiles of mRNA Therapeutics Comprising Unmodified or N1-Methyl-Pseudouridine-Modified Nucleosides Are Similar Following Repeated Administration.

Draycheva A, Millecam J, Caba E.Int J Toxicol. 2026 Jun 19:10915818261446630. doi: 10.1177/10915818261446630. Online ahead of print.PMID: 42319297

mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.

Skelly AN, Fan C, Keeffe JR, Ökten AB, Gavor E, Newby ML, Allen JD, Kreider EF, Ding W, Osbaldeston RA, Park Y, Connell AJ, Lituchy MG, Bibollet-Ruche F, Radford KM, P West A Jr, Peña-Hernández MA, Cruickshank K, Liu W, Li Y, Albertus A, McWilliams B, Russell RM, Konrath KM, Torres JL, Yuan M, Gao H, Montefiori DC, Saag MS, Goepfert PA, Kulp DW, Ward AB, Wilson IA, Shaw GM, Andrabi R, Crispin M, Weissman D, Wilen CB, Bjorkman PJ, Hahn BH.Proc Natl Acad Sci U S A. 2026 Jun 16;123(24):e2536870123. doi: 10.1073/pnas.2536870123. Epub 2026 Jun 8.PMID: 42258728

The effect of mobile phone messaging to support COVID-19 vaccination in Colombia: A randomized controlled clinical trial.

Vecino-Ortiz AI, Guzman-Tordecilla DN, Maniar V, Agudelo-Londoño S, Aya Pastrana N, Franco Suárez O, Rodríguez Patarroyo M, Mejia-Rocha M, Chavez Chamorro M, Ortiz Hoyos JL, Trujillo AJ, Ali J, Gibson DG.PLOS Glob Public Health. 2026 Jun 11;6(6):e0006387. doi: 10.1371/journal.pgph.0006387. eCollection 2026.PMID: 42275377

Willingness to pay for influenza vaccination among the elderly in Vietnam: A triple-bounded dichotomous choice analysis of economic and behavioral determinants.

Le MH, Tran ND, Nguyen TTT, Phan TTN, Pham TT, Tran ND.Vaccine. 2026 Jun 18;88:128852. doi: 10.1016/j.vaccine.2026.128852. Online ahead of print.PMID: 42314310

Respiratory syncytial virus infection in adults: Clinical manifestations, outcomes, and vaccines.

Hsu CH, Hsuan YT, Chan YJ, Chen HP.J Chin Med Assoc. 2026 Jun 19. doi: 10.1097/JCMA.0000000000001398. Online ahead of print.PMID: 42311194

L220-derived peptide-bioconjugated carbon nanotubes protect hamsters against amoebic liver abscess through IL-17A-Associated immune response.

Velarde-Calderón A, Guzmán-Mendoza JJ, Orrantia-Borunda E, Chávez-Flores D, Del Carmen González-Horta M, González-González AM, Talamás-Rohana P, Sánchez-Ramírez B.Nanomedicine. 2026 Jun 18:102972. doi: 10.1016/j.nano.2026.102972. Online ahead of print.PMID: 42314956

Differential immune responses elicited by two tetravalent epitope-based DNA vaccines differently designed for human hand-foot-and-mouth disease.

Bello AM, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, Roshorm YM.Vaccine. 2026 Jun 13;88:128824. doi: 10.1016/j.vaccine.2026.128824. Online ahead of print.PMID: 42287823

Circadian rhythm of dendritic cells directs the time-dependent efficacy of photodynamic therapy.

Zhang R, Dong S, Zheng Y, Fu Y, Sun T, Zhou J, Liu Y, Liu G, Wei X.Cell Commun Signal. 2026 Jun 20. doi: 10.1186/s12964-026-02973-2. Online ahead of print.PMID: 42323694

Clinical predictors of SARS-CoV-2 vaccine immunogenicity in kidney transplant recipients at a rural center.

Basuli D, Ross B, Rebellato LM.World J Transplant. 2026 Jun 18;16(2):119075. doi: 10.5500/wjt.v16.i2.119075.PMID: 42281871

Safety and Early Immune Dynamics Following First Dose of the MMR Vaccine in a Toddler Treated With a JAK Inhibitor.

Maritsi D, Neofytou A, Papadimitriou M, Marmarinos A.Pediatr Infect Dis J. 2026 Jun 16. doi: 10.1097/INF.0000000000005274. Online ahead of print.PMID: 42298336

Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.

Alharbi AS, Abu-Shraie N, Al Abdulkarim H, Alharbi IH, Averin A, Law AW, Mendes D, Quinn E, Zayed M, Behiry A, Haridy H, Mousa M.Infect Dis Ther. 2026 Jun 17. doi: 10.1007/s40121-026-01386-5. Online ahead of print.PMID: 42307865

Global, regional, and national burdens of human papillomavirus-associated cervical cancer attributable to sexually acquired human papillomavirus infections among individuals aged 10-54 years from 1990 to 2021: findings from the Global Burden of Disease study 2021.

Nov P, Wang D, Tan M, Virak V, Zhou X, Liu K, Zhu Y, Zhou S, Zhu H.Sex Med. 2026 Jun 16;14(4):qfag045. doi: 10.1093/sexmed/qfag045. eCollection 2026 Aug.PMID: 42312021

Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients.

Zhang H, Wang Y, Wang X, Duan H, Yu D, Kuang X, He L, Zhang W, Chen J, Dai J.J Transl Med. 2026 Jun 19. doi: 10.1186/s12967-026-08430-5. Online ahead of print.PMID: 42321862

Anchoring convenience survey samples to a baseline census for vaccine coverage monitoring in global health.

Dyrkton N, Alam S, Shepherd S, Sana I, Phelan K, Park JJH.Vaccine. 2026 Jun 11;88:128820. doi: 10.1016/j.vaccine.2026.128820. Online ahead of print.PMID: 42275800

Nationwide survey for household preparedness and vaccination acceptance during a novel influenza pandemic scenario in Japan, 2025.

Okubo Y, Honjyo R, Uda K, Miyairi I.Vaccine. 2026 Jun 20;86:128738. doi: 10.1016/j.vaccine.2026.128738. Epub 2026 May 22.PMID: 42176440

Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018-2024.

Masters NB, Farrar KG, Do D, Cartwright BMG.Hum Vaccin Immunother. 2026 Dec;22(1):2687231. doi: 10.1080/21645515.2026.2687231. Epub 2026 Jun 16.PMID: 42301805

Correlation between multiple protective health behaviors can determine the outcome of disease spread.

Mehta RS.Theor Popul Biol. 2026 Jun 11;170:11-25. doi: 10.1016/j.tpb.2026.04.003. Online ahead of print.PMID: 42276297

Leaving no child behind? developing zero-dose and under-immunized child archetypes to improve vaccine uptake in Nigeria.

Isah A, Ugochukwu EJ, Mbachu CO, Agu IC, Ekwueme CN, Uzochukwu BSC, Onwujekwe O.Vaccine. 2026 Jun 20;84:128678. doi: 10.1016/j.vaccine.2026.128678. Epub 2026 May 7.PMID: 42097104

Preparing for exotic foot-and-mouth disease virus outbreaks in the European neighbourhood: cross-neutralisation of internationally available vaccines against South American serotype O and serotype A field isolates.

Parekh K, Paton DJ, Browning C, Wilsden G, Mioulet V, Wood BA, McCarron A, Bull H, Baguisi J, Chantler V, Pituco EM, Sanchez-Vazquez MJ, J Knowles N, King DP, Ludi A.Vaccine. 2026 Jun 20;86:128718. doi: 10.1016/j.vaccine.2026.128718. Epub 2026 May 23.PMID: 42176438

Fusion with immunoglobulin Fc fragment enhances the immunogenicity of the African swine fever virus p30/p54 fusion protein.

Dang H, Ru Y, Wu G, Hao R, Xu J, Li Y, Zhao D, Jiang C, Han S, Hu X, Wu X, Yang Y, Zheng H.Appl Microbiol Biotechnol. 2026 Jun 15. doi: 10.1007/s00253-026-13919-6. Online ahead of print.PMID: 42298146

Engineering Komagataella phaffii for secreted and surface-displayed production of SARS-CoV-2 receptor-binding domain and its immunogenicity evaluation.

Dmytruk K, Dmytruk O, Semkiv M, Vasylyshyn R, Fayura L, Gaffke L, Podlacha M, Cyske Z, Pierzynowska K, Budylowski P, Ostrowski M, Wegrzyn G, Sibirny A.Microb Cell Fact. 2026 Jun 11. doi: 10.1186/s12934-026-03043-5. Online ahead of print.PMID: 42277856

COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study.

Heudel PE, Avrillon V, Mastroianni B, Boyle H, Assaad S, Ray-Coquard I, Spano JP, Chabaud S, Cropet C, Perol M, Blay JY.Eur J Cancer. 2026 Jun 18;241:116770. doi: 10.1016/j.ejca.2026.116770. Epub 2026 May 6.PMID: 42127458

Outcomes in adult liver transplant patients receiving recombinant herpes zoster vaccine.

Henkes NC, Heien HC, Inselman JW, Farraye FA, Keaveny AP.Vaccine. 2026 Jun 19;88:128859. doi: 10.1016/j.vaccine.2026.128859. Online ahead of print.PMID: 42322677

Nationwide spread of multidrug resistant Klebsiella pneumoniae across US communities.

Jiang J, Terlecky AJ, Rome KJ, Shashkina E, Manca C, Starolis MW, Larsen J, Olufunmi A, Aptekmann AA, Lozy T, Yen KK, Bucich MJ, Jones RS, Mathema B, Pitout JDD, Chen L, Kreiswirth BN.Nat Commun. 2026 Jun 11. doi: 10.1038/s41467-026-74379-0. Online ahead of print.PMID: 42277066

Impact of EV-A71 vaccination and non-pharmaceutical interventions on hand, foot, and mouth disease: A 14-year interrupted time series analysis.

Dong S, Li M, Huo D, Zhao H, Li R, Gao Z, Wang X, Zhang D, Tsang TK, Wang Q, Yang P.J Infect. 2026 Jun 12;93(2):106795. doi: 10.1016/j.jinf.2026.106795. Online ahead of print.PMID: 42285524

A six-proline stabilized trimeric spike DNA vaccine induces robust immunity and protects against SARS-CoV-2 delta challenge in K18-hACE2 transgenic mice.

Gül-Mete A, Gül C, Karakavuk T, Karakavuk M, Can H, Ülbeği-Polat H, Serhatlı M, Yazıcı H, Köm Ş, Ekiz AT, Abaci-Bayraktar İ, Aksoy Ö, Enül H, Adıay C, Uzar S, Saraç F, Değirmenci Döşkaya A, Gürüz AY, Döşkaya M, Hameş EE.Biomed Pharmacother. 2026 Jun 17;201:119679. doi: 10.1016/j.biopha.2026.119679. Online ahead of print.PMID: 42308922

Immune responses to glycoconjugate vaccines rely on a balance between polysaccharide length and glycosylation density.

Carboni F, Bechi N, Proietti D, Balocchi C, Casini D, Brogioni B, Luzzi E, Tontini M, Cartocci E, Brunelli B, Reyter S, Margarit I, Romano MR, Adamo R.Carbohydr Polym. 2026 Jun 15;382:125250. doi: 10.1016/j.carbpol.2026.125250. Epub 2026 Mar 26.PMID: 42002336

Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route.

Mandviwala AS, Liman K, Huckriede ALW, Mishra AC, Patil HP.Virology. 2026 Jun 13;623:111007. doi: 10.1016/j.virol.2026.111007. Online ahead of print.PMID: 42314330

Timing and frequency of antenatal care visits in relation to maternal respiratory syncytial virus vaccine opportunities in four Latin American countries.

Fleming JA, Colistro V, Knudson S, Colomar M.Vaccine. 2026 Jun 19;88:128854. doi: 10.1016/j.vaccine.2026.128854. Online ahead of print.PMID: 42320380

On the implications of shifting Hepatitis B vaccine policy for surgical patients.

Corpuz GS, Sidhu AS, Konig DJ, Waljee JF, Wooden WA.Vaccine. 2026 Jun 15;88:128791. doi: 10.1016/j.vaccine.2026.128791. Online ahead of print.PMID: 42296832

Prevalence and distribution of high-risk HPV in an organized hospital-based cervical cancer screening cohort.

Yacoub N, Domizio ND, Ramanah R, Lepiller Q, Prétet JL.J Gynecol Obstet Hum Reprod. 2026 Jun 13;55(7):103231. doi: 10.1016/j.jogoh.2026.103231. Online ahead of print.PMID: 42288120

The Slr protein of Streptococcus pyogenes is selectively expressed in vivo and is a target for protective antibodies.

Rumpret M, Lannergård J, Kristensen BM, Lynskey NN, Bowen C, Johnsson E, Nilsson OR, Norrby-Teglund A, Stålhammar-Carlemalm M, Lindahl G, McCarthy AJ.EMBO Mol Med. 2026 Jun 15. doi: 10.1038/s44321-026-00470-0. Online ahead of print.PMID: 42298213

Development, validation, and implementation of the antibody-secreting cell maturity index: Universal prediction of human plasma cell maturity.

Steinmetz TD, Yang G, de Nooijer T, van der Meer N, Karmi N, Wilbrink R, Bootsma H, Verstappen GM, Kroese FGM.iScience. 2026 May 22;29(6):116050. doi: 10.1016/j.isci.2026.116050. eCollection 2026 Jun 19.PMID: 42221829

Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia.

Giannini F, Hogan AB, Blyth CC, Glass K, Moore HC; STAMP RSV investigator team.Vaccine. 2026 Jun 20;86:128731. doi: 10.1016/j.vaccine.2026.128731. Epub 2026 May 23.PMID: 42176437

From global to local: Developing a context-specific BeSD-HPV tool through cultural and linguistic adaptation in Pakistan.

Noreen K, Noor M, Maryam S, Baig M.PLoS One. 2026 Jun 15;21(6):e0350162. doi: 10.1371/journal.pone.0350162. eCollection 2026.PMID: 42296125

Potentiating mild photothermal therapy via CDK12/13-mediated AKT suppression to orchestrate ferroptosis-apoptosis crosstalk for vaccine-like immunity.

Pan X, Yang W, Cai J, Li X, Shi M, Guo H, Wang W, Zhang J, Zhang L.Inflamm Res. 2026 Jun 11;75(1):139. doi: 10.1007/s00011-026-02274-x.PMID: 42274767

Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.

Forns J, Pajouheshnia R, Aurelius T, Bouck Z, Carreras JJ, Choi J, Royo AC, Correcher-Martínez E, Fernandez-Garcia S, Fry C, Gaspersz J, Giner-Soriano M, Gini R, Girardi A, Herings R, Huang WT, Hyeraci G, Kim J, Lane S, Layton D, Lee A, Lysen T, Martinez D, Mohammadi S, Morris D, Morros R, Ouchi D, Overbeek J, Perez-Gutthann S, Plana E, Platt RW, Roberto G, Roy D, Sturkenboom MCJ, Tarazjani AD, Uh HW, Urchueguía-Fornes A, Weibel D, Rebordosa C.Vaccine. 2026 Jun 20;86:128723. doi: 10.1016/j.vaccine.2026.128723. Epub 2026 May 20.PMID: 42161097

Intranasal fluorinated nano-adjuvant orchestrates CCL2-driven pre-DC recruitment and transmucosal antigen delivery to elicit long-term immunity against influenza.

Shen L, Yang H, Zhou H, Liu Z, Duan L, Wang S, Niu Q, Wu Y, Zhang G, He H.J Control Release. 2026 Jun 16;396:115102. doi: 10.1016/j.jconrel.2026.115102. Online ahead of print.PMID: 42303107

Comparative safety assessment of measles-containing vaccination schedules in Jiangsu Province, China: A population-based pharmacovigilance study (2014-2024).

Zhu Y, Yu J, Hu R, Wang Z, Sun X.Hum Vaccin Immunother. 2026 Dec 31;22(1):2686496. doi: 10.1080/21645515.2026.2686496. Epub 2026 Jun 17.PMID: 42306971

Preventive and therapeutic efficacy of mRNA/LNP vaccines encoding HPV16 E6 and E7 in an early-intervention HPV tumor mouse models.

Saithong S, Prompetchara E, Ketloy C, Khawsang C, Tharakhet K, Kaewpang P, Yostrerat N, Wangsoontorn P, Charsangbong K, Lam K, Heyes J, Weissman D, Ruxrungtham K.Hum Vaccin Immunother. 2026 Dec;22(1):2686510. doi: 10.1080/21645515.2026.2686510. Epub 2026 Jun 16.PMID: 42301768

Precision-engineered STING agonist nanoparticles enable coordinated mucosal-systemic immunity for durable pan-β-coronavirus protection.

Liu Z, Zhou J, Gao R, Wang Y, Liu M, Wang W, Wang Y, Wei P, Zhou K, Wang M, Pan S, Xing L, Zhang G, Xu W, Wang Q, Jiang X, Zhang J, Zhang Y, Zhang Y, Qi K, Pan J, Hsieh M, Zeng X, Wang X, Wang J, Yin R, Wu F, Zhao J, Liu W, Jiang S, Lu L.Nat Nanotechnol. 2026 Jun 17. doi: 10.1038/s41565-026-02188-z. Online ahead of print.PMID: 42310425

Molecular epidemiology of DS-1-like G1P[8] rotavirus strains in Vietnam, 2012-2016: Evolutionary dynamics of an unusual rotavirus reassortant.

Tam PT, Vu MH, Hoa-Tran TN, Dao THA, Nguyen TA, Duong TH, Dang TTH, Nguyen TT, Hoang HM, Nguyen TVH, Nguyen TH, Varja G, Sarah T, Bines JE, Donato CM, Hasebe F, Kodama T, Abe H, Nakagomi T, Nakagomi O.Arch Virol. 2026 Jun 17;171(7):214. doi: 10.1007/s00705-026-06675-5.PMID: 42310243

Robust cross-neutralizing antibody responses but variable cellular immunity following either Comirnaty and Spikevax JN.1-adapted mRNA vaccination in the elderly.

Tang YS, Chen C, Lv H, Sun Y, Tan CW, Yiu K, Ling KC, Chan KKP, Mok CKP, Hui DS.Vaccine. 2026 Jun 11;83:128634. doi: 10.1016/j.vaccine.2026.128634. Epub 2026 Apr 29.PMID: 42060980

Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model.

Li S, Morrison H, Duta M, Marshall JL, Harris SA, He W, Ateere A, Nassanga B, Satti I, McShane H.Cell Rep Med. 2026 Jun 16;7(6):102830. doi: 10.1016/j.xcrm.2026.102830. Epub 2026 May 21.PMID: 42167232

A newly developed eGFP-traceable recombinant rhesus lymphocryptovirus, a tool to study viral infection and replication *in vitro* and *ex vivo*, confirms gp350 as key for viral entry.

Kotey EN, Sharma P, Rodriguez E, Gonzalez-Dahua JP, Tello BA, Reidel IG, Escalante GM, Zhao Y, Wu X, Kincaid RP, Chen Y, Skalsky RL, Mutsvunguma LZ, Ogembo JG.J Virol. 2026 Jun 11:e0053726. doi: 10.1128/jvi.00537-26. Online ahead of print.PMID: 42274213

Symptomatic injection granuloma of buttock and management with ultrasound-guided barbotage procedure.

Dede BT, Oğuz M, Alyanak B, Bağcier F.Pain Manag. 2026 Jun 16:1-5. doi: 10.1080/17581869.2026.2688378. Online ahead of print.PMID: 42299468

Combination adjuvants drive long-lived plastic Th17 cells that convert to multi-functional Th1 cells and protect mice against fungal infection.

Wüthrich M, Okaa UJ, Ledesma Taira C, Dos Santos Dias L, Klein BS.mBio. 2026 Jun 11:e0050526. doi: 10.1128/mbio.00505-26. Online ahead of print.PMID: 42274269

Viral load-driven systemic immune exhaustion is an enabler of antibody breadth in HIV infection.

de Los Rios Kobara I, Mangalanathan U, Deline-Caballero S, Pinedo K, Stabile M, Espinosa Bernal CA, Itell HL, Chohan V, McClelland RS, Mandaliya K, Overbaugh J, Blish CA.bioRxiv [Preprint]. 2026 Jun 17:2026.06.05.730519. doi: 10.64898/2026.06.05.730519.PMID: 42327147

Boosting the immune response and protective efficacy of inactivated PRV vaccine using cGAMP as a mucosal adjuvant.

Chang C, Sun H, Hua T, Li Q, Yan X, Zhang H, Yin W, Wang H, Tang B.BMC Vet Res. 2026 Jun 18. doi: 10.1186/s12917-026-05636-z. Online ahead of print.PMID: 42316174

Respiratory syncytial virus vaccination induces delayed but robust humoral and cellular immunity in patients receiving hemodialysis.

Anft M, Paniskaki K, Franz D, Skrzypczyk S, Kaliszczyk S, Kohut E, Kurek J, Rosiewicz K, Schmueck-Henneresse M, Stervbo U, Westhoff TH, Kisters K, Cziborra M, Babel N.Kidney Int. 2026 Jun 16:S0085-2538(26)00473-4. doi: 10.1016/j.kint.2026.04.038. Online ahead of print.PMID: 42302931

Longevity of humoral response in recipients of rabies pre-exposure prophylactic vaccination with Abhayrab®.

Ganguly B, Bellamcapu R, Charepalli M, Susarla SK, Akkala SR, Sahoo DP, Tiwari S, Ghadage SB, Kanakasapapathy AK, Sudarshan MK.Biologicals. 2026 Jun 20;95:101897. doi: 10.1016/j.biologicals.2026.101897. Online ahead of print.PMID: 42322798

Elucidating the role of Toxoplasma gondii EF-hand containing protein 1 in parasite biology and its potential as a subunit vaccine antigen.

Tian X, Ma H, Gao S, Li Y, Zhu B, Zhang J, Wang J, Hu Y, Li Y, Wang Q, Zhang Z, Yang Z, Mei X, Wang S.Acta Trop. 2026 Jun 11;280:108179. doi: 10.1016/j.actatropica.2026.108179. Online ahead of print.PMID: 42276404

Public antibody clonotypes and deep learning identify SARS-CoV-2 and HIV broadly neutralizing antibodies in immune repertoires.

Zhou L, Yu Z, Lin S, Jiang Y, Gao J, Ma Y, Jiang W, Liang S, Chen Y, Zhang Y, Lin Y, Liang M, Dai J, Zhang L, Xiao Y, Li T, Kong Z, Liu Q, He S, Wu Y, Yuan Q, Liu F, Zhang J, Zheng Q, Yu H, Gu Y, Li S, Xia N.Cell Rep. 2026 Jun 19;45(7):117582. doi: 10.1016/j.celrep.2026.117582. Online ahead of print.PMID: 42319828

Presymptomatic transmission, vaccine breakthrough and anonymous contacts: a cluster of mpox in Canberra, Australian Capital Territory, 2024.

Marmor A, Crane R, Greenville F, Smythe J, Mathew C, Sloan-Gardner T, Anlezark J.Commun Dis Intell (2018). 2026 Jun 16;50. doi: 10.33321/cdi.2026.50.041.PMID: 42296956

Clinical and genomic surveillance of rotavirus causing acute gastroenteritis in the community of Madrid, Spain, 2021-2023: predominance of equine-like G3 strains.

Leon RS, Simón L, Camacho J, Ruiz-Carrascoso G, Fernandez AN, Quevedo S, Andrade-Lobato R, Garcia-Garcia ML, Garcia-Ibañez N, Cabrerizo M, Calvo C, Fernandez-Garcia MD.Sci Rep. 2026 Jun 12. doi: 10.1038/s41598-026-57740-7. Online ahead of print.PMID: 42286209

Expanding the applicability of a multicomponent nano-quantitative structure-property relationships approach from hard to soft nanomaterials: predicting liposome stability.

Jarzynska K, Ciura K, Mikolajczyk A, Puzyn T.Nanoscale. 2026 Jun 11;18(22):11769-11779. doi: 10.1039/d6nr00249h.PMID: 42108939

G-quadruplex-modulated nanoplatform triggers a Ca^{2+} storm via the mitochondria-associated endoplasmic reticulum membrane for anti-melanoma multimodal therapy.

Yang L, Chen X, Li Y, Xie X, Liu C, Qi Z.Acta Biomater. 2026 Jun 12:S1742-7061(26)00383-1. doi: 10.1016/j.actbio.2026.06.022. Online ahead of print.PMID: 42276183

Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.

Sasieni P, Falcaro M.Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918-9. Online ahead of print.PMID: 42309117

In silico comparison of the differential proteome produced by the tuberculosis vaccine candidate BCGdeltaBCG1419c and its parental BCG strain cultured as biofilms or planktonic cells.

Flores-Valdez MA, Velázquez-Fernández JB, Vallejo-Cardona AA, Aceves-Sánchez MJ, Rodríguez-Campos J.Vaccine. 2026 Jun 18;88:128855. doi: 10.1016/j.vaccine.2026.128855. Online ahead of print.PMID: 42314311

Immortal genome assumption significantly underestimates replication and death rates of *Mycobacterium tuberculosis* in mice and monkeys.

Friesen AD, Ganusov VV.Microbiol Spectr. 2026 Jun 15:e0302025. doi: 10.1128/spectrum.03020-25. Online ahead of print.PMID: 42294710

Varicella epidemiology, susceptibility and cost burden in Chongqing China: implications for prevention and control strategies.

Yao N, Kuang S, Deng J, Liu Y, Zhao H, Ji H, Zhou C, Xu J.BMC Infect Dis. 2026 Jun 18. doi: 10.1186/s12879-026-13815-4. Online ahead of print.PMID: 42316096

Comparison of self-collected vaginal swabs and first-void urine for detection of human papillomavirus in sexually active girls and women in three South Asian countries.

Telele N, Katuwal N, Kabir F, Rahman S, Shahi SB, Yadav RR, Aziz F, Hossain MA, Hill AM, Permatasari I, Lee Y, Cho H, Lee J, You YA, Ahn HS, Park S, Tamrakar D, Pasha A, Alam A, Rahman FN, Shiblee S, Ejaz M, Nisar MI, Querec TD, Lawal BJ, Choi EM, Watson-Jones D, Basnet P, Uranw S, Shrestha R, Shrestha A, Jehan F, Nahar Q, Hotwani A, Rahman M, Lynch JA, Unger ER.PLoS One. 2026 Jun 12;21(6):e0350049. doi: 10.1371/journal.pone.0350049. eCollection 2026.PMID: 42284270

Australian adults' views on influenza vaccination: Implications for communication and service quality from a qualitative study.

Christou-Ergos M, Sabahelzain MM, Bolsewicz KT, Kaufman J, Steffens M, Danchin M, Leask J.Vaccine. 2026 Jun 18;88:128846. doi: 10.1016/j.vaccine.2026.128846. Online ahead of print.PMID: 42314308

Italian regional data and oropharyngeal adverse events to drugs and vaccines: insights from a 3-year spontaneous reporting (2022-2024).

Sportiello L, Gaio M, Zinzi A, La Mantia G, Panzarella V, Colella G, Marra PM, Sottosanti L, Potenza S, Oteri G, Coppini M, Seminara G, Mauceri R, Morreale I, Fusco V, Campisi G, Capuano A.Pharmacol Rep. 2026 Jun 15. doi: 10.1007/s43440-026-00873-3. Online ahead of print.PMID: 42295693

Systematic review and meta-analysis of digital seasonal influenza vaccination promotion in people aged ≥50 years.

Chen S, Fang Y, Yu FY, Ding L, Mo PKH, Wang Z.Vaccine. 2026 Jun 19;88:128865. doi: 10.1016/j.vaccine.2026.128865. Online ahead of print.PMID: 42320382

Leading from behind the scenes: Community birth attendants, the unsung heroines of childhood vaccination in Ibadan urban slum communities.

Balogun FM, Omobowale OC.PLOS Glob Public Health. 2026 Jun 16;6(6):e0006691. doi: 10.1371/journal.pgph.0006691. eCollection 2026.PMID: 42302038

Does an off-label two-dose RotaTeq vaccine schedule translate into a higher incidence of rotavirus hospital admissions compared to the approved three-dose RotaTeq schedule? A Canadian immunization research network study.

Fortin É, Miron É, Grewal R, Wilson SE, Janjua NZ, Quach C, Sadarangani M, Kiely M, Naveed Z, Naus M, MacDonald SE, Swayze S, Brousseau N.Vaccine. 2026 Jun 11;83:128628. doi: 10.1016/j.vaccine.2026.128628. Epub 2026 May 2.PMID: 42070371

Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report.

Arslan S, Sert A, Özçelik M, Barış S, Aydoğmuş Ç, Kaba Ö, Çil Yılmaz B, Erdil S, Yırgın K, Gökmirza P, Çatak MC.J Clin Immunol. 2026 Jun 19;46(1):67. doi: 10.1007/s10875-026-02040-y.PMID: 42319627

Cell Envelope Remodeling and Lipid Metabolism Coordinate Extracellular Vesicle Output in Mycobacterium Tuberculosis.

Serrano-Mestre JL, Lerma L, Vázquez-Iniesta L, Salgueiro-Toledo VC, Palacios A, Alebouyeh S, Doddi A, Elortza F, Azkargorta M, Sampedro L, Atondo E, Pacual-Itoiz MÁ, Mayer O, Westwood T, Jacobs WR Jr, Prados-Rosales R.J Extracell Biol. 2026 Jun 17;5(6):e70156. doi: 10.1002/jex2.70156. eCollection 2026 Jun.PMID: 42328422

Structure of Human adenovirus 7 virus-like particles, a platform for developing nanotherapeutics and studying capsid assembly.

Madoo K, Mazboudi R, Islam ZM, Luo J, Kuschner RA, Gottlieb P, Dennehy JJ, Abzalimov RR, Galarza JM, Khayat R.Proc Natl Acad Sci U S A. 2026 Jun 23;123(25):e2526969123. doi: 10.1073/pnas.2526969123. Epub 2026 Jun 16.PMID: 42301791

Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay : A Target Trial Emulation.

Hayes KN, Harris DA, McConeghy KW, Grove LR, Joshi R, Han L, Davidson HE, Chachlani P, Bayer TA, Singh M, Abul Y, DeVone F, Gravenstein S.Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-25-04689. Online ahead of print.PMID: 42296498

Genetic insights into circulating very virulent infectious bursal disease virus strains in Kenyan broiler flocks.

Lizzi G, Quaglia G, Legnardi M, Graziosi G, Tomasoni R, Napolitano M, Messo W, Catelli E, Lupini C.Acta Trop. 2026 Jun 20:108194. doi: 10.1016/j.actatropica.2026.108194. Online ahead of print.PMID: 42322998

Impact of Rotavirus Vaccine on Rotavirus Diarrhea-Associated Hospitalizations among Children under 5 Years of Age in Uganda.

Nalunkuma C, Aanyu HT, Kaudha E, Gyagenda S, Nalumansi E, Nakiragga G, Mugisha D, Mulindwa A, Kisakye A, Chavers T, Weldegebriel GG, Katsande R, Shaba K, Mwenda JM, Parashar UD, Tate JE, Gastañaduy PA.J Pediatric Infect Dis Soc. 2026 Jun 12;15(6):piag037. doi: 10.1093/jpids/piag037.PMID: 42166185

Meningitis B: UK launches vaccine programme to protect students after fatal outbreaks.

Mahase E.BMJ. 2026 Jun 12;393:e567368. doi: 10.1136/bmj-2026-567368.PMID: 42285554

GBP5-triggered AIM2 inflammasome drives host defense and exacerbates disease severity during Neospora caninum infection.

Chen M, Zhang X, Wang X, Liu Z, Du B, Yuan X, Sun Z, Chen S, Yu Y, Gong P, Zhang N, Li H, Li J, Zhang X, Li X.Vet Res. 2026 Jun 20;57(1):113. doi: 10.1186/s13567-026-01769-z.PMID: 42323653

Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer.

Huang J, Wang Q, Yao Z, Wang Q, Ji Y, Yang M, Wang M, Shao S, Zhao X, Zhang F, Liang T, Hu Q.Adv Sci (Weinh). 2026 Jun 19:e76135. doi: 10.1002/advs.76135. Online ahead of print.PMID: 42318673

Selective Immune Tolerance: A Unifying Mechanism Linking Heavy Malaria Exposure, Waning Vaccine Antibodies, and Burkitt Lymphoma.

Bedsaul-Fryer JR, Mbulaiteye SM.J Infect Dis. 2026 Jun 18:jiag312. doi: 10.1093/infdis/jiag312. Online ahead of print.PMID: 42315117

Targeted cleavage site mutations in the Gn precursor enable efficient generation of replication-competent rVSV-based surrogates for emerging nairoviruses.

Jain S, Marot S, Karaaslan E, Sajadi MM, Baykam N, Yapar D, Shoemaker T, Montgomery JM, Spiropoulou CF, Albariño CG, Bergeron É.Emerg Microbes Infect. 2026 Dec;15(1):2678640. doi: 10.1080/22221751.2026.2678640. Epub 2026 Jun 11.PMID: 42281293

Dysphagia after COVID-19 Vaccination: A Report of Two Cases.

Sunami E, Aoyagi Y, Ohashi M, Asano Y, Onai D, Wakita S, Kaito Y, Kitagawa T, Yoneyama T, Ikeda S, Yozu A, Li Q.Intern Med. 2026 Jun 15;65(12):1720-1724. doi: 10.2169/internalmedicine.5450-25. Epub 2025 Nov 13.PMID: 41224265

B cell αv integrin regulates tissue specialization and clonal expansion of lung germinal center and memory B cells after viral infection.

Montiel-Armendariz A, Roe K, Lagos J, Martinez-Castro LV, Dufort MJ, Harrison OJ, Lacy-Hulbert A, Acharya M.Sci Adv. 2026 Jun 12;12(24):eaeb7633. doi: 10.1126/sciadv.aeb7633. Epub 2026 Jun 12.PMID: 42284418

Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.

Munro J, Melnyk D, Afzal M, Schimanski L, Cohen AA, Keeffe JR, Bjorkman PJ, James WS, Townsend AR, Tan TK.Sci Rep. 2026 Jun 13. doi: 10.1038/s41598-026-55581-y. Online ahead of print.PMID: 42288524

Efficacy of intranasal adenovirus vector vaccine is attenuated by type I IFN-induced NK cell activation.

Nakatani H, Tachibana M, Onishi R, Nakagaki T, Ishii KJ, Shimizu K, Sakurai F, Mizuguchi H.Mol Ther Adv. 2026 Apr 24;34(2):201742. doi: 10.1016/j.omta.2026.201742. eCollection 2026 Jun 11.PMID: 42164241

Updated COVID-19 Vaccine Boosters-The Message From Data Is Consistent but Not Getting Through.

Califf RM.JAMA Intern Med. 2026 Jun 15. doi: 10.1001/jamainternmed.2026.1945. Online ahead of print.PMID: 42295769

Predictors of COVID-19 vaccination status: a nationwide linkage study in Czechia.

Dzúrová D, Benešová K, Bernard J, Hulíková Tesárková K, Jarkovský J, Kahoun L, Kšiňanová G, Mužík J, Netrdová P, Szabo D, Bobák M.J Public Health (Oxf). 2026 Jun 16:fdag043. doi: 10.1093/pubmed/fdag043. Online ahead of print.PMID: 42302189

Proactive Mumps Immunization Strategies of Local Authorities, Subsidy Policies Based on Citizen-Involved Municipal Collaboration by Sendai City.

Yamamoto N.Tohoku J Exp Med. 2026 Jun 13;269(1):127-133. doi: 10.1620/tjem.2025.J018. Epub 2025 Feb 13.PMID: 39938910

MOG-Peptide Synergizes With Rapamycin to Drive CD4⁺ T Cells Into Protective Antigen-Specific Tregs in EAE.

Zafar MA, Lamba T, Tehseen A, Sarkar R, Nanda S, Prajapati S, Khan MA, Malik JA, Benamar M, Charbonnier LM, Sehrawat S, Agrewala JN.Immunology. 2026 Jun 15. doi: 10.1111/imm.70158. Online ahead of print.PMID: 42297731

Sustained mucosal delivery of SAMT-247 via an intravaginal ring reduces the risk of SIV_{mac251} acquisition in vaccinated macaques.

Rahman MA, Woode EK, Moss JA, Bissa M, Gunawardana M, Gutowska A, Schifanella L, Silva de Castro I, Brown S, Stamos JD, Sarkis S, Robello M, Castonguay AE, Butkyavichene I, Pise-Masison CA, Choo-Wosoba H, Doster M, Alilin AN, Killoran KE, Kramer J, Breed MW, Cardozo T, Appella DH, Baum MM, Franchini G.Cell Rep Med. 2026 Jun 16:102877. doi: 10.1016/j.xcrm.2026.102877. Online ahead of print.PMID: 42302793

Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.

Bronowski C, Mwendera CA, Kirkwood CD, Steele AD, Groome MJ, Jere KC.NPJ Vaccines. 2026 Jun 19;11(1):122. doi: 10.1038/s41541-026-01505-w.PMID: 42321211

Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.

Shao C, Yang L, Xiao C, Huang Y, Wang X, Chen L, Liu P, Chen S, Wei M, Jia S, Cui L, Ge Y, Xu M, Jia X, Li J.Emerg Microbes Infect. 2026 Dec;15(1):2686472. doi: 10.1080/22221751.2026.2686472. Epub 2026 Jun 21.PMID: 42324717

Early effects of HPV vaccination on high-grade cervical intraepithelial neoplasia in Brazil: Evidence from outpatient data.

Bierrenbach AL, Pungartnik PC, Gonçalves Queijo R, Rego JG, Parellada CI.Hum Vaccin Immunother. 2026 Dec;22(1):2684304. doi: 10.1080/21645515.2026.2684304. Epub 2026 Jun 15.PMID: 42295873

Understanding factors associated with under-five mortality rate in Indonesia: findings from an ecological study across 34 provinces.

Murti FAK, Efendi F, Sari K.Korean J Fam Med. 2026 Jun 19. doi: 10.4082/kjfm.25.0177. Online ahead of print.PMID: 42316417

Retraction notice to "Uptake pathways of cell-penetrating peptides in the context of drug delivery, gene therapy, and vaccine development" [Cellular Signalling 117 (2024) 111116].

Dowaidar M.Cell Signal. 2026 Jun 11:112611. doi: 10.1016/j.cellsig.2026.112611. Online ahead of print.PMID: 42276875

Dual Innovations Driving *Pseudomonas aeruginosa* Lipopolysaccharide Core Pentasaccharide Synthesis: Linker Configuration Control and One-Pot Bis-glycosylation.

Feng K, Ding X, Liu J, Zhou Y, Xue H, Yin Y, Jin H, Zhao W.Org Lett. 2026 Jun 12;28(23):7428-7432. doi: 10.1021/acs.orglett.6c01897. Epub 2026 Jun 2.PMID: 42230147

The prenylated pUS2 protein of pseudorabies virus contributes to phosphorylation of connexin 43 and suppression of gap junctional intercellular communication.

Tishchenko A, De Boeck B, Van Waesberghe C, van Raemdonck F, Fuchs W, Klupp BG, Mettenleiter TC, Vickman O, Smith GA, Favoreel HW.J Virol. 2026 Jun 18:e0077326. doi: 10.1128/jvi.00773-26. Online ahead of print.PMID: 42312837

Correction: Pneumococcal vaccine for prevention of acute otitis media in children: a meta-analysis.

Han L, Gao C, Liu J, Li Y, Liu M, Liu H, Wu J.BMC Infect Dis. 2026 Jun 13;26(1):1137. doi: 10.1186/s12879-026-13617-8.PMID: 42288823

Production of a Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases for Public Transportation Drivers: Protocol for a Scoping Review, a Delphi Study, and a Randomized Controlled Trial.

Salam M, El Dhaybe S, Ghannam L, Serhan M, Hassan M.JMIR Res Protoc. 2026 Jun 19;15:e89474. doi: 10.2196/89474.PMID: 42324927

Inhalable viromimetic polymer nanoparticle vaccine (iVPNVax) in a subcutaneous-prime/inhalation-boost vaccination schedule for eliciting durable mucosal and systemic immune protection.

Zhu Z, Zhuang X, Huang Z, Zhang C, Zhang T, Liu L, Sun A, Long J, Cao Y, Zhang Y, Xing Y, Yang S, Peng J, Huang S, Hu N, Tian M, Song W, Chen X.Biomater Sci. 2026 Jun 16;14(12):3313-3325. doi: 10.1039/d6bm00350h.PMID: 42132755

CellVision: A Deep Learning based Image Analysis Platform to Accelerate Immuno-Plaque Assay Data Processing for Dengue Vaccine Development.

Wang Y, Ngo MN, Wang S, Jarrah J, Salami H, Hofmann C, Joshi A, Skomski D, Loughney JW.SLAS Discov. 2026 Jun 17:100321. doi: 10.1016/j.slasd.2026.100321. Online ahead of print.PMID: 42309407

Development of flow cytometry bead-based opsonophagocytic assays to dissect cell-mediated functional antibody responses to malaria vaccines.

van den Brink DJ, Boero E, Ewer K, Rossi O.Malar J. 2026 Jun 20. doi: 10.1186/s12936-026-06008-6. Online ahead of print.PMID: 42323616

Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study.

Spila-Alegiani S, Massari M, Cutillo M, Menniti-Ippolito F, Da Cas R, Mayer F, Marano G, Belleudi V, Addis A, Desiderio V, Mores N, Lopes S, Balducci M, Ejlli L, Del Zotto S, Clagnan E, Samez S, Zappetti C, Rossi P, Sapigni E, Puccini A, Villa M, Visigalli C, Trifirò G, Luxi N, Morciano C.Vaccine. 2026 Jun 12;88:128806. doi: 10.1016/j.vaccine.2026.128806. Online ahead of print.PMID: 42284809

An appraisal of seasonal pattern of AES in Chennai - Special Emphasis on JEV infections.

Krishnasamy K, Gurunathan K, Sachidanandam M, Sivalingam L, Vijay N.Indian J Med Microbiol. 2026 Jun 20:101150. doi: 10.1016/j.ijmmb.2026.101150. Online ahead of print.PMID: 42323131

Risk-of-bias assessment of vaccine effectiveness studies: a scoping review of systematic reviews.

Davoodi Z, Laurie C, Tingley K, Skidmore B, Shaver N, Sundaram ME, Fell DB, Brouwers M, Sulis G.Epidemiol Infect. 2026 Jun 19:1-26. doi: 10.1017/S0950268826101794. Online ahead of print.PMID: 42317109

A genetic screen identifies O-antigen as essential for *Rickettsia parkeri* survival in macrophages by protecting from inflammasomes and interferon-stimulated genes.

Sun H, Guzman AA, Burke TP.bioRxiv [Preprint]. 2026 Jun 13:2026.06.12.731980. doi: 10.64898/2026.06.12.731980.PMID: 42327330

Spatial distribution and associated factors of non-uptake of DTP3 vaccination among children aged 12-23 months in East Africa: geospatial analysis.

Beshah BY, Abebe AW, Eticha BL, Desalegn HK, Bedada TD.BMC Public Health. 2026 Jun 18. doi: 10.1186/s12889-026-28118-1. Online ahead of print.PMID: 42316109

Lyophilizable Thermostable Nano-Aluminum Adjuvant and Combinations Induced Robust Antigen-Specific Humoral and Cellular Immunity in Mice.

Zhou J, Bian L, Zhao X, Cui L, Li D, Xu J, Shi M, Li G, Wang X, Zeng J, Xing L, Sun B, Jiang C, Chen Y, Zhang Y.Adv Healthc Mater. 2026 Jun 20:e05300. doi: 10.1002/adhm.202505300. Online ahead of print.PMID: 42322157

Molecular characterization and whole-genome sequencing-based genetic evolution of coxsackievirus A16 in Taiyuan City, 2023-2025.

Wang Y, Xu J, Zhao L, Li Y, Xu Y, Gao R, Guo X, Niu M, Zuo Z, An T, Wang J.Arch Virol. 2026 Jun 20;171(7):217. doi: 10.1007/s00705-026-06670-w.PMID: 42322358

The Social Amplification of Secondary Risk Perceptions: Online Media Attention, Interpersonal Discussion, and Dengue Vaccination Willingness in Singapore.

Ou M, Ho SS.J Health Commun. 2026 Jun 14:1-11. doi: 10.1080/10810730.2026.2687792. Online ahead of print.PMID: 42290146

Longitudinal evidence of differential pertussis antibody durability following natural infection among vaccinated children living in contrasting malaria transmission settings in coastal Kenya.

Safari MS, Gicheru ET, Mburu MW, Makori TO, Nyawa O, Odoyo SO, Shee F, Ndungu F, Foley DJ, Nyagwange J, Chege T, Sande CJ.Vaccine. 2026 Jun 18;88:128837. doi: 10.1016/j.vaccine.2026.128837. Online ahead of print.PMID: 42314312

Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort.

Shen Y, Shahn Z, Robertson MM, Gebo K, Nash D; CHASING COVID Cohort Study Team.Vaccine. 2026 Jun 20;84:128666. doi: 10.1016/j.vaccine.2026.128666. Epub 2026 May 8.PMID: 42102594

Convergent evolution of the N156K mutation in A(H1N1)pdm09 hemagglutinin contributes to antigenic drift and cluster transition.

Tian Y, Jiang D, Ma W, Nie J, Li Q, Zhao C, Xu S, Huang W, Wang Y.Emerg Microbes Infect. 2026 Dec;15(1):2687185. doi: 10.1080/22221751.2026.2687185. Epub 2026 Jun 21.PMID: 42267384

Comparative Long-Term Immunogenicity and Boosting of 3-Versus 4-Session Intradermal Rabies Post-Exposure Prophylaxis Regimens, Cambodia and Madagascar: The Resist-3 Study.

Parize P, Touch S, Raharimanga V, Ya N, Worsley-Tonks K, Kergoat L, Thai P, Andriamandimby SF, In S, Dreyfus A, Chan M, Razafindramparany MH, Duong V, Ramiandrasoa R, Peng Y, Cantaert T, Dussart P, de Melo GD, Ly S, Randremanana RV, Tarantola A, Bourhy H.Clin Infect Dis. 2026 Jun 15:ciag368. doi: 10.1093/cid/ciag368. Online ahead of print.PMID: 42296188

Viral load-driven systemic immune exhaustion is an enabler of antibody breadth in HIV infection.

de Los Rios Kobara I, Mangalanathan U, Deline-Caballero S, Pinedo K, Stabile M, Espinosa Bernal CA, Itell HL, Chohan V, McClelland RS, Mandaliya K, Overbaugh J, Blish CA.bioRxiv [Preprint]. 2026 Jun 17:2026.06.05.730519. doi: 10.64898/2026.06.05.730519.PMID: 42327147

Immunization with N2 neuraminidase can protect mice against a heterologous influenza A virus challenge even in the absence of cross-NA inhibiting antibodies.

Amelinck L, Smet A, Ysenbaert T, Sedeyn K, Warren W, Gomila R, Vogel TU, Saelens X, Catani JPP.mSphere. 2026 Jun 15:e0030026. doi: 10.1128/msphere.00300-26. Online ahead of print.PMID: 42294863

Corrigendum to "Breastfeeding women's attitudes towards and acceptance and rejection of COVID-19 vaccination: Implementation research" [Vaccine 41 (2023) 1198-1208].

Chawanpaiboon S, Anuwutnavin S, Kanjanapongporn A, Pooliam J, Titapant V.Vaccine. 2026 Jun 20;86:128752. doi: 10.1016/j.vaccine.2026.128752. Epub 2026 May 23.PMID: 42176435

Investigation of Correlates of Protection Against Gonococcal Infection by Comparative Immunoprofiling of Responses in Experimental and Clinical Studies.

McKeand SA, Bencomo FR, Soc A, Jones RA, Thistlethwaite A, Gu Z, Nduati E, Sanders EJ, Jerse AE, Derrick JP, Tang CM.J Infect Dis. 2026 Jun 16;233(6):e1443-e1453. doi: 10.1093/infdis/jiag216.PMID: 42053374

Increasing Intrinsic Protein Disorder Improves CD8+ Immunogenicity for a SARS CoV2 Vaccine Candidate Antigen.

Wan L, Xie B, Shuda M, O'Malley ME, Camacho CJ, Delgoffe GM, Chang Y, Moore PS.Mol Ther. 2026 Jun 15:S1525-0016(26)00504-6. doi: 10.1016/j.ymthe.2026.06.027. Online ahead of print.PMID: 42298822

Longitudinal antibody profiling after dengue reveals distinct dynamics by antibody specificity over 18 months.

Bos S, Singh T, Zambrana JV, Duarte E, Mercado-Hernandez R, Huffaker J, Graber A, Balmaseda A, Harris E.Nat Commun. 2026 Jun 21. doi: 10.1038/s41467-026-74406-0. Online ahead of print.PMID: 42323307

Mild exogenous inflammation reduces dynamic small-world topology in resting-state brain networks of healthy males.

Queirazza F, Krishnadas R.Brain Behav Immun. 2026 Jun 20:106880. doi: 10.1016/j.bbi.2026.106880. Online ahead of print.PMID: 42323056

Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.

Shim D, Mouton C, Moseman JE, Comas Rojas H, Jeon D, Idrissou MB, Hernandez R, Weichert JP, McNeel DG.J Immunother Cancer. 2026 Jun 19;14(6):e015261. doi: 10.1136/jitc-2026-015261.PMID: 42320982

Phased fragility and stability of non-genetic B cell states in the germinal center accelerate the genetic evolution of antibodies.

Xiang MY, Vaidehi Narayanan H, Kesarwani V, Vanheusden R, Wang T, Hoffmann A.Cell Syst. 2026 Jun 17;17(6):101590. doi: 10.1016/j.cels.2026.101590. Epub 2026 Apr 20.PMID: 42013839

Corrigendum to "Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia" ["Vaccine 50 (2025) 126846].

Sharma A, Kerkhoff AD, Haambokoma M, Shamoya B, Sikombe K, Simbeza SS, Zulu N, Geng EH, Eshun-Wilsonova I, Le Tourneau N, Pry JM.Vaccine. 2026 Jun 20;86:128757. doi: 10.1016/j.vaccine.2026.128757. Epub 2026 May 31.PMID: 42219862

Complete genome sequence of the goatpox virus vaccine isolate LRIGP01.

Akter Z, Ferdous KS, Jafrin F, Hayat S, Parvin R, Hosain MZ, Kamal MM.Microbiol Resour Announc. 2026 Jun 18:e0149525. doi: 10.1128/mra.01495-25. Online ahead of print.PMID: 42313068

Humoral Immune Abnormalities in Transient Childhood Neutropenia: Insights From a 10-year Cohort Study in a Tertiary Center.

Schorn E, Soomann M, Prader S, Pachlopnik Schmid J, Trück J.J Clin Immunol. 2026 Jun 18. doi: 10.1007/s10875-026-02042-w. Online ahead of print.PMID: 42315772

Clinical outcomes among SARS-CoV-2 omicron-infected adults according to prior infection and vaccination history in Iran: A retrospective registry-based study.

Torkaman-Asadi F, Bakhtiari S, Safarzadeh M, Riahi-Rad Z, Riahi-Rad Z, Doosti Irani A, Ansari N.Vaccine. 2026 Jun 20;88:128868. doi: 10.1016/j.vaccine.2026.128868. Online ahead of print.PMID: 42322678

No association of complex regional pain syndrome and other neurological disorders with human papillomavirus vaccination in a large-scale real-world database.

Kitano T, Yoshida S.Neuroepidemiology. 2026 Jun 11:1-15. doi: 10.1159/000552993. Online ahead of print.PMID: 42275267

GBP5-triggered AIM2 inflammasome drives host defense and exacerbates disease severity during Neospora caninum infection.

Chen M, Zhang X, Wang X, Liu Z, Du B, Yuan X, Sun Z, Chen S, Yu Y, Gong P, Zhang N, Li H, Li J, Zhang X, Li X.Vet Res. 2026 Jun 20;57(1):113. doi: 10.1186/s13567-026-01769-z.PMID: 42323653

Novel approach for vaccine delivery using mRNA lipid nanoparticles for in vivo production of monoclonal antibodies.

Lundstrom K.Mol Ther Nucleic Acids. 2026 May 7;37(2):102940. doi: 10.1016/j.omtn.2026.102940. eCollection 2026 Jun 16.PMID: 42164516

First report of a pseudorabies virus in porcupines: Genomic characterization of a recombinant strain and safety assessment of the Bartha-K61 vaccine.

Yan N, Xu J, Zheng L, Fan S, Guo H, Qi Y, Lai X, You Y, Zhang K, Liu J, Liu J, Dai A, Lin K, Fan K.Vet Microbiol. 2026 Jun 15;320:111121. doi: 10.1016/j.vetmic.2026.111121. Online ahead of print.PMID: 42308679

ACP, AMA Decry Executive Order to Change Childhood Vaccine Schedule.

Anderer S.JAMA. 2026 Jun 18. doi: 10.1001/jama.2026.8313. Online ahead of print.PMID: 42313555

Complete genome sequencing of the fowlpox virus vaccine strain from the Livestock Research Institute, Bangladesh.

Akter MS, Das A, Piyel SH, Islam MM, Haque S, Mozumder A, Mia R, Rahman MS, Bhuiyan MIU, Akter S, Hoque MN, Islam T, Hossain MG.Microbiol Resour Announc. 2026 Jun 15:e0050226. doi: 10.1128/mra.00502-26. Online ahead of print.PMID: 42294662

Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protection.

Williams BG, Barrett JR, Scott JB, Rigby CA, Cagiada M, Quinkert D, McHugh K, Huhn A, Burnap SA, Gourjault C, Byrne F, Raghavan SSR, Rodrigues A, Bergamaschi L, Balzarotti B, Watson S, Miller N, King LDW, Donnellan FR, Gladstone CA, Paterson J, Scalabrino S, Silk SE, Salkeld J, Minassian AM, Skinner K, Struwe WB, Deane CM, Reece ST, Ward AB, Draper SJ.Immunity. 2026 Jun 12:S1074-7613(26)00223-2. doi: 10.1016/j.immuni.2026.05.012. Online ahead of print.PMID: 42285102

Genomic wastewater surveillance of human and animal influenza A viruses in California during the 2024-2025 flu season.

Wang AL, Lamtyugina A, Jiang M, Yu AT, Lu C, Wadford D, Burnor E, Pipes L, Kantor R, Nelson KL.medRxiv [Preprint]. 2026 Jun 12:2026.06.10.26355323. doi: 10.64898/2026.06.10.26355323.PMID: 42326814

Corrigendum to "Estimating the effect of measles vaccination on child growth using 191 DHS from 65 low- and middle-income countries" [Vaccine 37 (2019) 5073-5088].

Bogler L, Jantos N, Bärnighausen T, Vollmer S.Vaccine. 2026 Jun 12;88:128813. doi: 10.1016/j.vaccine.2026.128813. Online ahead of print.PMID: 42284806

Corrigendum to "Impact of simultaneous administration on immune responses to vaccines routinely recommended for use during pregnancy: A targeted literature review" [Vaccine 79 (2026) 128408].

Lutz CS, Cox SN, Courtney LP, Paulenich A, Vichnin M, Deese J, Jodar L, Gessner BD, Atwell JE.Vaccine. 2026 Jun 13;88:128812. doi: 10.1016/j.vaccine.2026.128812. Online ahead of print.PMID: 42287824

Triple-gene deletion mutant (ΔmlaEΔompRΔdeoR) attenuates Pseudomonas plecoglossicida and elicits effective protective immunity in large yellow croaker.

Ahat P, Zhang Z, Song W, Liu Q, Zhang Y, Wang Q.Fish Shellfish Immunol. 2026 Jun 16;176:111521. doi: 10.1016/j.fsi.2026.111521. Online ahead of print.PMID: 4230306

Rare Survival of a 9-Year-Old Boy Managed for Post-Neonatal Tetanus Without Intensive Care at Soroti Regional Referral Hospital, Uganda: A Case Report.

Odiit A, Akello F, Lujuna T, Mukiibi JK, Engoru CE, Ochora M.Int Med Case Rep J. 2026 Jun 15;19:612887. doi: 10.2147/IMCRJ.S612887. eCollection 2026.PMID: 42327674

Patentes registradas en Patentscope

Estrategia de búqueda: *(Vaccine) AND DP:([11.06.2026 TO 21.06.2026]) as the publication date 54 records.*

1.WO/2026/119155RECOMBINANT ADENOVIRUS VECTOR TUMOR VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 11.06.2026

Clasificación Internacional C12N 15/12Nº de solicitud PCT/CN2025/139475Solicitante BRITIE BIOTECH CO., LTD.Inventor/a ZHENG, Xiuyu

A recombinant adenovirus vector tumor vaccine, a preparation method therefor, and use thereof. An antigen encoded by the recombinant adenovirus vector tumor vaccine comprises any one or a combination of two or

more of antigenic peptide epitopes of a KRAS protein. The recombinant adenovirus vector tumor vaccine encodes multiple KRAS tumor-specific antigenic peptides, and exhibits a good killing effect on tumors driven by KRAS mutations, especially on lung tumors. The vaccine can be administered via nebulized inhalation, intramuscular injection followed by nebulized inhalation, nebulized inhalation followed by intramuscular injection, intramuscular injection, or simultaneous intramuscular injection and nebulized administration. After nebulization, the vaccine can reach the lungs via nasal or oral inhalation, generating anti-tumor protective immune responses in the respiratory tract and lungs and throughout the body, thereby enhancing the utilization rate and therapeutic efficacy of the vaccine.

2.20260166134MRNA, MRNA VACCINE FORMULATION, AND PREPARATION METHOD AND USE THEREOF

US - 18.06.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19258958Solicitante Panru Biotechnology (Tianjin) Co., LtdInventor/a Yuanjie NIU

An mRNA, an mRNA vaccine formulation, and a preparation method and use thereof are provided. An amino acid sequence of the mRNA is set forth in SEQ ID NO: 2. Studies have demonstrated that the mRNA vaccine formulation prepared from the mRNA having the amino acid sequence set forth in SEQ ID NO: 2 can effectively stimulate dendritic cell maturation and secretion of pro-inflammatory cytokines, thereby activating effector T cells to kill prostate cancer cells. A preparation method of the mRNA vaccine formulation is simple and suitable for industrial-scale production. By using lipid nanoparticles (LNPs) as a carrier, the mRNA vaccine formulation achieves high encapsulation efficiency, enabling robust induction of immune responses in vivo with high immunogenicity.

3.WO/2026/122534IMMUNOGENS AND METHODS FOR INDUCING BROADLY NEUTRALIZING ANTIBODIES TARGETING THE HIV ENVELOPE APEX EPITOPE

WO - 11.06.2026

Clasificación Internacional A61K 39/21Nº de solicitud PCT/US2025/057683Solicitante THE SCRIPPS RESEARCH INSTITUTEInventor/a MA, Manyuan

The present invention provides compositions and methods for inducing broadly neutralizing antibodies (bnAbs) against HIV, specifically targeting the Apex epitope of the HIV envelope protein. The invention describes a novel immunogen, ApexGT6, an engineered HIV envelope trimer designed to bind precursors of Apex bnAbs. Methods of administering ApexGT6 as an adjuvanted protein or mRNA-lipid nanoparticle (LNP) to consistently induce Apex bnAb-related precursor B cells with long heavy chain complementarity determining region 3 (HCDR3) loops in non-human primates are disclosed. The invention further provides methods for evaluating the induced immune response, including assessing antibody affinity maturation and structural characterization of elicited antibodies. This technology represents a significant advancement in HIV vaccine development and may have broader applications in inducing antibodies with very long HCDR3s against other pathogens.

4.20260159586METHODS OF TREATING CANCER WITH A COMBINATION OF A CANCER VACCINE AND A TAAXCD28 BISPECIFIC ANTIGEN-BINDING MOLECULE

US - 11.06.2026

Clasificación Internacional C07K 16/28Nº de solicitud 19399807Solicitante Regeneron Pharmaceuticals, Inc.Inventor/a David DiLillo

The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a cancer vaccine (e.g., mRNA vaccine against a tumor) in combination with a bispecific antigen-binding molecule comprising a first antigen-binding domain that binds specifically CD28 and a second antigen-binding domain that binds specifically to a tumor-associated antigen (TAA). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival, as compared to a subject administered the cancer vaccine as monotherapy.

5.WO/2026/122786TIM-3-TARGETED VACCINES AND METHODS OF TREATING OR PREVENTING CANCER

WO - 11.06.2026

Clasificación Internacional C12N 5/0784Nº de solicitud PCT/US2025/058091Solicitante HENRY FORD HEALTH SYSTEMInventor/a JIANG, Aimin

Cancer vaccine and methods of treating or preventing cancer involve strategic use and engineering of anti-Tim3 antibodies. The vaccine is advantageously a dendritic cell (DC) vaccine. The vaccine includes a composition comprising a dendritic cell targeting platform and an anti-Tim-3 antibody conjugated with a tumor antigen. Methods of treating or preventing cancer may include administering a therapeutically effective amount of the composition to a patient.

6.4759833PROTEIN, ADENOVIRUS UND IMPFSTOFF GEGEN INFEKTION DES SUBTYPS DES SARS-COV-2 OMIKRON-MUTANTEN STAMMS XBB

EP - 17.06.2026

Clasificación Internacional C07K 19/00Nº de solicitud 24853641Solicitante WESTVAC BIOPHARMA CO LTDInventor/a WEI XIAWEI

The present invention relates to the field of medicine, and in particular to a protein, adenovirus and vaccine against infection of a subtype of SARS-CoV-2 Omicron mutant strain XBB. In order to solve the problem of lack of effective prevention and treatment drugs against infection of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, the present invention provides a protein, adenovirus and vaccine against the infection of the subtype of the SARS-CoV-2 Omicron mutant strain XBB. The vaccine is designed by optimizing the sequences of full-length S proteins of sub-lines XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2 of the SARS-CoV-2 Omicron mutant strain XBB, and RBD and RBD-HR sequences in the S proteins, can help a host to resist coronavirus infection, and in particular has a good prevention and treatment effect on cross infection caused by subtype viruses of the Omicron mutant strain XBB.

7.20260167702HUMAN BROADLY CROSSREACTIVE INFLUENZA MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF

US - 18.06.2026

Clasificación Internacional C07K 16/108Nº de solicitud 18707795Solicitante Dana-Farber Cancer Institute,

Inc.Inventor/a Wayne A. Marasco

The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.

8.WO/2026/119274COMPOSITION FOR PRECISE EXPRESSION IN SPLEEN, VACCINE COMPOSITION, AND USE THEREOF

WO - 11.06.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2025/140311Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor/a ZHANG, Weiguo

Provided are a composition for precise expression in the spleen, a vaccine composition, and use thereof. The composition for precise expression in the spleen comprises: component (1): at least one nucleic acid, comprising a nucleotide sequence encoding a target protein and one or more miRNA targeted binding sequences; and component (2): a lipid nanoparticle composition that easily accumulates in the spleen. The composition for precise expression in the spleen can be used for preparing lipid nanoparticles or a drug or a vaccine composition, and can be efficiently delivered into the spleen and tissues and cells thereof and significantly reduce the expression of target genes in non-spleen organs, thereby avoiding side effects caused by undesired expression, such as inflammatory responses or other off-target effects.

9.20260166137RECOMBINANT FOOT-AND-MOUTH DISEASE TYPE A VIRUS INDUCING STRONG ADAPTIVE IMMUNE RESPONSE AND OVERCOMING INTERFERENCE FROM MATERNALLY-DERIVED ANTIBODIES, AND FOOT-AND-MOUTH DISEASE VACCINE COMPOSITION COMPRISING SAME

US - 18.06.2026

Clasificación Internacional A61K 39/135Nº de solicitud 18710511Solicitante REPUBLIC OF KOREA(ANIMAL AND PLANT QUARANTINE AGENCY)Inventor/a Min Ja LEE

Proposed are a foot-and-mouth disease vaccine composition including recombinant foot-and-mouth disease viruses and an antigen isolated and purified from the viruses. In the early stages of vaccination, a humoral immune response is simultaneously induced through the induction of a robust cellular immune response, while in the presence of maternally-derived antibodies (MDAs), B cell receptors are stimulated. Through this, it is possible to provide the vaccine composition that enables active immunity and overcomes the interference of the maternally-derived antibodies and to provide a method of preventing or treating foot-and-mouth diseases using the same composition.

10.20260158132SERUM FREE INTRACELLULAR PATHOGEN VACCINE

US - 11.06.2026

Clasificación Internacional A61K 39/205Nº de solicitud 19465533Solicitante Intervet Inc.Inventor/a Joseph Koumans

A vaccine composition comprising a virus antigen wherein the composition comprises less than 5% serum,

wherein the virus antigen is a whole virus or derived from a whole virus. the vaccine composition reduces, prevents or avoids cross-stitch spinal deformity in the treated animal

11.WO/2026/123076MERS VACCINE ANTIGEN

WO - 18.06.2026

Clasificación Internacional A61K 39/215Nº de solicitud PCT/AU2025/051417Solicitante MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITEDInventor/a POUMBOURIOS, Pantelis

The field of the specification relates broadly to Middle East respiratory syndrome coronavirus vaccine (MERS-CoV) antigens and methods of using and manufacturing MERS-CoV antigens. The invention also relates to vaccines, kits, devices and strips comprising the MERS-CoV antigen. The invention also relates to ribonucleic acids encoding a S protein monomer of a coronavirus vaccine (MERS-CoV) antigen and methods of using and manufacturing the ribonucleic acid. The invention also relates to vectors, lipid nanoparticles, RNA vaccines, kits, devices and strips comprising the ribonucleic acid.

12.WO/2026/119273COMPOSITION FOR PRECISE LIVER EXPRESSION, VACCINE COMPOSITION AND USE THEREOF

WO - 11.06.2026

Clasificación Internacional C12N 15/113Nº de solicitud PCT/CN2025/140309Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor/a ZHANG, Weiguo

The present invention relates to the technical field of liver drug delivery. Provided are a composition for precise liver expression, a vaccine composition and the use thereof. The composition for precise liver expression contains component (1): at least one nucleic acid, which contains a nucleotide sequence encoding a target protein and one or more miRNA-targeting binding sequences; and component (2): a lipid nanoparticle composition that is easily enriched in the liver. The composition for precise liver expression can be used for preparing a lipid nanoparticle or a vaccine composition, can be efficiently delivered to the liver and tissue and cells thereof, and significantly reduces the expression of a target gene in non-liver organs, thereby preventing the side effects caused by undesired expression, such as inflammatory reactions or other off-target effects.

13.20260167681VACCINE DELIVERY CARRIER BASED ON ADHESIVE ADJUVANT PROTEIN AND ITS USES

US - 18.06.2026

Clasificación Internacional C07K 14/435Nº de solicitud 19180607Solicitante POSTECH Research and Business Development FoundationInventor/a Hyung Joon CHA

The present invention relates to a vaccine delivery carrier based on an adhesive adjuvant protein and its uses. The adhesive adjuvant protein according to the present invention exhibits excellent biocompatibility and outstanding immune-enhancing effects, making it applicable not only as a vaccine delivery carrier for carrying and delivering target antigens but also as an adjuvant for the treatment and research of various diseases.

14.20260158127ENHANCEMENT OF VACCINE EFFICACY VIA BIOMASS AND/OR RELATED MATERIAL IN ANIMAL DRINK AND FEED

US - 11.06.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19436778Solicitante ZIVO BIOSCIENCE, INC.Inventor/a Andrew A. Dahl

An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram-negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.

15.4759302IMMUNVERSTÄRKENDE ALUMINIUMEMULSION SOWIE HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON

EP - 17.06.2026

Clasificación Internacional A61K 9/107Nº de solicitud 24851030Solicitante UNIV XIAMENInventor/a ZHANG TIANYING

An immune-enhancing aluminum emulsion, and a preparation method therefor and a use thereof. Specifically provided are an oil-in-water emulsion containing an inorganic salt and a preparation method for the oil-in-water emulsion. Also provided are a vaccine adjuvant comprising the oil-in-water emulsion, a vaccine composition and a pharmaceutical composition. Also provided is a use of the oil-in-water emulsion as a vaccine adjuvant.

16.WO/2026/127385VACCINE COMPOSITION FOR PREVENTING INFLUENZA VIRUS INFECTION HAVING ENHANCED NEUTRALIZING ACTIVITY

WO - 18.06.2026

Clasificación Internacional C07K 14/005Nº de solicitud PCT/KR2025/018074Solicitante POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATIONInventor/a LEE, Jie-Oh

The present invention relates to a vaccine composition for preventing influenza virus infection, having enhanced neutralizing activity. A variant protein or fragment thereof according to the present invention has a stable pre-fusion structure, thereby enabling rapid preparation for influenza viruses with sequence variations that are difficult to predict each year. In addition, the variant protein or fragment thereof according to the present invention exhibits high neutralizing activity, thereby serving as an effective vaccine with superior protective ability against influenza virus. In particular, sequence optimization enables the efficient production of structurally stable proteins with high expression levels, while reducing production costs.

17.WO/2026/119879SEDIMENTATIONS-STABILISIERTE FORMULIERUNGEN FÜR HEFE—BASIERTE VAKZINE

WO - 11.06.2026

Clasificación Internacional A61K 47/02Nº de solicitud PCT/EP2025/085091Solicitante VEROVACCINES GMBHInventor/a RICHTER, Tilmann

Die Erfindung betrit stabile Vakzin-Formulierungen auf Basis von Hefen bzw. Hefezellen. Die Erfindung stellt insbesondere eine pharmazeutische Zusammensetzung für Hefezellsuspensionen bereit, umfassend 0 - 75 % (v/v) mindestens eines Acrylatpolymers; 0 - 5 % (m/v) mindestens eines Polymers ausgewählt aus der Gruppe bestehend aus Carboxymethylcellulose (CMC), Polyvinylpyrrolidon (PVP) und Poloxameren; Phosphat-Glycerol-Puer mit einer Phosphatkonzentration im Bereich von 1 mM - 100 mM und mit einem pH-Wert im Bereich 5 - 10, umfassend Glycerol und eine oder mehrere Verbindungen ausgewählt aus der Gruppe bestehend aus Dinatriumhydrogenphosphat, Kaliumdihydrogenphosphat und Natriumdihydrogenphosphat, wobei der Phosphat-Glycerol-Puer isoosmolar im Vergleich zu physiologischen Flüssigkeiten ist; und 0,1 - 200 mg/ml Hefezellen; wobei mindestens ein Acrylatpolymer oder mindestens ein Polymer aus der Gruppe bestehend aus Carboxymethylcellulose (CMC), Polyvinylpyrrolidon (PVP) und Poloxameren mit einem Anteil von > 0 Gew.-% in der pharmazeutischen Zusammensetzung enthalten ist, und wobei die pharmazeutische Zusammensetzung eine Impfstozusammensetzung ist. Die Erfindung stellt weiterhin ein dazugehörig entwickeltes Verfahren zur Messung der Suspensionsstabilität der pharmazeutischen Formulierung und ein Verfahren zur Quantifizierung von Polyacrylsäure-basiertem Adjuvans in der finalen Formulierung bereit.

18.WO/2026/122834LOW-SUGAR INFLUENZA VACCINE AND METHODS THEREOF

WO - 11.06.2026

Clasificación Internacional C07K 14/005Nº de solicitud PCT/US2025/058170Solicitante ROCK BIOMEDICAL, INC.Inventor/a LEE, Jeng-Shin

The present disclosure relates to a low glycosylated influenza hemagglutinin (HA) protein and a vaccine designed to express the HA protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated HA protein, which provides a broader protection across different influenza strains or lineages.

19.20260159574SYSTEMS AND METHODS FOR THE PRODUCTION OF HUMAN POLYCLONAL ANTIBODIES

US - 11.06.2026

Clasificación Internacional C07K 16/116Nº de solicitud 19379447Solicitante SAB, LLCInventor/a Jay HOOPER

Disclosed herein is a method for producing human antibodies against a pathogen comprising injecting a non-human animal with a pathogen-derived DNA vaccine in at least two locations of the animal; injecting the animal with an adjuvant in a location of the animal different from the location of the DNA vaccine location; collecting plasma from the animal after the injections; and purifying polyclonal antibody from the plasma.

20.WO/2026/118752METHOD FOR PREPARING NOVEL DENDRITIC CELL VACCINE AND USE THEREOF

WO - 11.06.2026

Clasificación Internacional C12N 5/0784Nº de solicitud PCT/CN2025/131767Solicitante THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (ZHEJIANG PROVINCIAL

FIRST HOSPITAL)Inventor/a LV, Zhimin

Provided in the present invention are a method for preparing a novel dendritic cell vaccine and use thereof. Specifically, disclosed in the present invention is a method for preparing modified dendritic cells, comprising: culturing dendritic cells in the presence of vitamin K2, thereby obtaining dendritic cells capable of inhibiting cell death caused by tumor antigen sensitization. The modified dendritic cells can enhance T-cell activation and tumor cell killing ability. Also disclosed in the present invention is a method for tumor immunotherapy using the dendritic cells in combination with T-cell vaccines, existing tumor vaccines, immune checkpoint inhibitors, or radiotherapy and chemotherapy.

21.20260166138COMPOSITIONS AND METHODS FOR ENHANCEMENT OF MRNA VACCINE PERFORMANCE AND VACCINATION AGAINST MPOX

US - 18.06.2026

Clasificación Internacional A61K 39/275Nº de solicitud 19127070Solicitante Yale UniversityInventor/a Sidi Chen

The current disclosure includes a modular vaccine platform. Also included are monkeypox vaccines that protect against pathogenic monkeypox (Mpox) species, as well as their variants. The vaccines typically include a modified mRNA encoding at least one immunogen, such as a viral envelope protein, cell surface binding protein, or a biologically effective/significant fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions that can be used to generate an immune response to pathogens, including monkeypox virus, in a subject.

22.WO/2026/122475DNA VACCINE AGAINST INFECTIOUS SALMON ANEMIA VIRUS

WO - 11.06.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/057594Solicitante ZOETIS SERVICES LLCInventor/a HAALAND, Espen

A DNA vaccine against Infectious Salmon Anemia Virus (ISAV) and methods of using same are provided.

23.WO/2026/119925POXVIRUS VACCINE

WO - 11.06.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/085175Solicitante NEC ONCOIMMUNITY ASInventor/a GHEORGHE, Marius

The present invention relates to vaccine compositions and uses thereof for the prophylactic or therapeutic treatment of an infection caused by viruses of the Poxviridae family, specifically the Orthopoxvirus genus of viruses in that viral family, which may stimulate a broad and effective adaptive immune response across multiple Poxviridae species and a diverse spectrum of human leukocyte antigen (HLA) alleles.

24.WO/2026/128689SCHISTOSOMA VACCINE ANTIGEN MODIFICATIONS AND USES THEREOF

WO - 18.06.2026

Clasificación Internacional G01N 33/50Nº de solicitud PCT/US2025/059165Solicitante TEXAS TECH

UNIVERSITY SYSTEMInventor/a CARTER, Darrick

Provided herein are compositions, assays, kits, and methods for detecting sera that binds to, and inhibits the activity of, a recombinant calcium-activated neutral protease or calpain of *Schistosoma mansoni*, a recombinant calcium-activated neutral protease or calpain; such as a detectable substrate for a *Schistosoma mansoni* calcium-activated neutral protease or calpain; and instructions in the kit for combining sera from a subject suspected of having been exposed to *Schistosoma mansoni*, or a vaccine thereto, with the calcium-activated neutral protease or calpain, wherein the sera blocks an activity of the calcium-activated neutral protease or calpain against the detectable substrate and is a surrogate for effectiveness of the immunization to *Schistosoma mansoni*.

25.20260158104CONFORMATIONALLY SPECIFIC VIRAL IMMUNOGENS

US - 11.06.2026

Clasificación Internacional A61K 38/16Nº de solicitud 19326552Solicitante Calder Biosciences Inc.Inventor/a Christopher Patrick Marshall

The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.

26.20260158130LOW-SUGAR INFLUENZA VACCINE AND METHODS THEREOF

US - 11.06.2026

Clasificación Internacional A61K 39/145Nº de solicitud 19409259Solicitante Rock BioMedical, Inc.Inventor/a Chung-Yi WU

The present disclosure relates to a low glycosylated influenza hemagglutinin (HA) protein and a vaccine designed to express the HA protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated HA protein, which provides a broader protection across different influenza strains or lineages.

27.WO/2026/119376SEDIMENTATIONS-STABILISIERTE FORMULIERUNGEN FÜR HEFE-BASIERTE VAKZINE

WO - 11.06.2026

Clasificación Internacional A61K 47/02Nº de solicitud PCT/EP2024/084517Solicitante VEROVACCINES GMBHInventor/a RICHTER, Tilman

Die Erfindung betrifft stabile Vakzin-Formulierungen auf Basis von Hefen bzw. Hefezellen. Die Erfindung stellt insbesondere eine pharmazeutische Zusammensetzung für Hefezellsuspensionen bereit, umfassend 0 - 75 % (v/v) mindestens eines Acrylatpolymers; 0 - 5 % (m/v) mindestens eines Polymers ausgewählt aus der Gruppe bestehend aus Carboxymethylcellulose (CMC), Polyvinylpyrrolidon (PVP) und Poloxameren; Wasser oder Phosphatpuffer (1 mM - 100 mM, pH 5 - 10) umfassend eine oder mehrere Verbindungen ausgewählt

aus der Gruppe bestehend aus Dinatriumhydrogenphosphat, Kaliumdihydrogenphosphat und Natriumdihydrogenphosphat; und 0,1 - 200 mg/ml Hefezellen; wobei mindestens ein Acrylatpolymer oder mindestens ein Polymer aus der Gruppe bestehend aus Carboxymethylcellulose (CMC), Polyvinylpyrrolidon (PVP) und Poloxameren mit einem Anteil von > 0 Gew.-% in der pharmazeutischen Zusammensetzung enthalten ist. Die Erfindung stellt weiterhin ein dazugehörig entwickeltes Verfahren zur Messung der Suspensionsstabilität der pharmazeutischen Formulierung und ein Verfahren zur Quantifizierung von Polyacrylsäure-basiertem Adjuvans in der finalen Formulierung bereit.

28.20260158109CD200AR LIGANDS FOR CANCER IMMUNOTHERAPY

US - 11.06.2026

Clasificación Internacional A61K 38/17Nº de solicitud 19307588Solicitante REGENTS OF THE UNIVERSITY OF MINNESOTAInventor/a Michael OLIN

The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.

29.WO/2026/119878VACCINE FOR INDUCING ANTIBODIES TO INHIBIT NATIVE INTERLEUKIN-11 SIGNALING

WO - 11.06.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2025/085090Solicitante ADAPTVAC APSInventor/a BERTELSEN, Adam Frederik Sander

The present disclosure pertains to antigens comprising an epitope of IL-11, fused to a peptide tag capable of forming an isopeptide bond. Additionally, the disclosure encompasses vaccines containing said antigen, their uses, and methods of manufacturing. The IL-11 antigen is designed in such a way that the vaccine induces antibodies which neutralise IL-11 by preventing its interaction with IL-11Rα but does not induce gp130 signaling.

30.20260158125PEPTIDE VACCINE

US - 11.06.2026

Clasificación Internacional A61K 39/00Nº de solicitud 18676282Solicitante ARGONAUT THERAPEUTICS LIMITEDInventor/a Nicholas LA THANGUE

The present invention provides one or more immunogenic peptides derived from a PRMT5-E2F1 axis regulated long non-coding RNA gene or a derivative thereof; a pharmaceutical composition comprising one or more of said peptides; a vaccine comprising one or more of said peptides and their use in therapy, including a method for eliciting an immune response in a mammalian subject by administration of an agent capable of presenting the peptides to the host. The invention also relates to the use of a PRMT5 inhibitor for use in treating cancer by stimulating host immunity.

31.20260168003METHOD AND SYSTEM FOR PRODUCING A MODIFIED PROTEIN

US - 18.06.2026

Clasificación Internacional C12P 21/02Nº de solicitud 19422655Solicitante YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventor/a Sarel-Jacob FLEISHMAN

The present invention relates to biological sciences, specifically to the design and stabilization of proteins for use in diagnostics and vaccine development. The present invention represents a system and method for producing a modified protein that provides an improvement of the technological field of protein design and stabilization by providing tools that enable the efficient design and production of proteins with enhanced stability characteristics compared to the parental protein, while retaining immunogenicity to naturally acquired human monoclonal antibodies. In particular, the suggested invention is efficiently applicable to proteins with large and topologically complex structures that have limited natural diversity of homologs and circumvent the requirement for a deep multiple-sequence alignment.

32.WO/2026/123993FATTY ACID-MODIFIED DIPHTHERIA TOXIN ANTIGEN AND USE THEREOF

WO - 18.06.2026

Clasificación Internacional C07K 14/34Nº de solicitud PCT/CN2025/130761Solicitante ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBERATION ARMY ACADEMY OF MILITARY SCIENCESInventor/a LIU, Bo

The present invention relates to the field of biomedicine and specifically to a fatty acid-modified diphtheria toxin antigen and a use thereof. In the diphtheria toxin antigen containing fatty acid modification, the fatty acid modification comprises a fatty acid-modified N-terminal cysteine (Cys), and the fatty acid-modified N-terminal Cys is Cys in which the sulfhydryl group is modified by diacylglycerol and/or the alpha-amino group is modified by a fatty acyl group. Compared with existing diphtheria toxin protein antigens, the fatty acid-modified diphtheria toxin antigen of the present invention not only achieves faster conventional intramuscular injection induction and a higher immune protection effect than the existing diphtheria toxin antigens, but can also induce respiratory mucosal immunity, providing a basis for a vaccine for immune prevention to block diphtheria infection and diffusion.

33.WO/2026/123468USE OF VIRUS IN PREPARATION OF PHAGE

WO - 18.06.2026

Clasificación Internacional C12N 7/00Nº de solicitud PCT/CN2025/079024Solicitante SOUTH CHINA AGRICULTURAL UNIVERSITYInventor/a SONG, Changxu

Provided in the present application is use of a virus in the preparation of a phage, pertaining to the technical field of phages. Provided in the present application is use of PCV2, phPCV2, PCV3, phPCV3, HEV, or phHEV in the preparation of a phage. The present application also prepares and obtains a RecA-deficient Bacillus subtilis live vector vaccine.

34.20260159563USE OF CCL11

US - 11.06.2026

Clasificación Internacional C07K 14/52Nº de solicitud 18722449Solicitante NEWISH TECHNOLOGY (BEIJING) CO., LTD.Inventor/a Hailong QI

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and/or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

35.202601679 42ADJUVANT FOR INTRADERMAL IMMUNIZATION AND USE THEREOF

US - 18.06.2026

Clasificación Internacional C12N 7/00Nº de solicitud 19536292Solicitante JIANGSU ACADEMY OF AGRICULTURAL SCIENCESInventor/a Bihua DENG

An adjuvant for intradermal immunization and a use thereof are provided. The adjuvant includes the following components in parts by mass: 10 parts to 25 parts of squalene, 10 parts to 25 parts of sea buckthorn oil, 25 parts to 35 parts of caprylocaproyl polyoxyl-8 glycerides, and 25 parts to 45 parts of Tween 80. The adjuvant for intradermal immunization has a low viscosity, is favorable for injection and absorption, and can significantly enhance the immunization efficacy of a vaccine.

36.WO/2026/123991IMMUNE COMPOSITION CONTAINING FATTY ACID-MODIFIED SPYCATCHER PROTEIN AND PREPARATION METHOD THEREFOR

WO - 18.06.2026

Clasificación Internacional C07K 14/315Nº de solicitud PCT/CN2025/130759Solicitante ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBERATION ARMY ACADEMY OF MILITARY SCIENCESInventor/a WU, Jun

Provided are an immune composition containing a fatty acid-modified SpyCatcher protein and a preparation method thereof, where the SpyCatcher protein (LipoSC) can self-assemble into nanoparticles and covalently link to antigens containing a SpyTag peptide through an isopeptide bond; also provided is an immune composition containing the fatty acid-modified SpyCatcher protein and a coronavirus RBD antigen, which can induce a strong RBD-specific immune response, particularly as a mucosal subunit vaccine, capable of inducing antigen-specific mucosal and humoral immunity. Further provided are a method for completing fatty acid modification of the SpyCatcher protein in Escherichia coli, and a method for preparing various immune compositions using this fatty acid-modified protein.

37.WO/2026/123994FATTY ACID-MODIFIED CORONAVIRUS ANTIGEN AND USE THEREOF

WO - 18.06.2026

Clasificación Internacional C07K 19/00Nº de solicitud PCT/CN2025/130762Solicitante ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBERATION ARMY ACADEMY OF MILITARY SCIENCESInventor/a WU, Jun

Disclosed in the present invention are a fatty acid-modified coronavirus antigen and use thereof, pertaining to the field of biomedicine. The fatty acid-modified coronavirus antigen comprises a fatty acid-modified N-

terminal cysteine (Cys) and a coronavirus antigen, and may comprise a linking domain. The coronavirus antigen is a coronavirus spike protein (S protein) receptor-binding domain (RBD). The fatty acid-modified coronavirus S protein RBD can self-assemble into nanoparticles. Compared with an RBD without fatty acid modification, the antigen can induce faster and higher humoral immunity by means of injection immunization, and can also induce mucosal immunity and humoral immunity by means of respiratory nebulization immunization, making it a candidate mucosal vaccine with potential medical value.

38.WO/2026/128536LIPOSOMAL ADJUVANT COMPOSITIONS FOR EPSTEIN BARR VIRUS VACCINES

WO - 18.06.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/058884Solicitante MERCK SHARP & DOHME LLCInventor/a AHL, Patrick L.

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

39.WO/2026/128401LIPOSOMAL ADJUVANT COMPOSITIONS FOR HUMAN PAPILLOMAVIRUS VACCINES

WO - 18.06.2026

Clasificación Internacional A61K 9/1272Nº de solicitud PCT/US2025/058671Solicitante MERCK SHARP & DOHME LLCInventor/a AHL, Patrick L.

The present disclosure provides a vaccine composition that includes, among other things, HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82 and a liposomal adjuvant, and methods of inducing an immune response to HPV or methods of preventing infection of or reducing the likelihood of infection by HPV using the compositions.

40.WO/2026/127647NOVEL RECOMBINANT ANTIGEN PROTEIN FOR JAPANESE ENCEPHALITIS, AND USE THEREOF

WO - 18.06.2026

Clasificación Internacional C07K 14/005Nº de solicitud PCT/KR2025/021307Solicitante REPUBLIC OF KOREA (KOREA DISEASE CONTROL AND PREVENTION AGENCY)Inventor/a KIM, Hyeon Guk

The present invention relates to a novel recombinant antigen protein for Japanese encephalitis and, more specifically, to a recombinant antigen protein for Japanese encephalitis, designed through protein structural stability analysis and introduction of point mutations. It has been identified that a composition comprising the recombinant antigen protein for Japanese encephalitis, according to the present invention, exhibits immunogenicity and protective efficacy against challenge inoculation that are superior to those of an approved live-attenuated vaccine. In particular, it has been experimentally identified that the recombinant antigen protein for Japanese encephalitis, of the present invention, exhibits excellent protective efficacy against Japanese encephalitis virus G5 and other genotypes. Therefore, the recombinant antigen protein for

Japanese encephalitis, of the present invention, can be variously used in the field of preventing infection by Japanese encephalitis virus G1 to G5.

41.WO/2026/118253ANTI-PD1 MRNA NANOFORMULATION, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 11.06.2026

Clasificación Internacional A61K 9/51Nº de solicitud PCT/CN2025/080443Solicitante HUANXIN BIOTECHNOLOGY (TAIZHOU) CO., LTD.Inventor/a ZOU, Jianhua

An anti-PD1 mRNA nanoformulation, a preparation method therefor, and use thereof. The anti-PD1 mRNA nanoformulation comprises: an anti-PD1 mRNA and a delivery nanocarrier, wherein the anti-PD1 mRNA is loaded in the delivery nanocarrier. The anti-PD1 mRNA nanoformulation can enable autologous generation of an anti-PD1 antibody to block the PD1 receptor on T cells, inhibiting the depletion of cytotoxic CD8 T cells.

42.4759827NUKLEINSÄUREIMPFSTOFF GEGEN DAS SARS-COV-2-CORONAVIRUS

EP - 17.06.2026

Clasificación Internacional C07K 14/005Nº de solicitud 26175581Solicitante PASTEUR INSTITUTInventor/a SIMON-LORIERE ETIENNE

43.20260165979LIPID NANOPARTICLES

US - 18.06.2026

Clasificación Internacional A61K 9/51Nº de solicitud 19109341Solicitante KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventor/a Go HIRAI

Candidate molecules may be constituent components of various lipid nanoparticles. A C-glycoside glycolipid compound of formula (I):

or formula (II):

a lipid nanoparticle comprising the same, or a pharmaceutical composition, particularly a vaccine, which comprises the lipid nanoparticle.

44.WO/2026/119880VACCINE FOR INDUCING ANTIBODIES TO INHIBIT THYMIC STROMAL LYMPHOPOIETIN

WO - 11.06.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2025/085092Solicitante ADAPTVAC APSInventor/a BERTELSEN, Adam Frederik Sander

The present disclosure pertains to antigens comprising an epitope of TSLP, fused to a peptide tag capable of

forming an isopeptide bond. Additionally, the disclosure encompasses vaccines containing said antigen, their uses, and methods of manufacturing.

45.202601607 59SYSTEMS AND METHODS FOR MULTIPLEX DETECTION OF BIOMARKERS

US - 11.06.2026

Clasificación Internacional G01N 33/543Nº de solicitud 19270869Solicitante Veravas, Inc.Inventor/a Joshua Caine Soldo

Provided herein are methods and systems for multiplex detection and/or measurement of biomarkers of a sample. The methods and systems can be used for rapid disease detection and/or monitoring, vaccine efficacy and immune response monitoring, therapeutic drug monitoring, and/or therapeutic safety and efficacy monitoring.

46.WO/2026/121908LIPID NANOPARTICLES FOR PREVENTING INFLUENZA VIRUS INFECTION AND PREPARATION METHOD THEREFOR

WO - 11.06.2026

Clasificación Internacional A61K 9/51Nº de solicitud PCT/KR2025/020841Solicitante SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATIONInventor/a KIM, Hyun Cheol

The present invention relates to a lipid nanoparticle and a method for preparing same, wherein melittin, a peptide capable of directly penetrating cell membranes and facilitating mucus layer penetration, is conjugated with a biocompatible lipid to form a melittin-lipid conjugate and is used in combination with an ionizable lipid, a helper lipid, cholesterol, and a lipid-PEG to prepare the lipid nanoparticle, whereby the lipid nanoparticle exhibits high stability and low toxicity while effectively delivering influenza A virus mRNA via intranasal administration to induce a prophylactic vaccine effect.

47.202601581 34COMPOSITIONS SUITABLE FOR USE IN A METHOD FOR ELICITING CROSS-PROTECTIVE IMMUNITY AGAINST CORONAVIRUSES

US - 11.06.2026

Clasificación Internacional A61K 39/215Nº de solicitud 18707694Solicitante King Abdullah University of Science and TechnologyInventor/a Jasdave Chahal

Immunogenic compositions and methods of use thereof, for eliciting an immune response against multiple coronaviruses, using a single vaccine composition are described. The compositions include an antigen from more than one pathogen, for example, more than one member of the β-coronavirus family, for example, SARS-CoV and MERS-CoV. Exemplary antigens include the receptor binding domain (RBD) of the coronavirus spike protein or a fragment thereof. The disclosed compositions are administered to a subject in need therefore, to generate an immune response against more than one pathogen, represented by the source of the antigens in the construct.

48.WO/2026/119906NEW VACCINE

WO - 11.06.2026

Clasificación Internacional A61K 39/395Nº de solicitud PCT/EP2025/085140Solicitante LETI PHARMA,

S.L.U.Inventor/a NAVARRO DIEZ, Gemma

Several novel engineered variants of Protein Q, or fragments thereof, are provided, mediating protective immune responses in the treatment and prevention of leishmaniasis in animal and in human subjects.

49.WO/2026/126165MATERIALS, METHODS AND SYSTEMS FOR STIMULATING HOST IMMUNE RESPONSES

WO - 18.06.2026

Clasificación Internacional A61K 39/39Nº de solicitud PCT/IB2025/062816Solicitante JANSSEN BIOTECH, INC.Inventor/a HABTE, Habtom H.

The present disclosure relates to inter alia novel designs, compositions, systems and formulations, etc. of nucleic acid(s) (polynucleotide or oligonucleotide, etc.) products, specifically compositions and formulations of nucleic acid immunity inducing agents, such as adjuvants, immunization and or vaccine products and accessory products and nucleic acid gene therapy products, and the like. The compositions of the disclosure enhance immunity, and provide nucleic acid based medicinal and pharmaceutical products. When introduced directly into a host, such as intradermal cells and or tissues, the embodiments described herein induces production of immune responses which specifically recognize targets, such as human targets.

50.WO/2026/128222METHODS FOR STABILIZING HENIPAVIRUS SURFACE GLYCOPROTEINS AND USES THEREOF

WO - 18.06.2026

Clasificación Internacional C07K 14/115Nº de solicitud PCT/US2025/057106Solicitante DUKE UNIVERSITYInventor/a MAY, Aaron

Described are structural identifications of the F and G proteins of a large variety Henipaviruses and their use in creating immunogens useful for vaccine compositions, and in prevention and treatment of Paramyxovirus and Henipavirus infections in a mammal. Also described are methods for screening viral fusion proteins for capability to transition from a pre-fusion to a post-fusion conformation. A monoclonal antibody specific for LayV-F is also provided.

51.20260159553MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE

US - 11.06.2026

Clasificación Internacional C07K 14/005Nº de solicitud 18707293Solicitante Kashiv BioSciences, LLCInventor/a Sudharti Gupta

The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants. Furthermore, the expression vector to produce mRNA expresses more than one structural protein to generate immune response against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants.

52.20260158131ROTAVIRUS B VIRUS-LIKE-PARTICLE COMPOSTIONS AND ANTIBODY ASSAYS

US - 11.06.2026

Clasificación Internacional A61K 39/15Nº de solicitud 19387411Solicitante University of Kentucky Research FoundationInventor/a Feng Li

Compositions and methods are provided for immunization against equine rotavirus group B (ERVB). The compositions comprise ERVB structural proteins VP4, VP2, VP6, and VP7, or VP2, VP6, VP7, and a modified VP4, which can be assembled into virus-like particles (VLPs). The invention includes immunogenic compositions and vaccines for administration to non-human animals, including pregnant mares to confer passive immunity to foals. Methods of stimulating immune responses, preventing ERVB spread, conferring passive immunity, evaluating vaccine efficacy, detecting ERVB antibodies, and producing VLPs in baculovirus-infected insect cells are disclosed. The compositions may further include inactivation agents. Nucleotides and vectors encoding the ERVB proteins are also provided.

53.20260167675VIRAL PEPTIDES AND USES THEREOF

US - 18.06.2026

Clasificación Internacional C07K 14/005Nº de solicitud 18871778Solicitante Regeneron Pharmaceuticals, Inc.Inventor/a Augustine CHOY

The present disclosure provides isolated peptides derived from hepatitis B virus (HBV), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treatment or prevention of HBV infection and/or HBV-induced diseases. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treatment or prevention of HBV infection and/or HBV-induced diseases. The present disclosure further provides methods and systems for identifying immunogenic virus-derived peptides.

54.WO/2026/120145VACCINE COMPOSITION COMPRISING HERV DERIVED EPITOPES AND THEIR USE IN TREATMENT OF AML

WO - 11.06.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2025/085671Solicitante EVAXION A/SInventor/a KLAUSEN, Michael Schantz

Provided are immunogenic agents and compositions tailored to induce immunity against hERV expression products in a high percentage of cancer patients as well. Also provided are methods for immune induction against cancer cells

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20260611"<=20260621 22 records*

Document ID	Title	Inventor	Applicant Name
US 20260167923 A1	IMMUNOGENIC ENGINEERED LIVE-ATTENUATED GRAM-NEGATIVE PATHOGEN VACCINES HAVING REDUCED ENDOTOXICITY	Ernst; Robert K. et al.	University of Maryland, Baltimore,The Government of The United States, as represented by the Defense Health Agency
US 20260166137 A1	RECOMBINANT FOOT-AND-MOUTH DISEASE TYPE A VIRUS INDUCING STRONG ADAPTIVE IMMUNE RESPONSE AND OVERCOMING INTERFERENCE FROM MATERNALLY-DERIVED ANTIBODIES, AND FOOT-AND-MOUTH DISEASE VACCINE COMPOSITION COMPRISING SAME	LEE; Min Ja et al.	REPUBLIC OF KOREA(ANIMAL AND PLANT QUARANTINE AGENCY)
US 20260166138 A1	Compositions and Methods for Enhancement of mRNA Vaccine Performance and Vaccination against Mpox	Chen; Sidi et al.	Yale University
US 20260166134 A1	mRNA, mRNA VACCINE FORMULATION, AND PREPARATION METHOD AND USE THEREOF	NIU; Yuanjie et al.	Panru Biotechnology (Tianjin) Co., Ltd
US 20260167681 A1	VACCINE DELIVERY CARRIER BASED ON ADHESIVE ADJUVANT PROTEIN AND ITS USES	CHA; Hyung Joon et al.	POSTECH Research and Business Development Foundation
US 12655477 B2	DNA vaccines	Hill; Vanessa	Touchlight IP Limited
US 12653872 B2	Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy	Mandler; Markus et al.	AC Immune SA
US 12653878 B2	Vaccine composition against Streptococcus suis infection	Seele; Jana et al.	CEVA SANTE ANIMALE S.A.

US 12653876 B2	M Hyo multivalent vaccine and uses thereof	Wilson; Keith et al.	BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
US 12653877 B2	Gut bacteria derived microvesicles for vaccine delivery	Stentz; Regis et al.	Quadram Institute Bioscience
US 12653875 B2	Live attenuated Leishmania parasite vaccines with enhanced safety characteristics	Nakhasi; Hira L. et al.	The U.S.A., as represented by the Secretary, Department of Health and Human Services,Ohio State Innovation Foundation,Matlashewski; Gregory,Zhang; Wen-Wei,Lypaczewski; Patrick
US 12653881 B2	Measles virus vaccine expressing SARS-CoV-2 protein(s)	Duprex; William Paul et al.	University of Pittsburgh-Of the Commonwealth System of Higher Education
US 12653874 B2	Nant cancer vaccine	Soon-Shiong; Patrick et al.	NantCell, Inc.,Nant Holdings IP, LLC
US 20260158130 A1	LOW-SUGAR INFLUENZA VACCINE AND METHODS THEREOF	WU; Chung-Yi et al.	Rock BioMedical, Inc.
US 20260158132 A1	SERUM FREE INTRACELLULAR PATHOGEN VACCINE	Koumans; Joseph et al.	Intervet Inc.
US 20260158125 A1	PEPTIDE VACCINE	LA THANGUE; Nicholas et al.	ARGONAUT THERAPEUTICS LIMITED
US 20260158127 A1	ENHANCEMENT OF VACCINE EFFICACY VIA BIOMASS AND/OR RELATED MATERIAL IN ANIMAL DRINK AND FEED	Dahl; Andrew A. et al.	ZIVO BIOSCIENCE, INC.
US 20260159553 A1	MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE	Gupta; Sudharti et al.	Kashiv BioSciences, LLC
US 20260158135 A1	VARIANT STRAIN-BASED CORONAVIRUS VACCINES AND USES THEREOF	Metkar; Mihir et al.	ModernaTX, Inc.
US 20260158129 A1	NUCLEIC ACID INFLUENZA VACCINES AND RESPIRATORY VIRUS COMBINATION VACCINES	Nachbagauer; Raffael et al.	ModernaTX, Inc.

US 20260158126 A1	RUMINAL AND METHANOGEN VACCINES AND USES THEREOF	Rajaniemi; Hannu et al.	HELIX NANOTECHNOLOGIES, INC.
US 20260159586 A1	METHODS OF TREATING CANCER WITH A COMBINATION OF A CANCER VACCINE AND A TAAXCD28 BISPECIFIC ANTIGEN-BINDING MOLECULE	DiLillo; David et al.	Regeneron Pharmaceuticals, Inc.

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES